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Cerebrovascular disease is a leading cause of disability and mortality in the elderly. 
The term describes a highly heterogeneous group of disorders manifesting as pa-
renchymal brain damage due to cerebral vascular pathology. Based on the size of 
the vessel affected one distinguishes cerebral large- and small vessel disease, i.e. 
atherosclerosis and arteriolosclerosis.
Histopathological studies show marked differences at the tissue level between 
these two processes. Atherosclerotic lesions are characterized by the presence of 
lipid laden macrophages, so called foam cells in the subendothelial areas in the early 
fatty streaks. Over years these lesions progress by accumulating smooth muscle 
cells and extracellular matrix proteins into advanced atherosclerotic plaques featur-
ing extensive fibrosis, necrotic and calcified tissue with cholesterol crystals (1). Both 
epidemiological and experimental studies underscore the central role lipids play 
in the development of atherosclerosis (1). The main histopathological features of 
arteriolosclerotic lesions is a thickening of the vessel wall due to vascular smooth 
muscle cell hyperplasia and fibrohyalinosis (2,3). Major and widely accepted risk 
factors for small vessel disease are age and hypertension (4). The development of 
arteriolosclerosis seems to be independent of lipids and lipoproteins.
From the genetic perspective both athero- and arteriolosclerosis are concep-
tualized as complex traits. The risk of an individual to develop these pathologies 
depends on an interaction between exposure to environmental factors and inher-
ited susceptibility. Efforts are undertaken to identify the genetic factors as their 
knowledge delivers information about etiology and pathomechanisms of these 
disorders and may facilitate the development of preventive and therapeutic strate-
gies on an individual basis. The clinical presentation of both atherosclerosis as well 
as arteriolosclerosis is heterogeneous and ranges from strokes with abrupt onset 
and clear-cut focal neurological deficits to slowly progressive signs and symptoms 
including cognitive impairment, gait disturbances and falls, incontinence and 
mood changes. Large and small vessel disease can also be clinically silent (5). The 
non-uniform phenotypes resulting from common vessel pathology clearly hampers 
genetic research of these traits. 
The heterogeneity can partly be reduced by the introduction of strict diagnostic 
criteria as well as by the use of intermediate, subclinical phenotypes as surrogate 
markers. A frequently used subclinical paradigm of cerebral large vessel disease 
(cLVD) is carotid intima media thickness (IMT) or the presence of atherosclerotic 
plaques as assessed by carotid Doppler sonography (6), while severe subcortical 
white matter hyperintensities and lacunar infarcts detected by magnet resonance 
imaging (MRI) are used as subclinical manifestations for cerebral small vessel dis-
ease (cSVD) (7). The development of uniform definitions and terminology for both 
cerebral large and small disease and its clinical sequelae is very much needed. Such 
“common language” creates a first step in reducing the inconsistency of current 
genetic association studies in cerebrovascular disease. The heritability estimates 
of carotid atherosclerosis vary from 20 to 40% (6). The heritabilty of cSVD is 
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significantly higher, in the range of 55 to 73% (8-10).
 Compared to the large body of literature available on carotid atherosclero-
sis, less is known about cSVD. This is partly due to the fact that detection of this 
phenotype is based on MRI which is a less easily accessable and more cost intensive 
examination than sonography. Only a small number of the large population-based 
studies incorporated brain MRI in their protocol. The prevalence of cSVD based 
on these studies is estimated to be 10-20% in the elderly population (11). It has been 
suggested that these lesions, in the past referred as leukoaraioses, progress gradually 
over time and ultimately may result in subcortical arteriosclerotic encephalopathy 
with concomitant cognitive decline (12). The rate and the determinants of cSVD 
progression as well as the clinical consequences of cSVD remain a major focus of 
research interest for those working on this field.
The aim of this thesis was to contribute to a better understanding of the de-
velopment of cSVD by studying the evolution of these lesions over time and by 
identifying genetic factors determining the risk for cSVD. Large and small vessel 
disease are clearly unique entities, nonetheless they are frequently associated with 
each other, suggesting that they share some common pathways in their develop-
ment. One approach that may help to increase our understanding of cerebrovascular 
disease in general is to search for genetic factors which concur in athero- and arte-
riolosclerosis but also to identify genetic factors which are unique for one of these 
two vessel pathologies. We took such an approach  in the setting of the Austrian 
Stroke Prevention Study (ASPS), a single center, prospective cohort study on the 
cerebral effects of vascular risk factors in the normal elderly population of the city 
of Graz, Austria.
In Chapter 2 we describe rate and determinants of WMH progression over a 
period of 3-year (Chapter 2.1) and 6-year (Chapter 2.2) follow up. 
In Chapter 3 we focus on the genetic determinants of cSVD. In chapter 3.1 we 
give an overview about the genetics of cSVD based on data available on the topic 
in year 2000 and suggest a model to select candidate genes for cSVD. Next we 
present the results of association studies investigating the role of candidate genes in 
cSVD. First we describe the association between cSVD and the apolipoprotein E 
isoforms 2, 3 and 4 (Chapter 3.2), as well as between cSVD and the paraoxonase 1 
polymorphisms at position 54 and 191 (Chapter 3.3). In a separate chapter, Chapter 
3.4 we pool a series of three manuscripts evaluating the role of angiotensinogen 
(AGT) gene promoter haplotypes in cSVD. In the first manuscript we describe 
the presence of five novel haplotypes at the AGT promoter and report a positive 
association between the B-haplotype and cSVD (Chapter 3.4.1). In the second 
manuscript we review the possible role of AGT in cSVD based on the literature 
and present our own first functional data (Chapter 3.4.2). In the third manuscript 
we investigate the effect of the B-haplotype on the transcriptional activity of the 
AGT gene and study the evolutionary relatedness of the different AGT haplotypes 
(Chapter 3.4.3).
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In Chapter 4 we present three studies on the genetics of carotid atherosclerosis. In 
Chapter 4.1. and Chapter 4.2 we investigate if carotid atherosclerosis is associated 
with polymorhisms in the paraoxonase and the AGT gene, which we identified 
as risk factors for cSVD (Chapter 3). In Chapter 4.3 we describe the association 
between beta-fibrinogen promoter polymorphism and carotid atherosclerosis, a 
polymorphism which was not associated with cSVD in our cohort. 
Finally, in Chapter 5 we discuss our main findings and summarise their possible 
implications for future research.
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Progression of cerebral white matter lesions: 
6-year results of 
the Austrian Stroke Prevention Study
Reinhold Schmidt, Christian Enzinger, Stefan Ropele, 
Helena Schmidt, Franz Fazekas
More than half of all elderly people have some degree of cerebral white 
matter lesions. However, the rate of progression of these lesions is uncer-
tain. We aimed toassess the progression of lesions in community-dwelling 
volunteers aged 50–75 years without neuropsychiatric disease. We used 
MRI to grade and measure the total volume of white matter lesions in 296 
volunteers at baseline, 3 years, and 6 years. 58 participants with no lesions 
and 123 with punctate abnormalities at baseline had a low tendency for 
lesion progression, whereas 14 participants with early confluent and nine 
with confluent lesions underwent median increases of 2·7 cm3 (IQR 0·5–
5·9) and 9·3 cm3 (7·1–21· 0), respectively, in lesion volume at 6 years. Lesion 
grade at baseline was the only significant predictor of lesion progression 
(p<0· 0001). Punctate white matter lesions are not progressive and are thus 
benign, whereas early confluent and confluent white matter abnormalities 
are progressive, and thus malignant. 
Lancet 2003; 361: 2046–48
Some degree of cerebral white matter change is almost endemic in elderly people. 
Lesions progress,1–3 but inwhich individuals is unclear. At the extreme end of 
the spectrum, full-blown dementia corresponds with diffuse demyelination and 
arteriolosclerosis.4 We aimed to assess the volume change of white matter lesions 
during 6 years in a community-dwelling cohort. 
 We randomly selected 2007 individuals aged 50–75 years without neuropsy-
chiatric disease from our community register. 509 study participants underwent 
brain MRI at baseline. Follow-up examinations were done at 3 years and at 6 
years. Sampling procedure and clinical assessment have been described.2 296 
volunteers underwent baseline MRI and at least one follow-up examination. 271 
people had a 3-year and 204 a 6-year follow-up assessment. 191 participants had 
all three MRI examinations. At baseline and at each follow-up 1·5 T-scanners 
from the same manufacturer (Philips Medical Systems; Eindhoven, Netherlands) 
and identical protocols were used.
C E identified white matter lesions, drew their outlines onto an overlaid transpar-
ency, and graded them into punctate, early confluent, or confluent lesions (figure). 
Blinding for the date of examinations was impossible since the format of hard cop
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ies changed between baseline and follow-up. Follow-up scans were compared with 
the baseline scan, and the lesions drawn as before. Scan series were reviewed by C E 
and R S and a consensus reached for borderline grades. The volume of lesions was 
quantified independently from visual analysis without knowledge of the sequence 
of the investigation by a trained technician with the DISPImage program (version 
4.8), with the hard copy as reference. Maximum intra-rater coefficient of variation 
was 6·4%. We analysed the scans of 50 randomly selected participants on two 
separate occasions to establish the error in volumetric assessment.3 We set the error 
range as the 95% CI of the most pronounced difference between repeated measure-
ments: –1·59 to 1·81 cm3. We constructed a generalised estimation equation (GEE) 
model including a-priori defined demographic and major vascular risk factors to 
establish predictors of white matter lesion progression. In a second GEE model we 
added the baseline grade of white matter lesions.
At 3-years’ and 6-years’ follow-up the median increase of lesion volume was 0 
cm3 (IQR 0–0·3) and 0·1 cm3 (0–0·7), respectively. Only 25 (9%) and 35 (17%) 
participants had lesions whose increase in volume exceeded possible measurement 
error (1·81cm3) at 3-years’ and 6-years’ follow-up, respectively. All drops in lesion 
volume were within the range of measurement variability.
Older age (=0·07, 95% CI 0·02–0·12, p=0·008) and arterial hypertension 
(=1·14, 0·47–1·81, p=0·001) were significant predictors of white matter lesion pro-
gression. There was a non-significant negative relation for diabetes, but there were 
only 13 people with diabetes in the study. The first model accounted for 10% of the 
variance in change of lesion volume. The addition of the baseline grade of white 
matter lesions increased the explained proportion of variance in volume change 
to 28·5%. In this second model, lesion grade was the only significant predictor of 
lesion progression (=1·78; 95% CI 1·39–2·12, p<0·0001); the relation with age and 
hypertension was no longer significant.
The table shows the change in volume from baseline of each grade of lesion. 
Participants who had no lesions at baseline had negligible changes in volume at 
both follow-up examinations. In none was progression of lesion load greater than 
1·81 cm3, even after 6 years’ follow-up. The change in lesion volume in partici-
pants with punctate lesions was only slightly higher than in the no-lesion group. 
By contrast, individuals with early confluent and confluent lesions at baseline had 
substantial median increases in lesion volume (table and figure). All participants 
with confluent lesions had lesion progression beyond measurement variability at 6 
years’ follow-up.
Our results show that baseline grading of lesions predicts their progression 
better than age and hypertension and is an intermediate factor in the association 
between these risk factors and progression. Since few participants had early conflu-
ent and confluent lesions our results should be confirmed in larger investigations. 
Our results might have been affected by a low response rate for enrolment into 
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the study, a high drop-out rate, and our inability to blind grading assessments for 
the date of examination.
We have shown previously that punctate white matter lesions often represent 
widened perivascular spaces without substantial ischaemic tissue damage, whereas 
early confluent and confluent lesions correspond to incomplete ischaemic destruc-
tion, often with focal transition to true infarcts with advanced microangiopathy.5 
Our results show that punctate white matter lesions are not ischaemic, not progres-
sive, and thus benign; whereas early confluent and confluent lesions areischaemic, 
progressive, and thus malignant. The clinical relevance of white matter lesion 
progression is unclear. Clinical stability in people with no or punctate lesions and 
reduction of functional abilities in individuals with coalescent lesions remains to 
be shown.
    A              B          C
 
   D                 E            F  
Baseline lesion grades in each group (A-C) and change in white matter lesion volume in a 64-year-
old woman (D-F) Arrows show punctate (A), early confluent (B), and confluent (C) lesions. Early 
confluent white matter lesions at baseline (D). In the single slice shown in this figure the volume 
of lesions increased by 2.6cm3 between baseline and 3-year follow-up (E) and by 8.1cm3 between 
baseline and 6-year follow-up (F).
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Baseline white matter lesion grade None (n=91) Punctate (n=164)
Early confluent (n=28) Confluent (n=13) 
3-year follow-up 
Participants, number 85 (93%) 149 (91%) 25 (89%) 12 (92%) 
Volume change from baseline, cm3, median 
(IQR)  
0·0 (0·0–0·0) 0·1 (0·0–0·4) 0·7 (0·1–3·1) 4·8 (1·9–8·8) 
Progression >1·81 cm3, number  0 7 (5%) 9 (36%) 9 (75%) 
6-year follow-up 
Participants, number 58 (64%) 123 (75%) 14 (50%) 9 (69%) 
Volume change from baseline, cm3, median 
(IQR)  
0·0 (0·0–0·0) 0·2 (0·0–1·1) 2·7 (0·5–5·9) 9·3 (7·1–21·0) 
Progression >1·81 cm3, number  0 18 (15%) 8 (58%) 9 (100%) 
Change in white matter lesion volume in each group 
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MRI Cerebral White Matter Lesions and Paraoxonase
PON1 Polymorphisms
Three-Year Follow-Up of the Austrian Stroke Prevention Study
Reinhold Schmidt, Helena Schmidt, Franz Fazekas, Peter Kapeller, Gudrun Roob, Anita Lechner,
Gert M. Kostner, Hans-Peter Hartung
Abstract—White matter lesions (WMLs) on magnetic resonance imaging (MRI) scans of older persons are thought to be
caused by cerebral small-vessel disease. As they progress, these brain abnormalities frequently result in cognitive
decline and gait disturbances, and their predictors are incompletely understood. Genetic risk factors have been
implicated but remain undetermined so far. We examined whether 2 common polymorphisms of the paraoxonase
(PON1) gene leading to a methionine (M allele)–leucine (L allele) interchange at position 54 and an arginine (B
allele)–glutamine (A allele) interchange at position 191 are associated with the presence and progression of WMLs. We
studied 264 community-dwelling subjects without neuropsychiatric disease (ages 44 to 75 years). All underwent
vascular risk factor assessment, brain MRI, and PON1 genotyping. MRI scanning was repeated after 3 years. The extent
and number of WMLs were recorded by 3 independent readers. Progression of WMLs was assessed by direct scan
comparison. The final rating relied on the majority judgment of the 3 readers. The LL, LM, and MM genotypes were
noted in 111 (42.0%), 118 (44.7%), and 35 (13.3%) subjects, respectively; the AA, AB, and BB genotypes occurred in
146 (55.3%), 98 (37.1%), and 20 (7.8%) individuals, respectively. Carriers of the LL genotype showed a nonsignificant
trend toward more extensive WMLs and more frequently demonstrated lesion progression over the 3-year observation
period (P0.03). The polymorphism at position 191 had no effect. Logistic regression analysis yielded age (odds ratio,
1.08/y), diastolic blood pressure (odds ratio, 1.05/mm Hg), and LL paraoxonase genotype (odds ratio, 2.65) to be
significant predictors of WML progression. These data suggest that the LL PON1 genotype at position 54 influences the
extent and progression of WMLs in elderly subjects. (Arterioscler Thromb Vasc Biol. 2000;20:1811-1816.)
Key Words: white matter lesions  cerebral small-vessel disease  paraoxonase  genetics
Magnetic resonance imaging (MRI) shows cerebralwhite-matter lesions (WMLs) in a large proportion of
individuals above the age of 50 years.1 Histopathological
studies have demonstrated that these changes occur in the
presence of arteriolosclerosis and are correlated with widen-
ing of the perivascular spaces, perivascular demyelination, or
lacunar infarcts.2 Such abnormalities may be recognized in
otherwise-normal individuals but are likely to become asso-
ciated with cognitive impairment and gait disturbances as
they progress.1 Identification of individuals prone to the
development and progression of WMLs is important, because
early control of causal factors in high-risk groups could
reduce their clinical consequences, which are a major source
of disability in the elderly population. So far, it is unclear
which factors other than advancing age1,3,4 and arterial
hypertension1,5,6 predispose individuals to this type of ische-
mic brain damage. A significant contribution of genetic
influence has only recently been demonstrated in a US study
on World War II veteran twins.7 That investigation reported
a probandwise concordance rate for severe WMLs of 61% in
monozygotic twins and of 38% in dizygotic twins compared
with a prevalence rate of 15% for the entire population. The
estimated heritability of WML volume was 73%.
The strong association of WMLs with aging and a previous
study of our own demonstrating an inverse relationship
between lesion extent and plasma levels of antioxidants8
suggest that genes involved in oxidative defense could play a
role in the etiology of such brain abnormalities. Free-radical
formation increases significantly with aging,9 and increased
lipid peroxidation and oxidative stress due to excess free-
radical activity and impaired antioxidant defenses have been
associated not only with large- but also with small-vessel
disease,10,11 the most likely cause of WMLs in the elderly.2
Paraoxonase has antioxidative potential12 and could thus
protect against both macrovascular and microvascular dis-
eases, even though they represent distinct vascular patholo-
gies. So far, there have been several publications relating
paraoxonase to pathological phenotypes of large-vessel dis-
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ease, such as coronary heart disease13–15 and carotid athero-
sclerosis16; a single study found an association with small-
vessel disease–related diabetic retinopathy.17 The
paraoxonase gene is located at q21 to q22 on the long arm of
chromosome 7.18 The ability of paraoxonase to detoxify
organophosphorus compounds has been known for years, and
its enzyme activity had been determined earlier by the use of
the pesticide paraoxon. White populations have a triphasic
distribution of paraoxonase activity toward paraoxon,19
which is caused by an amino acid substitution at position 191.
Glutamine (A allele) is replaced by arginine (B allele) in its
high-activity isoform.18 The B allele has been shown to be
associated with coronary heart disease.13–15 Another frequent
polymorphism at position 54 leads to a methionine (M
allele)–leucine (L allele) interchange.18 The 2 polymorphisms
are in linkage disequilibrium with leucine at position 54,
giving rise to arginine at position 191.18 We explored whether
these genetic variants influence the occurrence and progres-
sion of WMLs in a large cohort of randomly selected,
community-dwelling middle-aged and elderly individuals
who have been followed up over a time period of 3 years.
Methods
Individuals and Study Design
The study population consisted of participants in the Austrian Stroke
Prevention Study. The rationale and design of this study have been
previously described.20 In brief, 1998 participants without a history
or signs of neuropsychiatric disease were randomly selected from the
official community register. They underwent 3 blood pressure
readings, an ECG, and echocardiography, as well as laboratory
testing including blood cell count and a complete blood chemistry
panel. Every fourth, or in case of refusal, the next, study participant
was invited to enter phase 2 of the study, which included MRI and
Doppler sonography. From a total of 498 phase 2 participants, 458
volunteered to undergo an MRI study. At the second study panel, 3
years after baseline, we were able to contact 386 participants of the
original MRI sample or their proxies. Seven subjects had died and 7
had experienced a stroke, which was an end point in our study. There
were 27 subjects who did not want to undergo the extensive
diagnostic work-up a second time. A total of 21 individuals had
moved from the city, and 51 subjects could not be reached on the
occasion of 3 phone calls and did not respond to a written invitation.
The remaining 345 phase 2 attendees agreed to be reexamined, but
72 individuals refused to have a second MRI scan because they had
experienced claustrophobic sensations at the initial evaluation. Blood
sampling for DNA extraction was done in all but 9 individuals. The
current study cohort therefore comprises those 264 participants who
underwent MRI scanning at baseline and at the 3-year follow-up and
assessment of the PON1 polymorphisms. There were 128 women
and 136 men. The meanSD age was 59.96.1 years (median, 60.0
years) at baseline. The sample consisted exclusively of white
subjects of central European origin; the length of education ranged
from 9 to 18 years, with a mean of 11.7 years. The individuals who
participated in the follow-up MRI study did not differ from those
who dropped out in terms of age, sex, educational and occupational
status, and risk factors for stroke. This 3-year follow-up of the
Austrian Stroke Prevention Study is not prospective in design
because no data on PON1 polymorphisms for 25% of the original
group of subjects who volunteered to undergo a first MRI were
available.
Vascular Risk Factors
Historical information and laboratory findings at baseline and
follow-up were considered for diagnosis of arterial hypertension,
diabetes mellitus, and cardiac disease, including embologenic abnor-
malities, coronary heart disease, and left ventricular hypertrophy. We
also assessed smoking habits and body mass index (BMI). Lipid
status including the levels of plasma triglycerides, total cholesterol,
LDL cholesterol, HDL cholesterol, and Lp(a) lipoprotein, as well as
measurement of plasma fibrinogen, was determined for each study
participant at both examinations. A detailed description of the
definitions of risk factors and of the laboratory methods used has
been published previously.16 The means of systolic and diastolic
blood pressures, fasting blood sugar, BMI, lipid, and fibrinogen
values on baseline and follow-up measurements were calculated and
used for data analyses.
Isolation of DNA and Genotype Analysis
High-molecular-weight DNA was extracted from peripheral whole
blood by using Qiagen genomic tips (Qiagen Inc) according to the
protocol supplied by the manufacturer. Genotyping of the Met-
Leu54 polymorphism was done by polymerase chain reaction (PCR)
amplification of a 170-bp-long fragment and using the primers
described by Humbert et al.18 The PCR products were cleaved by
NlaIII in the presence of BSA at 37°C for 3 hours. The digested
products were analyzed on a 15% polyacrylamide gel, stained with
ethidium bromide, and examined under UV transillumination. The L
allele corresponded to the nondigested 170-bp-long fragment,
whereas the M allele corresponded to 126- and 44-bp fragments. A
similar protocol was used for genotyping the Gln-Arg191 poly-
morphism and also using the primers described by Humbert et al.18
Magnetic Resonance Imaging
MRI was performed on 1.5-T superconducting magnets (Gyroscan S
15 and ACS, Philips) with proton-density and T2-weighted (repeti-
tion time [TR]/echo time [TE], 2000–2500/30–90 ms) sequences in
the transverse orientation. T1-weighted images (TR/TE, 600/30 ms)
were generated in the sagittal plane. Slice thickness was 5 mm and
the matrix size used was 128256 pixels. The MRI protocols at
baseline and at the 3-year follow-up were identical. The scanning
plane was always determined by a sagittal and coronal pilot to ensure
consistency in image angulation throughout the study. The baseline
and follow-up scans of each study participant were read indepen-
dently by 3 experienced investigators who were blinded to the
clinical data of study participants. Blinding of the readers for the date
of the examinations was impossible because the format of hard
copies had changed from baseline to follow-up. According to our
scheme, WMLs included abnormalities in the subcortical region and
deep white matter as well as irregular periventricular lesions extend-
ing into the deep white matter.3 They were graded into absent (grade
0), punctate (grade 1), early confluent (grade 2), and confluent (grade
3) abnormalities.3 The number of WMLs was recorded and catego-
rized into 0, 1 to 4, 5 to 9, and 9 lesions.  Values for interrater
agreement regarding WML grade at baseline and at 3 years ranged
from 0.63 to 0.70 and from 0.66 to 0.68, respectively, in regard to the
number of lesions. We disregarded caps and pencil-thin periventric-
ular linings because they represent normal anatomic variants.21,22 We
also disregarded a smooth “halo” surrounding the lateral ventricles
because it is nonischemic in etiology, according to histopathological
correlations.21 A change of WMLs in grade or number from baseline
was determined by direct scan comparison. The final rating of WML
progression relied on majority judgment of the 3 assessors. In case of
complete disagreement, consensus was found in a joint reading
session. The interrater agreement for WML progression ranged from
0.58 to 0.68. The Figure displays examples for each WML grade and
for WML progression. We also recorded lacunes. They were defined
as focal lesions isointense to cerebrospinal fluid and involving the
basal ganglia, the internal capsule, the thalamus, or the brain stem
and not exceeding a diameter of 10 mm.
Carotid Artery Duplex Scanning
Color-coded equipment (Diasonics, Vingmed CFM 750) was used to
determine vessel wall abnormalities of the carotid arteries in all
participants. The imaging protocol, grading of atherosclerotic
changes, and the associations between duplex findings and paraoxo-
nase genotypes in our study population have been reported previ-
ously.16 In the current study, we describe the presence of atheroscle-
rotic changes among the genotype subsets and adjust for this variable
when assessing the influence of the paraoxonase polymorphisms on
WMLs.
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Statistical Analysis
We used the Statistical Package for the Social Sciences (SPSS 8.0) for
data analysis. Categorical variables among the paraoxonase geno-
types were compared by the 2 test. Assumptions of a normal
distribution for continuous variables were compared by Lilliefors
statistics. Normally distributed continuous variables were compared
by 1-way ANOVA, whereas the Kruskal-Wallis test was used for
comparison of nonnormally distributed variables. Allele frequencies
were calculated by the gene counting method, and Hardy-Weinberg
equilibrium was assessed by the 2 test. The relative contribution of
the paraoxonase genotypes to the presence of WMLs at baseline and
to WML progression at the 3-year follow-up was assessed by
multiple logistic regression analysis. Forward-selection stepwise
regression analysis was used to create a model of independent
predictors of MRI findings. At each step, each variable not yet in the
model was assessed for its contribution to the model, with the most
significant variable to be added. This process continued until no
further variable made a significant (P0.05) contribution to the
model. Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated from the  coefficients and their SEs.
Results
The LL, LM, and MM genotypes were noted in 111 (42.0%),
118 (44.7%), and 35 (13.3%) individuals, respectively. The
AA, AB, and BB genotypes occurred in 146 (55.3%), 98
(37.1%), and 20 (7.8%) individuals, respectively. These
frequencies are similar to those reported in other European
populations.18,23 The genotypes of both polymorphisms were
in Hardy-Weinberg equilibrium. There existed a moderate
association between the 2 polymorphisms, with arginine at
position 191 being, with 1 exception, always concurrent with
leucine at position 54.
Table 1 compares demographic variables and risk factors
among the LL, LM, and MM genotype subsets. Individuals
with the MM genotype had slightly higher fasting glucose
levels than did those with the LM or LL genotype, and there
was a nonsignificant trend for lower triglyceride levels in LM
carriers. These between-group differences diminished further
after correction for antidiabetic and lipid-lowering treatment.
There existed no significant difference among the AA, AB,
and BB genotype subsets when the demographic variables
and risk factors listed in Table 1 were compared (data not
shown). Duplex scanning showed atherosclerotic changes of
the carotid arteries in 71 (64.0%) subjects with the LL
genotype but in only 56 (47.5%) LM and 18 (51.4%) MM
carriers (P0.04). Carotid artery abnormalities were also
seen in 81 (55.5%) AA, 51 (52.0%) AB, and 13 (65.0%) BB
carriers (P0.56).
At baseline, 171 (64.8%) participants had WMLs on MRI.
After 3 years, progression of abnormalities had occurred in 47
(17.8%) subjects. Regression of abnormalities was never
observed by the majority of readers. A breakdown of WML
findings by paraoxonase genotypes is given in Table 2. As
shown in the Table, the PON1 polymorphisms had no
significant influence on baseline results. Yet subjects ho-
mozygous for the L allele at position 54 showed a trend
toward higher grades of WMLs at the initial MRI examina-
tion than did their counterparts with either the LM or MM
genotype. Progression of lesions over 3 years occurred at a
significantly higher frequency in the LL genotype subset.
There was a significant association between WML findings at
baseline and the presence of carotid atherosclerosis
(P0.017). The association was mainly due to a higher
frequency of grade 2 or 3 WMLs in subjects with carotid
changes than in those with a normal sonographic examination
(5.9% versus 16.6%). Progression of WMLs was not related
to the presence of carotid atherosclerosis. At baseline, lacunes
were found in a total of 17 subjects and were always seen in
the basal ganglionic/thalamic region. At the 3-year follow-up,
new lacunes had evolved in 8 subjects. There was no
significant difference in the distribution of subjects with
lacunes at baseline and with evolving lacunes at follow-up
among the genotypes, but the numbers in the comparative
subsets were small.
Logistic regression analysis yielded an unadjusted OR of
2.38 (95% CI, 1.25 to 4.53; P0.008) for progression of
WMLs in the LL genotype relative to the 2 other genotypes.
The OR after adjustment for age and sex was 2.55 (95% CI,
1.32 to 4.96; P0.005). Evaluation for the effect of the
Examples for each WML grade (A to D) and for WML progres-
sion (E, F). A, Grade 0absent; B, grade 1punctate (arrow); C,
grade 2early confluent; and D, grade 3confluent lesions. E,
Baseline scan in a 67-year-old study participant, showing few
punctate white matter foci in the centrum semiovale. F,
Follow-up study in the same subject after 3 years, demonstrat-
ing multiple, new, and partly confluent white matter changes
(arrows).
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Gln-Arg191 polymorphism demonstrated that WML progres-
sion occurred more commonly in BB carriers, but these
differences with respect to the AA and BB genotypes were
nonsignificant. The Gln-Arg191 polymorphism did not mod-
ulate the effect of the LL genotype on WML progression
because lesion progression was seen at almost identical
frequency in 11(23.9%) subjects in the LL/AA group and in 5
(26.3%) individuals in the LL/BB group. When we used
forward stepwise regression analysis to create a model of
predictors of WML progression, the LL genotype remained in
this model in addition to age and diastolic blood pressure.
Age entered the model first, the LL genotype second, and
diastolic blood pressure third (Table 3). All other variables,
including sex, BMI, systolic blood pressure, fasting glucose
level, diabetes, smoking status, cardiac disease, blood lipids,
plasma fibrinogen level, and carotid atherosclerosis did not
enter the model. When carotid atherosclerosis was forced into
the model, the OR for the association between the LL
genotype and WML progression did not materially change.
Discussion
We found that homozygosity for the L allele at position 54
tended to be associated with the extent of WMLs at baseline
and predicted WML progression in addition to advancing age
and diastolic blood pressure. As in the Cardiovascular Health
Study,24 we have seen an association between WMLs and
TABLE 1. Demographics and Risk Factors Among Paraoxonase Leu-Met54
Genotypes
Variable LL (n111) LM (n118) MM (n35) P
Age, y 59.65.9 60.16.4 60.45.6 0.73*
Sex, male, n (%) 55 (49.5) 61 (51.7) 20 (57.1) 0.74†
Hypertension, n (%) 46 (41.4) 39 (33.1) 17 (48.6) 0.19†
Diabetes, n (%) 7 (6.3) 5 (4.2) 3 (8.6) 0.58†
Fasting glucose, mg/dL 95.320.9 92.414.2 101.830.1 0.07*
Cardiac disease, n (%) 50 (45.0) 47 (39.8) 13 (37.1) 0.61†
Smoking status
Never, n (%) 66 (59.5) 64 (54.2) 20 (57.1)   
Former, n (%) 34 (30.6) 37 (31.4) 11 (31.1)   
Current, n (%) 11 (9.9) 17 (14.4) 4 (11.4) 0.87†
BMI, kg/m2 27.03.6 26.63.8 27.44.4 0.60*
Triglycerides, mg/dL 161.6142.9 129.361.0 151.071.3 0.06‡
Cholesterol, mg/dL 233.939.5 233.337.4 227.735.9 0.69‡
LDL cholesterol, mg/dL 151.336.0 154.234.2 147.730.5 0.59‡
HDL cholesterol, mg/dL 53.316.9 53.115.0 48.715.5 0.22*
Lipoprotein(a), mg/dL 25.028.8 23.125.0 28.933.1 0.88*
ApoB, mg/dL 137.431.5 133.727.9 137.833.0 0.60‡
ApoA-I, mg/dL 178.431.9 177.029.0 173.132.0 0.68‡
Fibrinogen, mg/dL 283.754.4 293.969.4 286.260.3 0.64*
*Kruskal-Wallis test; †2 test; ‡1-way ANOVA.
TABLE 2. Paraoxonase Genotypes and MRI WMLs: Baseline Findings and 3-Year Progression
LL
(n111)
LM
(n118)
MM
(n35) P *
AA
(n146)
AB
(n98)
BB
(n20) P *
WML grade, n (%)
0 38 (34.2) 44 (37.3) 11 (31.4) 54 (37.0) 32 (32.7) 7 (35.0)
1 52 (46.8) 66 (55.9) 22 (62.9) 78 (53.4) 52 (53.1) 10 (50.0)
2 16 (14.4) 6 (5.1) 2 (5.7) 11 (7.5) 11 (11.2) 2 (10.0)
3 5 (4.5) 2 (1.7) 0 0.08 3 (2.1) 3 (3.1) 1 (5.0) 0.93
WML number, n (%)
0 38 (34.2) 44 (37.3) 11 (31.4) 54 (37.0) 32 (32.7) 7 (35.0)
1–4 31 (27.9) 41 (34.7) 14 (40.0) 53 (36.3) 29 (29.6) 4 (20.0)
5–9 22 (19.8) 16 (13.6) 5 (14.3) 20 (13.7) 18 (18.4) 5 (25.0)
9 20 (18.0) 17 (14.4) 5 (14.3) 0.70 19 (13.0) 19 (19.4) 4 (20.0) 0.46
Progression, n (%)
Absent 83 (74.8) 104 (88.1) 30 (85.7) 120 (82.2) 83 (84.7) 14 (70.0)
Present 28 (25.2) 14 (11.9) 5 (14.3) 0.03 26 (17.8) 15 (15.3) 6 (30.0) 0.29
*2 test.
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carotid atherosclerosis at baseline, with carotid atherosclero-
sis being common among LL carriers. Yet the relationship
between the Leu-Met54 polymorphism and WML progres-
sion occurred independently of extracranial carotid disease.
We failed to detect a significant association between the
Gln-Arg191 polymorphism and WML progression, although
progression was more common in BB than in AB and AA
carriers. The frequency of lesion progression in subjects with
the combination of the LL/BB genotypes was virtually iden-
tical to that in the study participants with the combined LL/AA
genotypes. This indicates that the Gln-Arg191 polymorphism
has no effect on the natural course of WMLs per se and does
not modulate the effect of the L allele.
In line with these results, Garin et al25 found that the
Leu-Met54 polymorphism is of central importance to para-
oxonase function because it influences the serum activity and
concentration of the enzyme, whereas the 191 variant has
only little effect. This finding, together with the inconsistent
results of other studies on the association between the
Gln-Arg 191polymorphism and coronary heart disease in
genetically distinct populations,26 suggests that the PON1
polymorphism at position 191 is not causal but rather may be
in linkage disequilibrium with a functional sequence variant
in the vicinity. Whether the Leu-Met54 polymorphism rep-
resents this variant cannot be elucidated in allelic association
studies. PON1 belongs to a multigene family including PON2
and PON3 at the same locus on chromosome 7.27 Two
polymorphisms in the PON2 gene have only recently been
described. Their functional importance is not yet fully deter-
mined, but like the PON1 polymorphisms, they were linked
to coronary heart disease.28
Several studies support the role of paraoxonase in athero-
genesis. The enzyme is linked to HDL and may be partly
responsible for the antioxidative effect of this lipid frac-
tion.12,19 Paraoxonase decreases lipid peroxide accumulation
on LDL,29 a process that takes place in the subendothelial
space.30 In line with this presumed location of action, para-
oxonase was found to be present in interstitial fluid in an
enzymatically active form.31 Results in PON1 knockout mice
have demonstrated that HDL from PON1-deficient mice is
unable to prevent LDL oxidation in a coculture model of the
arterial wall.32 Paraoxonase immunoreactivity is seen in
atherosclerotic lesions, and its intensity increases with their
progression.33 There exists much less information on the
association between paraoxonase and microvascular disease,
which is the most likely cause of WMLs.2 Yet a study of Kao
et al17 investigated the role of PON1 polymorphisms in
small-vessel disease–related diabetic retinopathy and found
that the LL genotype at position 54 was associated with this
condition, whereas there existed no effect of the Gln-Arg191
polymorphism. These results are consistent with our findings
on WMLs. Importantly, in the context of our study results,
Primo-Parmo et al27 reported PON1 expression in adult
mouse brain and described sequence homologues isolated
from a postnatal human brain cDNA library.
Conceivably, the functional significance of the PON1
polymorphism at position 54 is due to its effect on enzyme
activity and concentration caused by altered gene expres-
sion.34 Unfortunately, we have no frozen serum from our
study participants and therefore could not measure these
variables in our study group.
In summary, our data suggest a moderate modulatory effect
of the Leu-Met54 polymorphism of the PON1 gene on the
extent and progression of small-vessel disease–related MRI
WMLs. Identification of individuals at risk for an unfavorable
evolution of these brain changes is important, because in-
creasing lesion load commonly results in cognitive decline
and other neurological signs and symptoms such as gait
disturbances and a tendency to falls.1,35
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Angiotensinogen Gene Promoter Haplotype and
Microangiopathy-Related Cerebral Damage
Results of the Austrian Stroke Prevention Study
Helena Schmidt, MD; Franz Fazekas, MD; Gert M. Kostner, PhD;
Cornelia M. van Duijn, PhD; Reinhold Schmidt, MD
Background and Purpose—Microangiopathy-related cerebral damage (MARCD) is a common finding in the elderly. It
may lead to cognitive impairment and gait disturbances. Arterial hypertension and age are the most important risk
factors. We assessed the association between MARCD and sequence alterations in the promoter region of the
angiotensinogen (AGT) gene.
Methods—We studied 410 randomly selected community-dwelling individuals aged 50 to 75 years. MARCD was defined
as early confluent or confluent white matter hyperintensities or lacunes on a 1.5-T MRI. The AGT promoter was
analyzed by temporal temperature gradient gel electrophoresis and automated sequencing.
Results—We detected 4 polymorphic sites, at positions �6, �20, �153, and �218. They created 5 haplotypes, which we
coded as A (�6:g, �20:a, �153:g, �218g), B (�6:a, �20:c, �153:g, �218:g), C (�6:a, �20:c, �153:a, �218:g), D
(�6:a, �20:a, �153:g, �218:g), and E (�6:a, �20:a, �153:g, �218:a). MARCD was seen in 7 subjects (63.6%)
carrying 2 copies of the B haplotype (B/B), in 12 subjects (38.7%) carrying 1 copy of the B haplotype in the absence
of the A haplotype (B�/A�), but in only 70 subjects (19.0%) in the remaining cohort (P�0.001). The odds ratios for
the B/B and the B�/A� genotypes were 8.0 (95% CI, 2.1 to 31.1; P�0.003) and 1.8 (95% CI, 0.8 to 4.2; P�0.14) after
adjustment for possible confounders.
Conclusions—The B haplotype of the AGT promoter in the absence of the wild-type A haplotype might represent a genetic
susceptibility factor for MARCD. (Stroke. 2001;32:405-412.)
Key Words: angiotensins � genetics � magnetic resonance imaging � small-vessel disease
Microangiopathy-related cerebral damage (MARCD) is acommon MRI observation in elderly persons and
includes white matter changes and lacunar infarcts.1,2 Al-
though these findings may be recognized in otherwise normal
individuals, they are likely to become associated with cogni-
tive impairment and gait disturbances as they progress.3,4
Identification of individuals prone to the development of such
brain lesions and early control of causal factors could reduce
the risk of these common clinical problems of the elderly.
Thus far, it is unclear which factors other than advancing age
and arterial hypertension predispose individuals to
MARCD.2–4 The significance of genetic influences was
demonstrated by an investigation of World War II veteran
twins. This investigation reported a probandwise concordance
rate for extensive white matter lesions of 61% in monozy-
gotic and of 38% in dizygotic twins compared with a
prevalence of 15% in the entire population. The estimated
heritability of lesion volume was 73%.5 The consistent
association between MARCD and arterial hypertension sug-
gests that genes involved in the regulation of blood pressure
may contribute to this strikingly high heritability.6,7
The renin-angiotensin system (RAS) is a major regulator of
blood pressure. Plasma angiotensinogen (AGT) synthesized
by the liver is processed to angiotensin II (Ang II) by the
serial action of renin and angiotensin-converting enzyme.
Importantly, the plasma level of AGT is rate limiting in this
cascade.8 Positive correlation between plasma AGT concen-
tration, RAS activity, and blood pressure in humans and in
animal models supports this assumption.8–11 Production of
AGT in the liver is regulated mainly at the transcriptional
level.11,12 Two common polymorphisms in the promoter
region at position �6:g3a and �20:a3c have been previ-
ously described and were shown to alter the transcriptional
efficiency of the AGT gene.11–16 Genetic linkage between the
AGT locus and essential hypertension has been repeatedly
reported,9,17 but there are also studies in Chinese and Finnish
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populations that do not confirm these results.18–20 Similarly,
conflicting data have been described for the association
between the T235 AGT gene variant and hypertension.9,21–27
These controversial findings suggest ethnic variation in the
genetics of hypertension, yet differences in the definition of
the phenotype may also be responsible for these
inconsistencies.
In the present study we investigated the association be-
tween AGT gene polymorphisms and MARCD in a cohort of
community-dwelling middle-aged and elderly individuals.
The study focused on variants in the promoter region of the
gene since they are likely to influence AGT expression and
may prove to be functionally important.
Subjects and Methods
Study Population
The study population consisted of participants of the Austrian Stroke
Prevention Study, a single-center, prospective, cohort study on the
cerebral effects of vascular risk factors in the normal elderly
population of the city of Graz, Austria. The study was approved by
the Medical Ethics Committee of Karl-Franzens University. Written
informed consent was obtained from all study participants. We
randomly selected 8193 individuals aged 50 to 75 years stratified by
sex and 5-year age groups from the official community register.
Between September 1991 and March 1994, individuals received a
written invitation containing a full description of the purpose of the
investigation to participate in the study. Overall, 2794 of the invited
subjects returned a card stating their willingness to participate.
Recruitment into the study was stopped after enrollment of 2000
eligible participants. They were all white and of Central European
origin. Individuals were excluded from the study if they had a history
of neuropsychiatric disease, including previous cerebrovascular at-
tacks and dementia, or an abnormal neurological status determined
on the basis of a structured clinical interview and a physical and
neurological examination. A random age- and sex-stratified sample
of 200 nonresponders was interviewed by telephone and did not
differ in terms of length of education, occupational status, and
history of vascular risk factors, including arterial hypertension,
diabetes mellitus, and cardiac disease. Every fourth study participant,
or in case of refusal the next participant, was invited to enter phase
II of the study, which included MRI and Doppler sonography. Since
1993 DNA samples of phase II subjects had been collected. From a
total of 498 phase II participants, 458 volunteered to undergo a MRI
study. The current study cohort consists of those 410 individuals who
underwent both MRI examination and genotyping of the AGT gene.
There were 214 women (52.2%) and 196 men (47.8%). The mean
age of this cohort was 60.1�6.0 years. The study sample did not
differ from the remaining Austrian Stroke Prevention Study cohort in
terms of age, sex, educational and occupational status, and risk
factors for stroke.
Vascular Risk Factors
The diagnosis of major risk factors for stroke, including arterial
hypertension, diabetes mellitus, and cardiovascular disease, was
determined by the history of the individual and appropriate labora-
tory findings. A detailed description of the laboratory methods used
and the definition of these risk factors are given elsewhere.28
DNA Analysis
Genomic DNA extracted from peripheral blood was polymerase chain
reaction (PCR) amplified with the following oligonucleotides: AGT-
PROM5: 5�-GC-Clamp-CTTGGCCCCGACTCCTGCAAACT-3� and
AGTPROM3: 5�-CCCCCGGCTTACCTTCTGCTGTA-3� in 40 cycles
consisting of 1 minute at 94°C, 1 minute at 65°C, and 2 minutes at 72°C.
The PCR products (354 bp long, containing a part of the AGT
promoter and exon 1, from �268 to �41 nucleotide, as well as a
40-bp-long GC clamp) were genotyped by temporal temperature
gradient gel electrophoresis (TTGE) with the use of the Dcode
Universal mutation detection system (Bio-Rad Laboratories). TTGE
is a sensitive method for the detection of virtually all poly-
morphisms, whether new or already known, and their precise
combination within the amplified fragment in a single step without
the need for further processing of the samples by, eg, restriction
enzyme digestion.29 Melting domain map was calculated with the
MacMelt computer algorithm (Bio-Rad Laboratories). PCR products
were electrophoresed on 9% polyacrylamide gels containing 8 mol/L
urea at 130 V with a temperature gradient of 57°C to 66°C, at a
heating rate of 1.5°C/h. Heterozygous DNA samples were used as
positive controls on each gel to check gel resolution efficiency. At
least 3 samples within each of the 15 distinct banding pattern groups
seen on TTGE were sequenced on an ABI 373 automated sequencer
(Perkin Elmer/Applied Biosystems).
Magnetic Resonance Imaging
MRI was performed on 1.5-T superconducting magnets (Gyroscan S
15 and ACS, Philips) with the use of T2-weighted (repetition time,
2000 to 2500 ms; echo time, 30 to 60 ms) sequences in the transverse
plane. T1-weighted images (repetition time, 600 ms; echo time, 30
ms) were generated in the sagittal and transverse planes. Slice
thickness was 5 mm, and the matrix size used was 128�256 pixels.
All scans were read by an experienced investigator without knowl-
edge of the clinical and laboratory data. The scans were evaluated for
white matter hyperintensities (WMH) and lacunar lesions. WMH
were graded according to our scheme as absent, punctate, early
confluent, and confluent.30 Caps and periventricular lining were
disregarded because they probably represent normal anatomic vari-
ants.31,32 Lacunes were focal lesions involving the basal ganglia,
internal capsule, thalamus, or brain stem not exceeding a maximum
diameter of 10 mm. Assessment of intrarater variability for WMH
grading and for presence of lacunar lesions was done in a subset of
70 randomly selected study participants and yielded � values of 0.90
and 0.86, respectively. After the scans were read, individuals were
considered to have MARCD if they presented with early confluent or
confluent WMH or lacunes or any combination of these findings.
Punctate WMH were not included in the definition of MARCD
because these foci cannot definitely be attributed to cerebral ische-
mia according to histopathological correlations.32
Statistical Analysis
We used the Statistical Package for Social Sciences (SPSS/PC�,
version 8.0.0; SPSS Inc) for data analysis. Categorical variables
among the genotypes were compared by the �2 test or by Fisher’s
exact test. Assumption of normal distribution for continuous vari-
ables was tested by Lilliefors statistics. Normally distributed vari-
ables were compared by 1-way ANOVA and nonnormally distrib-
uted variables by the Kruskal-Wallis test. To estimate the
relationship between genotype and MARCD, we first performed an
unadjusted comparison of the frequency of MARCD by genotypes.
Logistic regression modeling was then done to assess the relative
contribution of a given genotype on the presence of these brain
lesions. We considered the dichotomized variables sex, hyperten-
sion, diabetes, and cardiac disease, the categorical variable smoking,
and the continuous variables age, total cholesterol, and fibrinogen as
possible confounders in the model. The analyses were also done with
systolic and diastolic blood pressure in place of hypertensive status.
Odds ratios (ORs) and 95% CI were calculated from the � coeffi-
cients and their SEs.
Results
We screened a part of the AGT gene promoter and exon 1
(from �268 to �41 nucleotide related to the transcription
start) for the presence of point mutations using TTGE in 410
elderly, neurologically asymptomatic subjects. TTGE showed
15 different banding patterns indicating the presence of 15
genotypes within this population. There were 5 banding
patterns containing 1 homoduplex band (homozygotes) and
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10 banding patterns containing 2 homoduplex and 2 hetero-
duplex bands (heterozygotes) (Figure 1). This is in accor-
dance with the presence of 5 alleles combined in 15 geno-
types. We designated the 5 alleles on the basis of their gel
positions as A, B, C, D, and E alleles. The frequencies of the
alleles A (wild-type) to E were 0.567, 0.151, 0.043, 0.138,
and 0.101, respectively. The alleles and genotypes were in
Hardy-Weinberg equilibrium (�2obt�2.7, P�0.99; �2crit�23.68,
df�14). We sequenced at least 3 samples within each
genotype group. Samples with the C/C or D/D genotypes
were all sequenced because they could not be unequivocally
designated on the basis of TTGE alone. All samples within 1
TTGE banding pattern group showed identical results on
sequencing. Altogether we sequenced each allele at least 15
times (3 times in homozygous state and 12 times as a
component of a heterozygous genotype). We detected 4
polymorphic sites at positions �6:g/a, �20:a/c, �153:g/a,
and �218:g/a in our cohort. Respective allele frequencies
were 0.57 (�6:g) and 0.43 (�6:a), 0.81 (�20:a) and 0.19
(�20:c), 0.95 (�153:g) and 0.05 (�153:g), and 0.90
(�218:g) and 0.10 (�218:a). The alleles and the genotypes at
the single-nucleotide polymorphisms were in Hardy-
Weinberg equilibrium, as demonstrated by the respective �2obt
and probability value (�6: �2obt�0.05, P�0.95; �20:
�2obt�0.12, P�0.90; �153: �2obt�0.25, P�0.98; �218:
�2obt�0.44, P�0.95; �2crit�5.991, df�2). Each of the 5 alleles
contained a distinct combination of these polymorphic nucle-
otides and represented a haplotype (Table 1). Except for these
polymorphisms, there was no deviation from the published
AGT promoter sequence.33
MARCD was seen in 89 subjects (21.7%). A total of 59
individuals (14.4%) had early confluent or confluent WMH,
16 (3.9%) had lacunar lesions, and 14 (3.4%) had both types
of brain abnormalities. Subjects with MARCD were older
(62.6�5.7 years versus 59.4�6.0 years; P�0.0001) and had
a higher frequency of hypertension (50.6% versus 27.5%;
P�0.0001), higher systolic (144.7�22.8 versus
136.9�19.3 mm Hg; P�0.004) and diastolic (87.6�9.6 ver-
sus 85.1�10.6 mm Hg; P�0.015) blood pressure, and a
higher frequency of cardiac disease (49.4% versus 34.4%;
P�0.009) than their counterparts without MARCD.
The frequency of MARCD in the different genotype
subsets defined by the single-nucleotide polymorphisms is
shown in Table 2. Only the�20:c allele in homozygotic state
was significantly associated with an increased prevalence of
MARCD (P�0.017). A weak linear association between this
polymorphism and MARCD was also present (P�0.04). The
association between the �6:a polymorphism and MARCD
was borderline (P�0.054). The other 2 polymorphic sites
were not associated with MARCD.
Next we investigated the association of MARCD with the
15 genotypes reconstructed from the haplotypes. Overall,
there was a significant association between the genotypes and
MARCD (P�0.017). Subsequently, we performed pairwise
comparisons between the A/A genotype as reference group
and the other genotypes to further elucidate their association
with MARCD (Figure 2). Homozygotes for the B haplotype
had the highest frequency of MARCD, while homozygotes
for the C, D, and E haplotype showed very similar MARCD
frequency as A/A carriers (Figure 2A). MARCD prevalence
was also similar in all A haplotype carriers, including those
with the A/B genotype (Figure 2B). However, there existed a
trend toward higher MARCD frequency in individuals with 1
copy of the B haplotype in the absence of the A haplotype
(B/C, B/D, B/E) (Figure 2C). The remaining genotypes, C/D,
C/E and D/E, had MARCD frequencies similar to those of the
wild-type A/A genotype (data not shown).
On the basis of these findings, we pooled the subjects into
3 investigational subsets. The first group consisted of the B
homozygotes (B/B subset). The second group consisted of
those B heterozygotes who carried the B haplotype in the
absence of the wild-type A haplotype (B/C, B/D, and B/E)
TABLE 1. Nucleotide Sequence at Polymorphic Sites in
the 5 Haplotypes
Position
Haplotypes
A B C D E
�6 g a a a a
�20 a c c a a
�153 g g a g g
�218 g g g g a
Figure 1. TTGE banding patterns of the
15 AGT promoter genotypes related to
the haplotypes. A detailed description of
TTGE conditions is given in Subjects and
Methods.
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(B�/A� subset). The third group contained the remaining
genotypes (A/A, A/B, A/C, A/D, A/E, C/C, C/D, C/E, D/D,
D/E, and E/E) and was designated as the reference cohort (RC
subset). Distribution of demographics and vascular risk fac-
tors among the 3 investigational subsets is shown in Table 3.
Overall, MARCD was seen in 7 subjects (63.6%) in the
B/B group, in 12 subjects (38.7%) in the B�/A� group, but
in only 70 subjects (19.0%) in the RC group (Fischer’s exact
test, P�0.001; Mantel-Haenszel test for linear association,
P�0.001). The age-adjusted ORs for MARCD relative to the
RC subset were 7.6 (95% CI, 2.1 to 27.7) in the B/B and 2.2
(95% CI, 1.0 to 4.9) in the B�/A� subset.
To evaluate the extent to which the B�/A� genotype is
associated with MARCD, we performed logistic regression
analysis. The AGT genotype remained a significant pre-
dictor of MARCD (P�0.0035) after adjustment was made
for age, sex, hypertension, diabetes, cardiac disease, smok-
ing, plasma fibrinogen, and total cholesterol (Table 4). The
respective ORs for the B/B and B�/A� genotypes re-
mained unchanged when systolic (OR, 8.6; 95% CI, 2.26 to
32.7; OR, 1.9; 95% CI, 0.84 to 4.3) or diastolic blood
pressure (OR, 8.6; 95% CI, 2.25 to 32.7; OR, 1.9; 95% CI,
0.83 to 4.3) levels instead of hypertension status were
included in the model.
TABLE 2. Association of MARCD With AGT Promoter Polymorphisms
Genotypes P* P†
Position �6 gg (n�131) ga (n�203) aa (n�76)
MARCD 28 (21.4%) 37 (18.2%) 24 (31.6%) 0.054 0.16
Position �20 aa (n�267) ac (n�127) cc (n�16)
MARCD 53 (19.8%) 28 (22.0%) 8 (50%) 0.017 0.04
Position �153 gg (n�376) ga(n�33) aa (n�1)
MARCD 82 (21.8%) 7 (21.2%) 0 (0%) 0.868 � � �
Position �218 gg (n�330) ga (n�77) aa (n�3)
MARCD 71 (21.5%) 17 (22.1%) 1 (33.3%) 0.878 � � �
*�2 test.
†Mantel-Haenszel test for linear association.
Figure 2. Frequency of MARCD among the
AGT promoter genotypes reconstructed from
the haplotypes. In each panel MARCD fre-
quencies are compared with wild-type A
homozygotes. A, Comparison with homozy-
gotes for the B, C, D, and E haplotypes. B,
Comparison with heterozygote A haplotype
carriers. C, Comparison with subjects carrying
at least 1 copy of the B haplotype in the
absence of the A haplotype. Probability values
represent �2 or Fisher’s exact test results.
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Finally, we investigated the association between MARCD
and the B haplotype in subgroups defined by age, sex, and
hypertension status. MARCD frequency in subjects aged�60
years was 22 (11.1%) in the RC, 4 (40%) in the B�/A�, and
4 (66.7%) in the B/B group (P�0.001). The respective
frequencies were 48 (28.4%), 8 (38.1%), and 3 (69%) in
subjects aged �60 years (P�0.09). MARCD prevalence in
normotensive subjects was 35 (13.8%) in the RC, 5 (29.4%)
in the B�/A�, and 4 (66.7%) in the B/B group (P�0.001).
The respective frequencies in the hypertensive group were 35
(30.7%), 7 (50%), and 3 (60%) (P�0.06). The prevalence of
MARCD in men was 35 (20.0%) in the RC, 5 (35.7%) in the
B�/A�, and 4 (57.1%) in the B/B group (P�0.03). Among
women, the respective frequencies were 35 (18.1%), 7
(41.2%), and 3 (75.0%) (P�0.002).
Discussion
We report 4 new findings. First, we identified the presence of
5 novel haplotypes reconstructed from 4 polymorphisms at
the AGT gene promoter. Second, we found that the �20:c
allele, which was shown to alter transcriptional efficiency of
the AGT promoter in vitro,16 is significantly associated with
MARCD. Third, we described that 1 of the 5 haplotypes,
designated as the B haplotype (nucleotide sequence at poly-
morphic positions �6:a, �20:c, �153:g, �218:g) predicts
MARCD considerably better than the �20:c single-nucleo-
tide allele. Fourth, the association between the B haplotype
and MARCD was independent of hypertension. Our study
was conducted in a homogeneous European population,
making bias due to population admixture unlikely.
We found that homozygotes for the B haplotype had an
8-fold increased risk for MARCD. Persons carrying 1 copy
of the B haplotype in the absence of the A haplotype
showed a trend toward higher risk for MARCD. There was
a significant linear association between B haplotype copy
number and MARCD, suggesting a gene-dose effect. This
gene-dose effect could also be observed in the subgroups
of younger and older individuals, in men and in women,
TABLE 3. Demographics and Risk Factors Among the AGT Promoter Haplotype Subsets
Variable
Genotypes
P
RC
(n�368)
B�/A�
(n�31)
B/B
(n�11)
Age, y 59.9�5.98 62.8�6.1 61.1�6.8 0.042*
Male sex, n 175 (47.6%) 14 (45.2%) 7 (63.6%) 0.549*
Hypertension, n 114 (31.1%) 14 (45.2%) 5 (45.5%) 0.178†
Systolic blood pressure, mm Hg 138.0�19.9 143.9�24.2 141.4�22.0 0.391*
Diastolic blood pressure, mm Hg 85.4�10.4 87.6�11.1 86.8�10.1 0.5141*
Diabetes mellitus, n 21 (5.7%) 3 (9.7%) 0 (0%) 0.469†
Fasting glucose, mmol/L 5.16�1.14 5.50�2.03 4.74�0.40 0.399*
Cardiac disease, n 132 (36.0%) 20 (64.5%) 2 (18.2%) 0.003†
Smoking
Ex-smokers, n 49 (13.4%) 2 (6.5%) 1 (9.1%)
Current smokers, n 112 (30.5%) 8 (25.8%) 4 (36.4%) 0.695†
Body mass index, kg/m2 26.5�3.6 26.7�3.5 25.2�2.8 0.622*
Triglycerides, mmol/L 1.62�0.92 1.91�1.58 1.39�0.44 0.811*
Cholesterol, mmol/L 5.91�1.00 6.28�1.17 6.15�1.17 0.041‡
LDL cholesterol, mmol/L 3.86�0.92 4.20�1.00 4.16�0.99 0.076‡
HDL cholesterol, mmol/L 1.33�0.42 1.24�0.42 1.34�0.34 0.833*
Fibrinogen, mg/dL 301.5�79.3 308.6�84.7 301.6�60.5 0.503*
*Kruskal-Wallis test.
†�2 test.
‡One-way ANOVA.
TABLE 4. Independent Predictors for MARCD in the Logistic Regression Model
Variable SE df P OR 95% CI
AGT genotype 2 0.005
B�/B� genotype 2.081 0.692 1 0.003 8.01 2.1–31.1
B�/A� genotype 0.614 0.420 1 0.144 1.84 0.8–4.2
Age, y 0.077 0.022 1 0.001 1.08 1.03–1.13
Hypertension 0.818 0.265 1 0.002 2.26 1.35–3.81
Adjustment was made for diabetes, cardiac disease, smoking, fibrinogen, cholesterol, and sex.
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and also among hypertensive and normotensive subjects.
Given their relation to protein levels, promoter poly-
morphisms are expected to have strongest effects in
homozygotes and milder effects in heterozygotes. Our data
support the presence of a gene- dose effect only for the
haplotype but not for the single-polymorphic sites. Persons
carrying the B haplotype in combination with the wild-type
A haplotype did not show a higher risk for MARCD,
indicating that the A haplotype might protect against the
deleterious effect of the B haplotype. The observed asso-
ciation was not mediated by hypertension, since it re-
mained virtually unchanged when adjustment was made
for age and hypertension or for age alone.
With respect to the statistical assessment of the associ-
ation between the AGT genotypes reconstructed from the
haplotypes and MARCD, it is important to emphasize that
the relationship was significant when a single comparison
of MARCD frequency among the 15 genotypes was
performed. We used pairwise comparisons between the
wild-type A/A genotype and the other genotypes to further
explore the association of each genotype with MARCD.
We expected a priori that carriers of the B and the C
haplotypes have higher MARCD frequencies than carriers
of the other haplotypes. This was based on in vitro and in
vivo data describing functional importance for the �20:c
and the �6:a mutations,13–16 both of which are only present
in the B and C haplotypes. Our observation of a significant
association between the �20:c allele and MARCD lends
further support to this assumption. The results of the
pairwise comparisons are not statistically significant after
Bonferroni correction with the very conservative signifi-
cance level of 0.0036. Adjustment for multiple testing is,
however, difficult when haplotypes are studied because
these are statistically dependent observations as a result of
linkage dysequilibrium. It is noteworthy that the strength
of the association increased by using the haplotype in place
of the single-nucleotide markers, as expected if a true
causal relation is involved. Yet, despite the plausibility of
the association between the B haplotype and MARCD, we
cannot exclude with certainty that this is a chance finding.
At this point it is important to note that our results apply
strictly to a single cohort, and larger, probably concerted
studies are needed to confirm these findings. The current
investigation was exploratory. Overall, our findings show
that the haplotype allows a more sensitive analysis of the
association than the polymorphic sites alone. There are
several explanations for this observation. It may be that the
combination of the previously described sequence alter-
ations in the B haplotype is functionally important or that
the B haplotype captures an unknown sequence alteration
functionally related to MARCD. The B haplotype may also
be in linkage dysequilibrium, with a functional poly-
morphism underlying the association.
On the basis of in vitro and in vivo data, a causal
relationship between AGT genotype and hypertension
seems plausible.9–27 However, we have seen that the B
haplotype is associated with MARCD independent of
arterial hypertension. This suggests that it may operate
through the local rather than through the systemic RAS.
Genetic variations at the AGT locus might alter tissue
AGT expression. In preeclampsia, the expression of AGT
in decidual arteries was associated with the T235 variant.34
It is noteworthy that a strong linkage dysequilibrium
between the B haplotype and the T235 variant existed in
our cohort. All B/B and 28 of the 31 B�/A� subjects were
homozygous for the T235 allele. The remaining 3 B�/A�
subjects were heterozygous for the M235T polymorphism.
Conceivably, the association between the AGT B hap-
lotype and MARCD might be mediated by an altered
expression of AGT in the brain,35 which in turn leads to an
altered local availability of AGT. Studies investigating
AGT expression in the brain dependent on the haplotype
have been initiated in our laboratory. If tissue RAS activity
is also regulated by the AGT level, as is systemic RAS,
then changes in AGT concentration may result in a higher
level of Ang II at this site. It is known that Ang II acts on
a variety of cell types in the brain.36,37 In the present
context the effect of Ang II on vascular smooth muscle
cells is of particular interest. Ang II is a potent regulator of
vascular tone and can lead to vasoconstriction and vaso-
dilation in the cerebral arterioles, depending on the species
studied.38–43 Notably, MARCD was found to be related not
only to hypertension but also to intermittent hypotensive
episodes.6,7 Ang II promotes vascular smooth muscle cell
hyperplasia and hypertrophy.44–48 It was shown to enhance
the activity of NADH/NADPH oxidase and extracellular
superoxide dismutase activity in the vessel wall.49,50 It is
also thought to alter the production of extracellular matrix
proteins in the vessels.51,52 Therefore, alterations in the
local availability of Ang II might result in imbalance of
physiological processes such as brain perfusion, autoregu-
lation of cerebral blood flow, the oxidative state of the vessel
wall, or function of the blood-brain barrier. Each of these
processes might be involved in the development of MARCD.
In summary, we found that a certain haplotype of the
AGT gene is significantly associated with MARCD in a
community-dwelling cohort of elderly individuals. If
larger studies can replicate our results, then this haplotype
might serve as a genetic marker for the identification of
individuals prone to develop these lesions and their clinical
consequences. An association of small-vessel disease–
related cerebral damage with genetic variants in the RAS
system independent of arterial hypertension might not only
extend our etiologic understanding of these brain lesions
but might also point to possible favorable effects of drugs
acting on the RAS system beyond those expected from
lowering blood pressure alone.
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Angiotensinogen Promoter B-Haplotype Associated With
Cerebral Small Vessel Disease Enhances Basal
Transcriptional Activity
Helena Schmidt, MD, MSc; Yurii S. Aulchenko, PhD; Natascha Schweighofer, MSc;
Reinhold Schmidt, MD; Sasa Frank, PhD; Gerhard M. Kostner, PhD; Erwin Ott, MD;
Cornelia van Duijn, MD
Background and Purpose—Previously, we described the presence of 5 haplotypes (A to E) at the angiotensinogen (AGT)
promoter and reported a significant association between the B-haplotype (nucleotide substitutions �6:G3A and
�20:A3C compared with the wild-type A-haplotype) and magnetic resonance imaging correlates of cerebral small
vessel disease (cSVD). The association was independent of hypertension, suggesting a brain-specific effect of this
haplotype. In the current study, we investigated transcriptional activities of the 5 promoter haplotypes in astrocytes, the
main source of cerebral AGT, and in hepatocytes, the main source of systemic AGT, as well as determined the
evolutionary relatedness of the promoter haplotypes.
Methods—Transcriptional activity depending on the haplotypes and the �6:A and �20:C substitutions was measured in
transiently transfected A172 and HepG2 cells. We genotyped 5 new single nucleotide polymorphisms (SNPs) at the AGT
gene and measured linkage disequilibrium (LD) among SNPs and the promoter haplotypes. An evolution-based
haplotype tree was constructed.
Results—The B-haplotype increased transcriptional activity in both cell types. Its effect was stronger in astrocytes than in
hepatocytes (2.4�0.09-fold, P�0.001 versus 1.6�0.06-fold, P�0.014). Importantly, in astrocytes the combination of
the �6:A and the �20:C was mandatory for increased activity, whereas in hepatocytes the �20:C on its own was
sufficient. Strong LD between the 5 new SNPs and the promoter haplotypes allowed the reconstruction of 9 haplotypes
over the AGT gene. Cladistic analyses suggest that the B-haplotype represents an ancient promoter variant.
Conclusions—Combination of the �6:A and �20:C substitutions in the B-haplotype may promote the development of
cSVD by enhancing cerebral angiotensinogen expression. (Stroke. 2004;35:2592-2597.)
Key Words: angiotensinogen � gene expression regulation � genetics � white matter
Cerebral small-vessel disease (cSVD) is an important causeof stroke, cognitive decline, and dementia.1–2 cSVD can be
visualized by magnetic resonance imaging of the brain as early
confluent and confluent white matter hyperintensities and lacu-
nar infarcts. The estimated heritability of cSVD is 73%, suggest-
ing that genetic factors play an important causative role.3
Arterial hypertension is the major risk factor for cSVD, which
also has a high heritability in most populations.4
The renin-angiotensin system (RAS) is an important reg-
ulator of blood pressure. Plasma angiotensinogen (AGT)
synthesized by the liver is processed to angiotensin II (AT-II)
by the serial action of renin and angiotensin-converting
enzyme. Liver production of AGT is regulated mainly at the
transcriptional level.5–6 Sequence alterations at position �6
and �20 have been shown to affect transcriptional efficiency
of the promoter.7–11 There is a positive correlation between
plasma AGT concentration, RAS activity, and blood pres-
sure.5,6,12,13 The AGT gene has been implicated in hyperten-
sion by association and linkage studies.13–15
Previously, we described 5 haplotypes (A wild-type to E)
at the AGT promoter created by nucleotide substitutions at
positions�6,�20,�152, and�217 relative to the transcrip-
tion start (Figure 1).16 Homozygosity for the B-haplotype
(�6:A, �20:C, �152:G, �217:G) conferred an 8-fold in-
creased risk for cSVD in our cohort. The association was
independent of hypertension, suggesting that the effect of the
haplotype is mediated through the local RAS of the brain
rather than through the systemic RAS.
The B-haplotype differs from the wild-type A at positions�6
(G3A) and at�20 (A3C). We hypothesize that either one of
these single nucleotide polymorphisms (SNPs) or their combi-
nation alters promoter activity of the AGT gene in the brain,
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which may then promote development of cSVD through in-
creased cerebral RAS activity. To test this hypothesis, we
investigated AGT promoter activity dependent on the promoter
haplotypes and on the single �6:A and �20:C substitutions in
astrocytes, which represent the major source of cerebral AGT,
and in hepatocytes, which represent the major source of systemic
AGT.5
Because it is also possible that the association between the
B-haplotype and cSVD is not functional but is rather caused by
linkage disequilibrium (LD), we genotyped 5 additional sequence
variations scattered over theAGT gene and estimated themagnitude
of LD between the new SNPs and the promoter haplotypes. Based
on these data, we performed a cladistic analysis and investigated the
evolutionary relatedness of the haplotypes.
Materials and Methods
Cell Culture
A172 cells were maintained in DMEM containing 10% fetal bovine
serum, 4.5 g/L glucose, 100 000 U/L penicillin, and 0.1 g/L
streptomycin, and HepG2 cells were maintained in DMEM contain-
ing 10% fetal bovine serum, nonessential amino acids, sodium
pyruvate, 100 000 U/L penicillin, and 0.1 g/L streptomycin.
Construction of Plasmids
Genomic DNA from subjects homozygous for the A-, B-, C-, D-, or
E-haplotypes was amplified by polymerase chain reaction (PCR)
between positions �1222 and �44 (AF424741) and cloned into
XhoI/HindIII sites of the pGL3-basic reporter vector (Promega)
upstream of the firefly luciferase gene.
The reporter vector including the A-haplotype was used to introduce
the �6:A (MutAB-6) and the �20:C substitutions (MutAB-20) by
oligonucleotide-directed mutagenesis. To introduce the�6:A mutation,
a fragment spanning positions �120 to �10 (primers: 5�-
GATCCCAGCCTGTGGTCTGGCCAAGTGA-3� and 5�-AGCA-
GCTTCTTCCCCTGGCC-3�) and a fragment spanning positions �53
to �44 (primers 5�-GCTCCATCCCCACCCCTCA-3� and 5�-
ATTTAAAGCTTCGGCTTACCTTCTGCTGTAG-3�) were created.
The 2 fragments were then combined by amplification with the primers
5�-GATCCCAGCCTGTGGTCTGGCCAAGTGA-3� and 5�-
ATTTAAAGCTTCGGCTTACCTTCTGCTGTAG-3�. The �20:C
mutation was introduced similarly except that a fragment spanning
position �120 to �14 was created in the first step (primers 5�-
GATCCCAGCCTGTGGTCTGGCCAAGTGA-3� and 5�-TCAC-
GAGGCCCTATTTATAGCTGAG-3�). The combined fragments were
subcloned into the PflMI/HindIII sites of the plasmid carrying the
A-haplotype. All inserts were verified by DNA sequencing.
Transient Transfection Assays
Cells were plated at a density of 4�105 cells/60-mm dish and trans-
fected 24 hours later by calcium phosphate coprecipitation with the
reporter constructs (10 �g). In each experiment, phRG-TK control
plasmid (20 ng) was cotransfected to normalize for transfection effi-
ciency. Luciferase activity was measured 48 hours after transfection
using the Dual-Luciferase Reporter Assay System (Promega) on a
LUMAT LB9501 luminometer (Berthold). All measurements were
performed in triplicate and have been repeated in at least 3 independent
experiments. Results are expressed as the ratio of firefly to renilla
luciferase activity (�SEM). Statistical significance was tested by the
Student t test and 1-way ANOVA (SPSS for Windows 10.0.5.0).
Subjects and Design
The study population consisted of participants of the Austrian Stroke
Prevention Study, a single-center, prospective, follow-up study on the
cerebral effects of vascular risk factors in the normal elderly population
of Graz, Austria. Study design, sampling procedure, and definition of
vascular risk factors have been previously described.16,17 The present
study consisted of those 662 individuals who underwent both magnetic
resonance imaging analyses and DNA sampling. There were 357
women and 305 men. The mean age was 63.1 years. The sample
consisted exclusively of whites of central European origin. The study
was approved by the ethical committee of the University of Graz. All
subjects gave informed consent to participate in the study.
Mutation Screening and Genotyping
We screened the promoter region upstream of the haplotypes (positions
�704 to�245bp) and the 3�-UTR (positions�11407 to�11712bp) for
SNPs. Genomic DNA was PCR-amplified using the oligonucleotides:
fragment 1 (spanning position �532): 5�-GC-clamp-
GGTCATGTGAAACTTACCATTTGC-3� and 5�-CAAAGAGCCT-
ACCCTGTGCAAAG; fragment 2 (spanning position �386): 5�-GC-
clamp-AAGTTTGCAGGAGTCGGGGCCAAG and 5�-GCTGA-
AGGTCACACATCCCATGAGC; and fragment 3 (spanning positions
�11407 and �11712bp):5�-GC-clamp-CACCTAAAACTTC-
AAAGGACTGC-3� and 5�-CATTGCCTTCGGTTTGTATTTAG-3�.
The sequence of the GC-clamp was 5�-CGCCCGCCGCGCCCCGCG-
CCCGGCCCGCCGCCCCCGCCCG-3�. PCR products were screened
for the presence of mutations by TTGE (Dcode Universal mutation
detection system; Bio-Rad Laboratories). Melting domain map was
calculated with the MacMelt algorithm (Bio-Rad Laboratories). Heterozy-
gous DNA samples were used as positive controls on each gel to check gel
resolution efficiency. At least 3 samples with a distinct banding pattern on
TTGE were sequenced (CEQ 2000XL DNA analyses system; Beckman
Coulter). The M235T polymorphism was genotyped using PCR-refraction
fragment length polymorphism.18
Statistical Analysis
The haplotype tree was inferred with the maximum likelihood
method, using DNAML 3.573c (Phylip; http://evolution.genetics.
Figure 1. Comparison of the transcriptional
activities of AGT promoter haplotypes in
astrocytes and hepatocytes. A, Position
and nucleotide sequences at polymorphic
sites in the promoter haplotypes (�1222 to
�44). B, Transcriptional activities of the
promoter haplotypes in HepG2 cells (dark
bars) and A172 cells (white bars). Tran-
scriptional activities are presented as per-
centage of the activity of the A-haplotype.
Each measurement was performed in tripli-
cates and repeated in at least 3 indepen-
dent experiments. Values are the
means�SEM. Transcriptional activities of
the B-, C-, D-, and E-haplotypes were
compared with the A-haplotype pairwise
(Student t test, *P�0.05, **P�0.01,
***P�0.001; NS indicates not significant).
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washington.edu/phylip.html).19 We assumed equal base frequency
and a transition to transversion ratio of 2.0. Haplotype frequencies
were estimated by the expectation-maximization method (Arlequin
v. 2001; http://lgb.unige.ch/arlequin/).20
Pairwise LD was characterized by D� (normalized Lewontin measure
of LD) and by the probability value from the test of significance of LD,
and was estimated by GOLD software package (http://www.sph.u-
mich.edu/csg/abecasis/GOLD/).21,22 The relation between physical
distance and LD was assessed using the booLD software
(http://www.geneticepi.com/Research/software/software.html).23
Results
Transcriptional Activities of the
Promoter Haplotypes
Basal transcriptional activities of the haplotypes in astrocytes
(A172 cells) and hepatocytes (HepG2 cells) are shown in Figure
1. Among the 5 haplotypes, the B-haplotype had the highest
promoter activity in both cell types (hepatocytes: 1.6�0.06-fold,
P�0.014; astrocytes, 2.4�0.09-fold increase, P�0.001 com-
pared with the A-haplotype). The C-haplotype showed similar
promoter activity as the A-haplotype in hepatocytes (P�0.5) and
a 1.5�0.09-fold increased activity in astrocytes (P�0.007). The
D-haplotype decreased promoter activity by �50% in both cell
lines (HepG2, P�0.02; A172, P�0.003). The E-haplotype did
not change promoter activity in hepatocytes (P�0.5) but de-
creased activity by �30% in astrocytes (P�0.01).
Transcriptional Activities of the MutAB-6 and the
MutAB-20 Constructs
To elucidate the individual effect of the �6:A and �20:C
substitutions distinguishing the B-haplotype from the
A-haplotype, we transiently transfected A172 and HepG2
cells with the reporter constructs containing either only the
�6:A substitution (MutAB-6) or the �20:C substitution
(MutAB-20) (Figure 2A). The promoter activities of these
constructs were compared with the promoter activities of
both the A- and B-haplotypes. In astrocytes, MutAB-6 had
a significantly increased promoter activity (1.6�0.07-fold,
P�0.001) compared with the A-haplotype, but its tran-
scriptional activity was still significantly lower than that of
the B-haplotype (P�0.001). MutAB-20 had similar pro-
moter activity in astrocytes (P�0.3) as the A-haplotype.
By contrast, in hepatocytes promoter activity of MutAB-6
was similar to that of the A-haplotype (P�0.2), whereas
MutAB-20 had a 2.5�0.06-fold increased promoter activ-
ity (P�0.001) (Figure 2B). This is comparable with the
effect of the B-haplotype in these cells (P�0.8)
Pairwise LD and Haplotype Analyses
We genotyped our cohort for the SNPs �532C3T and
�386G3A in the promoter region, and for the SNPs
�11535:C3A and �11553C3delC in the 3�-UTR as well as
for the M235T polymorphism. Allele and genotype proportions
for all the SNPs were in Hardy–Weinberg equilibrium (Table 1).
The allele frequencies in our cohort were similar to the previ-
ously published frequencies in a sample of white subjects (Utah
CEPH pedigrees) (Table 1).24
The magnitude of LD among the SNPs is shown in Figure 3.
There was no decline of LD with physical distance (constant LD
versus exponential decline models, P�0.1). Average LD be-
tween the SNPs as assessed by D� was 0.841.
Including the 5 newly investigated SNPs and the 4 SNPs
determining the promoter haplotypes, we inferred 9 haplotypes over
theAGT gene in our cohort. These haplotypes coded fromH1 toH9
based on their frequencies are described in Table 2. The evolution-
ary relatedness of these haplotypes in form of a haplotype tree is
presented in Figure 4. Overall, 80% of the promoter B-haplotype
was present onH4, 12% onH8, and 8% onH9, both closely related
to H4. The H4 AGT haplotype is equivalent to the published
Figure 2. Effect of the �6G and �20C sub-
stitutions on the transcriptional activities of
AGT promoter in astrocytes and hepato-
cytes. A, Nucleotide sequences of the A-
and B-haplotypes and of MutAB-6 and
MutAB-20 constructs within the core pro-
moter region (�25 to �8bp). Nucleotide
exchanges in MutAB-6 and MutAB-20 are
marked with a frame. The remaining
sequence of MutAB-6 and MutAB-20 corre-
sponds to that of the A-haplotype (�1222 to
�44 bp). B, Promoter activities of the
MutAB-6 and MutAB-20 constructs in
HepG2 cells (dark bars) and A172 cells (white bars). Each measurement was performed in triplicate and repeated in at least 3 independent experi-
ments. Transcriptional activities are presented as percentage of the A-haplotype activity (mean�SEM). The first probability value compares mutated
constructs versus A-haplotype, and the second probability value compares mutated constructs versus B-haplotype (Student t test, *P�0.05,
**P�0.01, ***P�0.001; NS indicates not significant).
TABLE 1. Distribution of the AGT Polymorphisms
Position
Base
Change* N ASPS† HWE ASPS
Frequency
ASPS SLC
�532 C3T 513 0.63 0.11 0.09
�386 G3A 650 0.87 0.02 0.04†
�217 G3A 638 0.77 0.11 0.16
�152 G3A 638 0.96 0.03 —
�20 A3C 638 0.95 0.18 0.16
�6 G3A 638 0.59 0.43 0.42
4072 T3C 643 0.26 0.44 0.44
11535 C3A 642 0.64 0.32 0.32
11553 C3delC 642 0.96 0.01 —
*Allele with lower frequency in ASPS sample comes second.
†Frequency is based on data of Jeunemaitre et al (1992).
ASPS indicates Austrian Stroke Prevention Study; N ASPS, number of
genotypes unambiguously established in the ASPS; HWE ASPS, p-values from
the test for Hardy–Weinberg equilibrium in the ASPS; SLC, Salt Lake City.
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chimpanzee sequence (AF193457.1), suggesting that the
B-haplotype represents an ancient promoter variant.
Discussion
In the current study, we show that the AGT promoter
B-haplotype, which was associated with cSVD in our
previous investigation,16 significantly enhances basal tran-
scriptional activity of the AGT gene. The association was
independent of hypertension, indicating that it might be
mediated through an altered cerebral AGT expression. We
found that the B-haplotype increases promoter activity
more strongly in astrocytes, which are the major source of
cerebral AGT, than in hepatocytes, which are the major
source of systemic AGT.
If tissue RAS is regulated at the AGT level as is the
systemic RAS, then a higher AGT transcription in astro-
cytes may lead to elevated AT-II concentration in the
brain. AT-II is a potent regulator of vascular tone,25,26 it
promotes vascular smooth muscle cell growth, and modu-
lates the production of extracellular matrix proteins.27–29 It
enhances the activity of NADH/NADPH oxidase and of
extracellular superoxide dismutase in the vessel wall.30,31
Alteration in the local availability of AT-II may therefore
result in an imbalance of physiological processes such as
brain perfusion, autoregulation of cerebral blood flow, the
oxidative state of the vessel wall, or function of the
blood–brain barrier,32 and by these mechanisms may lead
to the development of cSVD.
The B-haplotype contains 2 nucleotide substitutions,
�6:G3A and �20:A3C, compared with the wild-type
A-haplotype. We found that in contrast to hepatocytes, the effect
of the B-haplotype in astrocytes is dependent on the presence of
both of these substitutions, because neither the �6:A nor the
�20:C mutation alone was able to enhance promoter activity to
the level observed for the B-haplotype. This is in line with our
previous genetic epidemiological data, showing that the
B-haplotype is stronger and more significantly associated with
Figure 3. Pairwise LD in AGT, evaluated
by D� (left) and minus logarithm of the
probability value coming from the test of
LD significance (right).
TABLE 2. Frequencies of Haplotypes in the AGT Gene, as
Estimated by the EM Algorithm
Designation
AGT Haplotype Composition
Frequency
SNP
�532
SNP
�386
Promoter
Haplotype
SNP
4072
SNP
11535
SNP
11553
H1 C G A T T C 0.299
H2 C G A T C C 0.248
H3 C G D C C C 0.119
H4 C G B C C C 0.112
H5 T G E C C C 0.102
H6 C G C C C C 0.031
H7 C G A C C C 0.022
H8 C A B C C C 0.017
H9 C G B C T C 0.011
Only the haplotypes with a frequency of 1% or more are shown. These
haplotypes account for 95.9% of haplotypes observed in ASPS population.
Figure 4. Haplotype tree for AGT haplotypes, based on the 9 SNPs.
The size of the circle corresponds to the frequency of the haplotype.
The letter in the brackets shows the promoter haplotype carried.
Schmidt et al Promoter Activity of Angiotensinogen B-Haplotype 2595
Genetic Determinants of Cerebral Small Vessel Disease
81
cSVD than either the�20:C or the�6:A alleles. An interaction
between the �6:A and the �20:C mutation is biologically
plausible because these 2 mutations are located in 2 distinct
regulatory elements of the core promoter.9,11
The 5 promoter haplotypes showed a cell type-specific
and differential effect on the transcriptional activity, sug-
gesting that the effect of the �20:C and the �6:A
mutations are further modulated by other sequence varia-
tions at the AGT promoter. This is in line with previous
findings indicating that the sequence between positions
�25 to �1 mediate the responsiveness of the core pro-
moter to upstream cis-acting elements.8
A further, although indirect, support for the functional
relevance of the B-haplotype is suggested by its ancient
origin. It had been hypothesized that the AGT haplotype
carrying the �6:A and the 235T mutations was advanta-
geous during human evolution in the low-salt environment
of Africa by allowing for a higher salt reabsorption
through enhanced AGT expression and aldosterone secre-
tion.13,24 When our ancestors moved to the high-salt
environment in Europe, however, this ancient haplotype
may have become disadvantageous. The B-haplotype is in
complete LD with the 235T variant, and the enhanced risk
for cSVD associated with 235T variant might be caused by
LD with the B-haplotype.33 Importantly, although the
B-haplotype contains the �6:A substitution and also per-
fectly predicts the presence of C at position 4072, which
codes for the 235T variant, only 34% of the 235T allele is
associated with the B-haplotype and may therefore en-
hance the risk for cSVD.
A strength of our study is that we investigated the effect
of naturally occurring promoter haplotypes on the tran-
scriptional activity of the AGT gene, and that we dissected
the individual effect of the �6:A and �20:C mutations
present on the B-haplotype. We used astrocytes as a
cellular model for cerebral AGT expression. It is important
to realize, however, that other cell types, like vascular
smooth muscle cells, endothelial cells, or eventually neu-
rons, may also contribute to AGT production at the site of
cSVD.
In conclusion, we showed that the combination of the
�6:A and �20:C mutations in the B-haplotype enhances
angiotensinogen promoter activity in astrocyte. This find-
ing together with our previous epidemiological data sug-
gests that increased cerebral RAS activity is involved in
the cause of cSVD. Further studies are needed to investi-
gate the role of the B-haplotype in independent popula-
tions, and to elucidate the biological role of the SNPs at the
AGT gene in cSVD. A causal relation between B-haplotype
and cSVD independent of hypertension points to interven-
tion in the RAS as a possible treatment strategy in cSVD,
a highly prevalent entity in elderly subjects for which no
treatment has been proven to be effective until now.
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Paraoxonase PON1 Polymorphism Leu-Met54 Is Associated
With Carotid Atherosclerosis
Results of the Austrian Stroke Prevention Study
Helena Schmidt, MD; Reinhold Schmidt, MD; Kurt Niederkorn, MD; Anita Gradert;
Martin Schumacher, MD; Norbert Watzinger, MD; Hans-Peter Hartung, MD; Gert M. Kostner, PhD
Background and Purpose—Genetic polymorphism at the paraoxonase locus is associated with serum concentration and
activity of paraoxonase and with increased risk for coronary heart disease. Two frequent polymorphisms present at the
paraoxonase gene are the methionine (M allele) leucine (L allele) interchange at position 54 and the arginine (B allele)
glutamine (A allele) interchange at position 191. This is the first study to determine the effect of these polymorphisms
on carotid atherosclerosis.
Methods—The paraoxonase genotypes at positions 54 and 191 of 316 randomly selected individuals aged 44 to 75 years
were determined by polymerase chain reaction–based restriction enzyme digestion. Carotid atherosclerosis was assessed
by color-coded Duplex scanning and was graded on a 5-point scale ranging from 0 (normal) to 5 (complete luminal
obstruction).
Results—The LL, LM, and MM genotypes at position 54 were noted in 137 (43.4%), 132 (41.8%), and 47 (14.9%)
subjects; the AA, AB, and BB genotypes at position 191 occurred in 172 (54.4%), 124 (39.2%), and 20 (6.3%)
individuals. The LL genotype was significantly associated with the presence and severity of carotid disease (P0.022),
whereas the 191 polymorphism had no effect. Logistic regression analysis with age and sex forced into the model
demonstrated plasma fibrinogen (odds ratio [OR], 1.005 per mg/dL), LDL cholesterol (OR, 1.01 per mg/dL), cardiac
disease (OR, 1.75), and the paraoxonase LL genotype to be significant predictors of carotid atherosclerosis. The ORs
for the associations with age and sex were 1.09 (P0.0003) and 1.66 (P0.052) per year.
Conclusions—These data suggest that the paraoxonase LL genotype may represent a genetic risk factor for carotid
atherosclerosis. (Stroke. 1998;29:2043-2048.)
Key Words: atherosclerosis  carotid arteries  genetics  paraoxonase
Carotid atherosclerosis is considered to be a major causeof ischemic stroke.1 In recent years, oxidative stress has
been demonstrated to play an important role in the pathogen-
esis of atherosclerosis.2 Low-density lipoprotein (LDL) seems
to be the major target of oxidative modification, making it
particularly atherogenic.3,4 Identification of factors protecting
against oxidative modification of LDL are therefore of major
interest. High-density lipoprotein (HDL) has been shown to
have antioxidative potential; however, the mechanism(s) of
its action is not known.5 One mechanism might be the
enzymatic removal of lipid peroxides accumulating on the
LDL particle by enzymes present on HDL.6 Paraoxonase is
tightly associated with HDL and has been shown to reduce
the accumulation of lipid oxidation products on LDL.7,8
The human serum paraoxonase is a 43- to 45-kDa protein.
Its gene is located at q21 to q22 on the long arm of
chromosome 7.9 The amino acid sequence of paraoxonase is
highly conserved among animal species, suggesting an im-
portant metabolic role for this enzyme.10 The ability of
paraoxonase to detoxify organophosphorous compounds has
been known for years. Its activity was determined earlier by
the use of paraoxon, a widely used pesticide. The physiolog-
ical substrate of paraoxonase is yet unknown. Watson et al11
reported recently that an oxidized phospholipid may represent
a potential candidate. White populations have a triphasic
distribution of serum paraoxonase activity towards paraoxon
but not to other substrates such as phenylacetate.7 This
difference in enzyme activity is caused by an amino acid
substitution at position 191. Glutamine (A allele) is replaced
by arginine (B allele) in the high-activity isoform.9 The B
allele has been shown to be associated with coronary heart
disease.12–14 Another frequent polymorphism present at posi-
tion 54 involves a methionine (M allele) leucine (L allele)
interchange.9 The 2 polymorphisms are in linkage disequilib-
rium, with leucine at position 54 giving rise for arginine at
position 191.9 The suspected role of paraoxonase in the
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protection of LDL against oxidative modification, and the
positive association found between paraoxonase genotypes
and coronary heart disease, prompted us to investigate the
effect of both 54 and 191 polymorphisms on carotid athero-
sclerosis in a normal middle-aged and elderly population.
Subjects and Methods
Study Population
Individuals aged 44 to 75 years and stratified by sex and 5-year age
groups were randomly selected from the official register of residents
of the city of Graz, Austria. They received a written invitation to
participate in the Austrian Stroke Prevention Study (ASPS), a
single-center prospective follow-up study in our community. The
study has been approved by the Medical Ethics Committee of the
Karl-Franzens University of Graz. Written informed consent was
obtained from all study participants. The rationale and design of the
ASPS have been previously described.15 Briefly, the objective of the
study is to examine the frequency of cerebrovascular risk factors and
their effects on carotid atherosclerosis, as well as on cerebral
morphology and function, in the normal elderly. The inclusion
criteria for the study were no history of neuropsychiatric disease and
a normal neurological examination. From a total of 8193 individuals
invited between September 1991 and March 1994, a sample of 2794
subjects agreed to participate, with 1998 individuals fulfilling the
inclusion criteria. All study participants underwent a structured
clinical interview, a physical and neurological examination, 3 blood
pressure readings, ECG, and echocardiography, as well as laboratory
testing including blood cell count and a complete blood chemistry
panel. Every fourth study participant was then invited to enter phase
II of the ASPS, which included Doppler sonography, MRI, SPECT,
and neuropsychological testing. Since 1993, we started to establish a
gene bank in all phase II attendees. The present study cohort consists
of those 316 individuals who underwent both carotid duplex scan-
ning and assessment of the paraoxonase polymorphisms. There were
158 women and 158 men. The mean age of this cohort was 60.06.1
years.
Vascular Risk Factors
Diagnosis of vascular risk factors relied on the individuals’ histories
and appropriate laboratory findings. Arterial hypertension was con-
sidered present if a subject had a history of arterial hypertension with
repeated systolic/diastolic blood pressure readings 160/95 mm Hg
or if the readings at examination exceeded this limit. Diabetes
mellitus was coded present if a subject was treated for diabetes at the
time of the examination or if the fasting blood glucose level at
examination exceeded 140 mg/dL. Cardiac disease was assumed to
be present if there was evidence of cardiac abnormalities known to
be a source for cerebral embolism,16 evidence of coronary heart
disease according to the Rose questionnaire17 or appropriate ECG
findings18 (Minnesota codes I: 1 to 3; IV: 1 to 3; or V: 1 to 2), or if
an individual presented with signs of left ventricular hypertrophy on
echocardiogram or ECG (Minnesota codes III: 1; or IV: 1 to 3).
Study participants were defined as smokers if they currently
smoked10 cigarettes a day. From current smokers and ex-smokers
information was obtained as to the daily number of tobacco products
smoked and smoking duration in years. The data on the amount of
tobacco were converted into grams of tobacco consumed during the
lifetime using the following conversion factors: 1 cigarette1 g, 1
cheroot3 g, 1 cigar5 g. For measurements of hematocrit, blood
was obtained from a large antecubital vein without stasis.
The body mass index was calculated as weight (kg)/height (m2).
The regular use of estrogen replacement therapy was recorded
among all female study participants.
A lipid status including the level of triglycerides, total cholesterol,
LDL and HDL cholesterol, as well as lipoprotein(a) [Lp(a)], apoli-
poprotein (apo) B, and apoA-I was determined for each study
participant. Thirty minutes after venipuncture, the coagulated blood
samples were centrifuged at 1600g for 10 minutes, and the serum
was transferred to plastic tubes and analyzed within 4 hours.
Triglycerides and total cholesterol were enzymatically determined
using commercially available kits (Uni-Kit III “Roche” and MA-Kit
100 “Roche,” Hoffman-La-Roche). HDL cholesterol was measured
by the use of the TDx REA Cholesterol assay (Abbott). LDL
cholesterol was calculated by the equation of Friedewald. The Lp(a)
concentration was determined by the electroimmunodiffusion
method using a reagent kit containing monospecific anti-Lp(a)
antiserum and Rapidophor M3 equipment (Immuno AG). The levels
of apoB and apoA-I were assessed by an immunoturbidometric
method using polyclonal antibodies and a laser nephelometer
(Behringwerke AG).
The plasma fibrinogen concentration was measured according to
the Clauss method19 using the prescription and reagents of Behring-
werke AG.
Isolation of DNA and Genotype Analysis
High-molecular-weight DNA was extracted from peripheral whole
blood using Qiagen genomic tips (Qiagen Inc) according to the
protocol of the manufacturers.
Genotyping of the Leu-Met54 polymorphism was done by poly-
merase chain reaction (PCR) amplification of a 170-bp-long frag-
ment using the primers described by Humbert et al.9 The PCR
products are cleaved by NlaIII in the presence of BSA at 37°C for 3
hours. The digested products are analyzed on a 15% polyacrylamide
gel, stained with ethidium bromide, and examined under UV
transillumination. The L allele corresponded to the nondigested
170-bp-long fragment, while the M allele corresponded to a 126-bp
and a 44-bp fragment. A similar protocol was used for genotyping
the Gln-Arg-191 polymorphism using the primers described by
Humbert et al.9
Carotid Duplex Scanning
Color-coded equipment (Diasonics, VingMed CFM 750) was used to
determine atherosclerotic vessel wall abnormalities of the carotid
arteries. All B-mode and Doppler data were transferred to a Macin-
tosh personal computer for postprocessing and storage on optical
disks. The imaging protocol involved scanning of both common and
internal carotid arteries in multiple longitudinal and transverse planes
and has been previously described.20,21 The examinations were done
by one experienced physician. Image quality was assessed and
graded into good (common and internal carotid arteries clearly
visible and internal carotid arteries detectable over a distance of 2
cm), fair (common and internal carotid arteries sufficiently visible
and internal carotid arteries detectable over a distance of at least 2
cm), and poor (common and internal carotid arteries insufficiently
visible or internal carotid arteries detectable over a distance of 2
cm). The image quality was good in 308 (97%) and fair in 8 (3%)
individuals. It was never poor. Measurements of maximal plaque
diameter were done in longitudinal planes, and the extent of
atherosclerosis was graded according to the most severe visible
changes in the common and internal carotid arteries as 0normal,
1vessel wall thickening (1 mm), 2minimal plaque (2 mm),
3moderate plaque (2 to 3 mm), 4severe plaque (3 mm), and
5lumen completely obstructed. Assessment of the intrarater reli-
ability of this score was done in 50 randomly selected subjects and
yielded a  value of 0.83.
Statistical Analysis
We used the Statistical Package for Social Sciences (SPSS/PC) for
data analysis. Categorical variables among the paraoxonase geno-
types were compared by 2 test. Assumption of normal distribution
for continuous variables was tested by Lilliefors statistics. Normally
distributed continuous variables were compared by 1-way ANOVA,
whereas the Kruskal-Wallis test was used for comparison of non-
normally distributed variables. ANCOVA and logistic multivariate
regression analysis were used to adjust for possible confounding in
the comparison of risk factors among paraoxonase genotypes. Allele
frequencies were calculated by the gene counting method, and
Hardy-Weinberg equilibrium was assessed by 2 test. To test the
differences in sonographic score among the 3 genotypes at both
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polymorphic sites, Kruskal-Wallis 1-way ANOVA was used. To
assess the relative contribution of the paraoxonase genotypes on the
presence of carotid atherosclerosis, we used multiple logistic regres-
sion analysis. The sonographic score was dichotomized into normal
(grade 0) or abnormal (grade 1 through 5). Vessel wall thickening
(grade 1) was considered to be abnormal because it has been shown
to represent an early stage of atherosclerosis and to be associated
with an increased risk for future stroke.22,23 Forward selection
stepwise regression analysis with age and sex forced into the model
assessed independent predictors of carotid disease. At each step, each
variable not in the model was assessed as to its contribution to the
model, and the most significant variable was added to the model.
This process continued until no variable not in the model made a
significant (P0.05) contribution. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated from the  coefficients
and their standard errors.
Results
The genotypes LL, LM, and MM were noted in 137 (43.4%),
132 (41.8%), and 47 (14.9%) study participants. The AA,
AB, and BB genotypes occurred in 172 (54.4%), 124
(39.2%), and 20 (6.3%) study participants, respectively. The
genotypes of both polymorphisms were in Hardy-Weinberg
equilibrium. As shown in Table 1, there was a moderate
association between the 2 polymorphisms, with arginine at
position 191 being with 1 exception always concurrent with
leucine at position 54.
Table 2 compares demographic variables and risk factors
among the LL, LM, and MM genotype subsets. There was no
significant difference between groups, with the exception of
lower glucose levels and less frequent cardiac disease in those
with the LM genotype. The significant difference in blood
glucose level remained unchanged after adjustment for age,
sex, and cardiac disease (P0.03) but was no longer present
after correction for use of antidiabetic treatment (P0.26).
Correction for use of lipid-lowering treatment did not mate-
rially change the results of comparisons of blood lipids
between the 3 investigational subsets. The between-group
difference for cardiac disease remained significant after
adjustment for age, sex, and glucose level (P0.04). There
was no significant difference among the AA, AB, and BB
genotype subsets when the demographic variables and risk
factors listed in Table 2 were compared (data not shown).
Sonographic scores among the 3 genotypes for both poly-
morphisms are shown in Table 3. Overall, there were 63
(47.7%) subjects with the LM genotype and 23 (48.9%)
subjects with the MM genotype, but 86 (62.7%) subjects with
the LL genotype showed an abnormal sonographic score.
Subjects homozygous for the L allele had higher grades of
carotid abnormalities than subjects with either the LM or MM
genotype (P0.022). Logistic regression analysis yielded an
unadjusted OR of 1.86 (95% CI, 1.18 to 2.94; P0.007) for
abnormal sonographic findings in the LL genotype relative to
the other 2 genotypes. The OR after adjustment for age and
TABLE 1. Distribution of Paraoxonase Genotypes Defined by
Amino Acid Substitution at Positions 54 and 191
AA AB BB Total
LL 47 71 19 137
LM 81 50 1 132
MM 44 3 0 47
Total 172 124 20 316
A indicates glutamine; B, arginine at position 191; L, leucine; and M,
methionine at position 54.
TABLE 2. Demographics and Risk Factors Among Paraoxonase
Leu-Met54 Genotypes
Variable
Genotypes
PLL (n137) LM (n132) MM (n47)
Age, y 59.85.9 60.06.4 60.06.1 0.61*
Sex, no. male (%) 64 (46.7) 68 (51.5) 26 (55.3) 0.54†
Hypertension, n (%) 41 (29.9) 34 (25.8) 18 (38.3) 0.27†
Diabetes mellitus, n (%) 10 (7.3) 3 (2.3) 3 (6.4) 0.16†
Fasting glucose, mg/dL 95.523.0 89.913.6 97.725.8 0.045*
Cardiac disease, n (%) 57 (41.6) 37 (28.8) 21 (44.7) 0.03†
Smoking status, n (%)
Never smoker 67 (48.9) 74 (56.1) 30 (63.8)
Ex-smoker 50 (36.5) 37 (28.0) 11 (23.4)
Current smoker 20 (14.6) 21 (15.9) 6 (12.8) 0.35†
Body mass index, kg/m2 26.83.7 26.43.8 26.53.5 0.60*
Hematocrit, % 36.514.5 35.815.2 34.616.6 0.18*
Triglycerides, mg/dL 157.2100.8 134.075.3 149.375.5 0.46*
Cholesterol, mg/dL 228.439.1 227.039.4 227.337.9 0.65‡
LDL cholesterol, mg/dL 148.436.6 149.234.0 149.332.8 0.64‡
HDL cholesterol, mg/dL 49.016.0 50.6514.5 48.215.5 0.71*
Lipoprotein(a), mg/dL 26.329.0 19.623.1 48.215.5 0.47*
Fibrinogen, mg/dL 308.475.1 303.172.4 299.066.4 0.84*
*Kruskal-Wallis test, †2 test; ‡1-way ANOVA.
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sex was 1.98 (95% CI, 1.23 to 3.20; P0.005) and 1.88 (95%
CI, 1.16 to 3.05; P0.01) when adjusting for age, sex, fasting
glucose level, and cardiac disease. Evaluation of the effect of
the Gln-Arg-191 polymorphism on carotid atherosclerosis
demonstrated that subjects with the BB genotype had the
highest prevalence of carotid abnormalities. This difference
between the genotypes did not reach statistical significance
(P0.481).
The Gln-Arg-191 polymorphism did not modulate the
effect of the LL genotype on carotid disease because athero-
sclerotic changes were present in almost identical frequency
in 74 (62.7%) subjects in the LL/AA group and in 12 (63.2%)
individuals in the LL/BB group.
The relative contribution of the paraoxonase LL genotype
to the presence of carotid atherosclerosis was determined by
stepwise forward logistic regression analysis (Table 4). Age
and sex was forced in the model. This analysis demonstrated
the LL genotype to be significantly and independently asso-
ciated with carotid atherosclerosis (P0.014). Plasma fibrin-
ogen entered first (OR, 1.005 per mg/dL), LDL cholesterol
second (OR, 1.012 per mg/dL), the LL genotype third (OR,
1.907), and cardiac disease fourth (OR, 1.748). No other
variables such as total cholesterol, HDL cholesterol, triglyc-
erides, hypertension, diabetes mellitus, smoking, hematocrit,
or body mass index were entered into the model. The ORs for
the associations with age and sex were 1.09 (P0.0003) and
1.66 (P0.05) per year, respectively.
Discussion
Our data suggest that the paraoxonase LL genotype at
position 54 is a significant and independent predictor of
carotid atherosclerosis in a middle-aged and elderly popula-
tion. Homozygosity for the L allele is associated with higher
frequency and severity of carotid abnormalities, whereas
heterozygosity for this allele results in no risk increase.
We failed to detect a significant association between the
Gln-Arg-191 polymorphism and carotid disease, although
atherosclerotic lesions were more common in BB than in AB
or AA carriers. We found that individuals with the combina-
tion of the LL/BB genotypes had frequency of atherosclerosis
virtually identical to that of those with combined LL/AA
genotypes. This indicates that the Gln-Arg-191 polymor-
phism has no effect on carotid atherosclerosis per se and does
not modulate the effect of the L allele on atherosclerosis. The
Gln-Arg-191 polymorphism was defined as the molecular
basis for the difference of paraoxonase activity observed
against the artificial substrate, paraoxon.9 It was frequently
reported to be associated with coronary heart disease.12–14
Blatter-Garin et al24 reported for the first time that in whites
the Leu-Met54 polymorphism was significantly and indepen-
dently of the polymorphism at position 191 associated with
the concentration and activity of paraoxonase. These authors
also found that the LL genotype predicted coronary heart
disease.24 Similarly to our results, the effect was present in LL
homozygotes only, indicating a recessive effect of the L
allele. Sanghera et al25 investigated the effect of the Gln-Arg-
191 polymorphism on coronary heart disease in the geneti-
cally distinct populations of Chinese and Asian Indians and
found a race-specific association with coronary heart disease
with the B allele only in Indian cohort. The inconsistency of
associations in different populations strongly indicates that
the polymorphism at position 191 is not causally related to
atherosclerosis but is rather a marker for a functional se-
quence variant in its vicinity. Whether the Leu-Met54 poly-
morphism represents this functional variant is unclear and
cannot be elucidated by association studies.
TABLE 3. Paraoxonase Genotypes and Duplex Score
Duplex
Score
Genotype Leu-Met54 Genotype Gln-191-Arg
LL (n137) LM (n132) MM (n47) P * AA (n172) AB (n124) BB (n20) P *
0 51 (37.2%) 69 (52.3%) 24 (51.1%) 80 (46.5%) 57 (46.0%) 7 (35.0%)
1 5 (3.6%) 7 (5.3%) 1 (2.1%) 6 (3.5%) 6 (4.8%) 1 (5.0%)
2 52 (38.0%) 38 (28.8%) 15 (31.9%) 58 (33.7%) 41 (33.1%) 6 (30.0%)
3 22 (16.1%) 10 (7.6%) 6 (12.8%) 21 (12.2%) 11 (8.9%) 6 (30.0%)
4 7 (5.1%) 8 (6.1%) 1 (2.1%) 0.022 7 (4.1%) 9 (7.3%) 0 0.481
*Kruskal-Wallis test.
TABLE 4. Final Logistic Regression Analysis: Predictors of
Carotid Atherosclerosis
Variable  SE df P OR 95% CI
Age, y* 0.082 0.022 1 0.0003 1.086/y 1.04–1.135
Sex* 0.507 0.261 1 0.0519 1.660 0.996–2.768
Fibrinogen, mg/dL 0.005 0.002 1 0.0057 1.005/mg/dL 1.001–1.009
LDL cholesterol, mg/dL 0.012 0.004 1 0.0028 1.012/mg/dL 1.004–1.019
LL paraoxonase genotype 0.646 0.264 1 0.0144 1.907 1.137–3.198
Cardiac disease 0.558 0.275 1 0.0423 1.748 1.020–2.997
*Forced into the model.
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Several recent publications support the role of paraoxonase
in atherosclerosis. Paraoxonase is tightly associated with
antiatherogenic HDL. According to recent studies, only
certain subfractions of HDL are able to reduce the risk of
atherosclerosis. Results from apoA-I and apoA-II transgenic
(tg) mice underline this assumption.26–28 ApoA-II tg mice are
prone to atherosclerosis while apoA-I tg mice were found to
be protected against it, even though both had significantly
increased HDL levels compared with control mice.29 HDL
isolated from the apoA-I tg mice had been shown to protect
against the accumulation of lipid peroxides on LDL, whereas
HDL from apoA-II tg mice had no similar effect. The loss of
ability of the apoA-II HDL to protect against LDL oxidation
was associated with a decreased level of paraoxonase. Sub-
stitution of apoA-II HDL with paraoxonase restored its
antioxidative ability.29 Paraoxonase is associated with a cer-
tain subfraction of HDL also containing apoA-I and apoJ.7
This HDL subfraction seems to play a central role in the
antioxidative effect of HDL.30 Navab et al31 have found that in
HepG2 cell culture, minimally oxidized LDL induces an
increase in the apoJ/paraoxonase ratio due to altered tran-
scriptional rates. They also reported an increase in the
apoJ/paraoxonase ratio in different animal models of athero-
sclerosis on atherogenic diet, such as in mice prone to
atherosclerosis, in apoE knockout mice, and in LDL receptor
knockout mice. Interestingly, normolipidemic patients with
coronary artery disease also had a significantly higher apoJ/
paraoxonase ratio than normolipidemic controls.30
Moreover, paraoxonase immunoreactivity was found in
atherosclerotic lesions, and the intensity of immunoreactivity
in the arterial walls increased with the progression of athero-
sclerosis.32 Recently, it was described by the same authors
that paraoxonase is present in the interstitial fluid in an
enzymatically active form.33 This is in line with the hypoth-
esis that paraoxonase prevents the accumulation of lipid
peroxides on LDL, a process that has to take place in the
subendothelial space. If paraoxonase is involved in athero-
genesis by its ability to prevent accumulation of lipid perox-
ides on LDL, and if the association between the L allele and
carotid atherosclerosis is causal, then one would expect that
the L isoform is less effective in preventing the oxidative
modification of LDL than the M isoform. A recent report
from Mackness et al34 supports this hypothesis. These authors
investigated the antioxidative effect of HDL isolated from
individuals carrying the AA, AB, or BB genotype on Cu2-
induced oxidation of LDL. They found that HDL from BB
subjects completely lost its ability to prevent LDL oxidation
within 6 hours, whereas HDL from AB or AA individuals still
kept 23% and 40% of its original protective activity, respec-
tively. Given the strong linkage disequilibrium between the B
and the L allele, it is most likely that the L isoform has similar
effects. In line with this suggestion, another recent work from
Mackness et al35 showed that HDL from subjects with the
MM/AA genotype most effectively protects oxidative modi-
fication, whereas HDL from subjects with the LL/BB geno-
type has the lowest antioxidative potential.
Several groups reported that the genotype at the paraoxo-
nase locus influences the concentration and/or activity of
serum paraoxonase, which partly maybe due to an altered
expression of the paraoxonase gene.36 A weakness of our
study is that due to the lack of frozen serum from our
participants, we were not able to measure paraoxonase
concentration and activity to test the effect of genotype on
these parameters in our collective.
Our study is an allelic association study and cannot provide
an explanation for the mechanism(s) of the paraoxonase
genotypes leading to carotid disease. It might be that there
exists a true causal relationship between leucine at position
54 in the paraoxonase enzyme and atherosclerosis; however,
the possibility that the association is due to a linkage
disequilibrium between the L allele and another functional
allele in its neighborhood cannot be excluded. The PON1
gene is a member of a multigene family including PON2 and
PON3 located at the same locus on chromosome 7.37 Re-
cently, Hegele et al38 and Sanghera et al39 described 2
polymorphisms present in the PON2 gene with possible
clinical relevance. However, function of the PON2 gene
product is still unknown, making the estimation of the
importance of these findings difficult.
In summary, this is the first report on a positive association
between the paraoxonase LL genotype and carotid atheroscle-
rosis. Independent of other vascular risk factors, homozygos-
ity for the L allele was associated with a 1.91-fold increased
risk for carotid disease. If our results can be confirmed in
other ethnic groups, the Leu-Met54 variant, which can be
easily determined by conventional DNA technology, may be
considered to be included in the early risk assessment for
stroke.
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Angiotensinogen Polymorphism M235T, Carotid
Atherosclerosis, and Small-Vessel Disease–Related
Cerebral Abnormalities
Reinhold Schmidt, Helena Schmidt, Franz Fazekas, Lenore J. Launer, Kurt Niederkorn,
Peter Kapeller, Anita Lechner, Gert M. Kostner
Abstract—The angiotensinogen M235T polymorphism has been linked to hypertension and cardiovascular disease. We
studied the role of this polymorphism as a risk factor for carotid atherosclerosis and small-vessel disease–related brain
abnormalities. A total of 431 randomly selected community-dwelling subjects without clinical evidence for strokes
underwent angiotensinogen genotyping and carotid Duplex scanning; 1.5-T brain magnetic resonance imaging (MRI)
was done in 396 individuals. At 3-year follow-up, we reexamined 343 and 267 study participants by ultrasound and brain
MRI, respectively. Carotid atherosclerosis was graded on a 5-point scale. Small-vessel disease–related brain
abnormalities were deep or subcortical white matter lesions or lacunes. Progression of carotid atherosclerosis and MRI
findings was rated by direct imaging comparison by 3 independent raters. The M/M, M/T, and T/T genotypes were seen
in 20.9%, 52.9%, and 18.1% of subjects, respectively. The M235T polymorphism was neither associated with baseline
carotid findings nor with progression of carotid atherosclerosis. There was a trend toward more frequent small-vessel
disease–related MRI abnormalities in the T/T than in the other genotypes at the baseline examination. Progression of
brain lesions occurred significantly more commonly in T/T than in M/M and M/T carriers (P�0.001). Logistic
regression analysis identified the T/T genotype (odds ratio, 3.19; P�0.002) and arterial hypertension (odds ratio, 3.06;
P�0.03) as significant independent predictors of lesion progression. These data suggest that the angiotensinogen T/T
genotype at position 235 is a genetic marker for brain lesions from and progression of small vessel disease but not for
extracranial carotid atherosclerosis. (Hypertension. 2001;38:110-115.)
Key Words: angiotensinogen � genetics � carotid arteries � atherosclerosis � vessels
Angiotensinogen is a liver protein that interacts with reninto produce angiotensin I, the prohormone of angiotensin
II, which increases vascular tone and promotes sodium
retention. The plasma concentrations of angiotensinogen have
been directly related to arterial blood pressure and were found
to be modified by variations in the angiotensinogen gene.1 A
missense mutation in exon 2 of the angiotensinogen gene
(T704-C) encoding threonine instead of methionine at posi-
tion 235 (M235T) of the amino acid sequence commonly
occurs among various ethnic groups. The frequency of the
T235 allele ranges from 0.35 in whites to approximately 0.80
in blacks.2 A recent meta-analysis with an overall sample size
of 27 906 subjects attributed an increased risk for arterial
hypertension to the presence of the T-allele. In comparison
with the MM reference group, the excess risk was 31% in TT
homozygotes and 11% in MT heterozygotes.3 Moreover,
several studies found this genetic variant to be associated
with coronary artery disease and myocardial infarction.4–7
There is little information on a possible link between
this genetic variant and cerebrovascular disease. Two
studies showed no relation with carotid intima-media-
thickness,8,9 but there have been no investigations assess-
ing the relation of the M3T interchange with atheroma-
tous carotid disease and intracranial small vessel disease,
for which arterial hypertension is the most important risk
factor.10 It is also undetermined as to whether the M235T
polymorphism relates to progression of extracranial or
intracranial atherosclerosis. We therefore extended previ-
ous work by investigating the association between the
M235T polymorphism with carotid atherosclerosis and
with small-vessel disease–related cerebral damage in the
setting of a longitudinal study in community-dwelling
middle-aged and elderly persons. We used Doppler sonog-
raphy and brain magnetic resonance imaging (MRI) to
monitor the study participants over a time period of 3
years.
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Methods
Subjects and Design
The study population consisted of participants of the Austrian Stroke
Prevention Study, a single-center, prospective follow-up study on the
cerebral effects of vascular risk factors in the normal elderly
population of the city of Graz, Austria. The study was approved by
the institutional review committee of the Department of Neurology
and by the ethics committee of the Karl-Franzens University Graz,
Austria. The procedure of recruitment and diagnostic workup of
study participants has been described previously.11 The baseline
cohort consisted of 2000 persons without a history or signs of
neuropsychiatric disease. Every fourth study participant or, in case of
refusal, the next, was invited to enter phase II of the study, which
included carotid Doppler sonography and brain MRI. From a total of
496 phase II participants, all underwent Duplex scanning of the
carotid arteries, and 461 volunteered to undergo an MRI study. Since
1993, blood sampling for DNA analysis was done in a total of 431
individuals. There were 207 men and 224 women. The mean age was
60.2�6.1years. The sample consisted exclusively of whites of
central European origin. Doppler sonography was available in all of
them and MRI in 396 individuals. At the second study panel 3 years
after baseline, we were able to reexamine 341 individuals of the 431
participants who underwent neuroimaging and DNA sampling,
following the same protocol. From the 90 individuals who could not
be reexamined, 7 had died and another 7 had had a stroke, which is
an end point in our study. Sixty-five subjects were contacted by
telephone but refused to undergo the extensive diagnostic workup a
second time. Eleven individuals could not be reinvited because we
were unable to reach them after 3 phone calls and a letter. All
attendees who were reexamined after 3 years underwent a second
duplex scanning, but 74 refused to undergo a second MRI study
because of claustrophobic sensations at the initial evaluation. The
individuals who participated in the duplex scan and MRI follow-up
studies did not differ from those who dropped out in age, gender, and
risk factors for stroke. They were also comparable in terms of
genotype frequency and baseline sonographic and MRI findings.
Historic information and laboratory findings at baseline were
considered for risk factor diagnosis. The definitions for risk factor
diagnosis have been previously described.11
DNA Isolation and Genotyping
Genomic DNA was isolated from whole blood by Qiagen genomic
tips. The M235T polymorphism was identified by a nonisotropic
method involving restriction typing after polymerase chain reaction,
as described elsewhere.12 The DNA was visualized directly by
ethidium bromide staining. After digestion, the M235 allele that
lacked the restriction site was a 163-bp fragment and the T235 allele
that had the restriction site was a 140-bp fragment.
Carotid Duplex Scanning
Color-coded equipment (Diasonics, VingMed CFM 750) was used to
determine atherosclerotic vessel wall abnormalities of the carotid
arteries at baseline and 3-year follow-up examination. All B-mode
and Doppler data were transferred to a Macintosh personal computer
for processing and storage on optical disk. The imaging protocol
involved scanning of both common carotid arteries (CCA) and
internal carotid arteries (ICA) in multiple longitudinal and transverse
planes and has been previously described.13 The examinations were
performed by 3 readers without knowledge of the clinical data of the
individuals. Image quality was assessed and graded as good (CCA
and ICA clearly visible and ICA detectable over a distance of �2
cm), fair (CCA and ICA sufficiently visible and ICA detectable over
a distance of at least 2 cm), and poor (CCA or ICA insufficiently
visible or ICA detectable over a distance of �2 cm). There was no
poor quality study at the baseline and follow-up examination. At
baseline and follow-up, the extent of atherosclerosis was graded
according to the most severe visible changes in the CCA and ICA as
0, normal; 1,vessel wall thickening �1 mm; 2, minimal plaque
(�2 mm); 3, moderate plaque (2 to 3 mm); 4, severe plaque
(�3 mm), and 5, lumen completely obstructed. The interrater
variability for grading the extent of sonographic changes was
independently assessed in 200 vessels in 50 subjects. The � values
for interrater agreement for the sonographic score between the 3
sonographers ranged from 0.89 to 0.95. The most severe change in
any vessel and the sum of scores of the 4 vessels has been recorded.
The difference of the sum of scores of both CCA and ICA between
baseline and follow-up was used to define regression or progression
of carotid atherosclerosis.
Magnetic Resonance Imaging
MRI was performed on 1.5-T superconducting magnets (Gyroscan S
15 and ACS, Philips) with proton-density and T2-weighted (TR/TE
2000 to 2500/30 to 90 ms) sequences in the transverse orientation.
T1-weighted images (TR/TE 600/30 ms) were generated in the
sagittal plane. Slice thickness was 5 mm, and the matrix size used
was 128�256 pixels. MRI protocols at baseline and 3-year
follow-up were identical. The scanning plane was always determined
by a sagittal and coronal pilot to ensure consistency in image
angulation throughout the study. The baseline and follow-up scans of
each study participant were read independently by 3 investigators
blinded to the clinical data of study participants. Blinding of the
readers for the date of the examinations was impossible because the
format of hard copies changed from baseline to follow-up. The scans
were evaluated for small-vessel disease–related abnormalities. Ac-
cording to numerous histopathological correlations, these changes
consisted of white matter hyperintensities (WMH) and lacunar
lesions.14,15 WMH were graded according to our scheme as absent
(grade 0), punctate (grade 1), early confluent (grade 2), and confluent
(grade 3).16 The � values for interrater agreement regarding WMH
grade ranged from 0.63 to 0.70. The number of WMH was also
recorded. Caps and periventricular lining were disregarded because
these changes probably represent normal anatomical variants.15
Lacunes were focal cerebrospinal fluid–containing lesions that in-
volved the basal ganglia, the internal capsule, the thalamus, or brain
stem not exceeding a maximum diameter of 10 mm. Progression of
small-vessel disease–related brain lesion was defined to be present if
WMH increased in grade or number or if new lacunar lesions
occurred at the follow-up examination. Rating of lesion progression
was determined by direct scan comparison and relied on majority
judgment of the 3 assessors. In the case of complete disagreement,
consensus was found in a joint reading session. The � values for
interrater agreement for progression of small-vessel disease–related
brain abnormalities ranged from 0.61 to 0.69. We also looked at
different grades of progression. We considered a change from
baseline by 1 to 4 punctate WMH to represent minor progression.
Progression was rated to be marked if there was a difference of more
than 4 WMH or a transition to early confluent or confluent WMH or
if new lacunar lesions were seen. The Figure displays examples for
punctate and confluent WMH representing the range of WMH extent
seen in our study as well as examples for lacunes and for WMH
progression.
Statistical Analysis
We used the Statistical Package for Social Sciences (SPSS 8.0) for
data analysis. The degree of agreement for sonographic and MRI
rating was expressed by the means of � statistics. According to
Fleiss,17 a � value �0.40 reflects poor agreement; between 0.40 and
0.75, fair to good agreement; and �0.75, excellent agreement.
Categoric variables among the M235T genotypes were compared by
means of the �2 test. Assumption of normal distribution for contin-
uous variables was assessed by Lilliefors statistics. Normally dis-
tributed continuous variables were compared by 1-way ANOVA; the
Kruskal-Wallis test was used for comparison of nonnormally distrib-
uted variables. Allele frequencies were calculated by the gene-
counting method, and Hardy-Weinberg equilibrium was assessed by
means of the �2 test. Logistic regression analysis assessed the relative
contribution of the M235T genotypes on carotid ultrasound and brain
MRI findings. Analyses with ultrasound findings as the dependent
variable were adjusted for age and gender. In the selection of
covariates for analyses on small-vessel disease–related brain dam-
age, we followed a recent review on risk factors for these MRI
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lesions.18 Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated from the � coefficients and their standard errors.
Results
The frequencies of the M and T alleles were 0.55 and 0.45.
The MM, MT, and TT genotypes were noted in 125 (29.0%),
228 (52.9%), and 78 (18.1%) study participants. The geno-
types were in Hardy-Weinberg equilibrium. Table 1 com-
pares demographic variables and vascular risk factors among
the genotype subsets. As can be seen from this table, TT
carriers were older and had a higher frequency of heart
disease and arterial hypertension. There was also a nonsig-
nificant trend toward higher diastolic blood pressure values at
examination in participants with the TT genotype. The
association with hypertension was more pronounced in
women than in men. A total of 16 (26.2%) and 29 (24.4%)
women with the MM and MT genotype were hypertensive as
opposed to 21 (47.7%) female TT carriers (P�0.03). The
figures in men were 22 (34.4%), 37 (33.9%), and 14 (41.2%),
respectively (P�0.57). The systolic and diastolic blood pres-
sure values were also highest in the TT genotype subset in
both genders. Yet, when ANCOVA was used to correct for
the between-group differences in age and antihypertensive
medication, the association remained only significant for
diastolic blood pressure in women (P�0.04).
A total of 231 (53.6%) study participants showed athero-
sclerotic changes of the carotid arteries. They occurred in 74
(59.2%) subjects with the MM genotype, 117(51.3%) with
the MT genotype, and 40 (51.3%) with the TT genotype
(P�0.33). A breakdown of the severity of carotid atheroscle-
rosis by genotype is given in Table 2. There were no
significant differences among the 3 investigational subsets.
At the 3-year follow-up examination, regression of carotid
lesions occurred in 2 (0.6%) individuals, 259 (75.5%) sub-
jects had stable findings, and 82 (23.9%) participants showed
plaque progression. Plaque progression occurred at similar
frequencies among the 3 genotypes. It was seen in 27 (28.1%)
MM carriers, 40 (21.9%) MT carriers, and 15 (23.4%) TT
carriers (P�0.57). There existed no gender difference for the
associations between the M235T variant and baseline fre-
quency or progression of carotid atherosclerosis. The age-
and gender-adjusted odds ratios of the MT and TT genotypes
relative to the MM genotype for the presence of carotid
atherosclerosis were 0.73 (95% CI, 0.45 to 1.16; P�0.18) and
0.61 (95% CI, 0.33 to 1.11; P�0.11). Those for progression
of sonographic findings were 0.69 (95% CI, 0.28 to 1.23;
P�0.21) and 0.72 (95% CI, 0.39 to 1.54; P�0.40).
At baseline, MRI detected WMH in 183 (46.2%) study
participants. Lacunar lesions were seen in 32 (8.1%) subjects.
Homozygotes for the T allele had higher grades of WMH and
tended to show lacunes more frequently than their counter-
parts with either the MM or MT genotypes (Table 3). The
number of WMH was also highest in the TT subset, but the
differences to the other genotypes were not significant. The
difference for WMH grade between the 3 genotypes seen in
the univariate analysis was no longer significant when multi-
nominal logistic regression analysis was used to correct for
possible confounding by age, gender, hypertension, heart
disease, and systolic and diastolic blood pressure. After 3
years, we noted progression of small-vessel disease–related
cerebral abnormalities, including both WMH or lacunes in 52
(19.5%) participants. As shown in Table 3, lesion progression
was more than twice as common in subjects with the TT
genotype than in the comparative groups (P�0.001). The
most pronounced difference between the genotype subsets
was seen for marked progression. The association between
the TT genotype and progression of brain abnormalities was
significant in women (P�0.03) and in men (P�0.01). Logis-
tic regression analysis yielded an unadjusted OR of 3.78
(95% CI, 1.89 to 7.56; P�0.0001) for lesion progression in
the TT genotype relative to the two other genotypes. Adjust-
ment for age and gender altered the OR only marginally to
3.42 (95% CI, 1.70 to 6.66; P�0.001) and 3.75 (95% CI, 1.87
to 7.52; P�0.0001). We used multivariable logistic regres-
sion to assess the relative contribution of the TT relative to
the other two genotypes combined on the progression of
Composite shows WMH at top, single left basal ganglionic
lacune in middle, and progression of WMH at bottom. A, Punc-
tate WMH (arrow); B, widespread confluent WMH. A and B rep-
resent observed extremes of WMH. C and D, Lacunar lesion is
demonstrated on corresponding T2-weighted (C) and
T1-weighted (D) images. Lacunes are isointense to cerebrospi-
nal fluid in each scan sequence. E, Baseline scan in 67-year-old
study participant showing few punctate WMH in centrum semi-
ovale. F, Follow-up study in same subject after 3 years demon-
strates multiple, new, and partly confluent WMH (arrows).
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small-vessel disease–related brain abnormalities with adjust-
ment for the putative confounders age, gender, arterial hy-
pertension, hypertensive treatment, diabetes mellitus, heart
disease, and plasma fibrinogen. Table 4 displays this risk
factor model. As can be seen from this table, the TT genotype
and arterial hypertension were the only variables found to be
significantly associated with the progression of small-vessel
disease–related brain abnormalities. The interaction term
arterial hypertension�TT genotype was not associated with
lesion progression (OR, 0.67; P�0.58).
Discussion
WMHs and lacunes represent small-vessel disease–related
brain damage, which, in early stages, is often clinically
silent.18 Our study in an elderly population has shown that the
T235 variant of the angiotensinogen gene is associated with
the presence and progression of these brain abnormalities.
The relation between the M235T polymorphism and lesion
progression occurred independent of arterial hypertension,
which per se was moderately linked to both the genomic
variant and lesion progression. Clinically, progression of
small-vessel disease–related cerebral abnormalities is thought
to be associated with cognitive dysfunction and gait distur-
bances, symptoms known to be a major source of disability in
our aging societies.18 Identification of factors relating to the
progression of this type of brain damage is thus of relevance
regarding the prediction of possible clinical consequences
and the development and initiation of preventive measures.
In line with the population-based ARIC study and the
NHLBI family heart study,9 which measured intima-media
thickness of the common carotid arteries, and a single
case-control study8 assessing also the degree of stenosis, we
failed to show a relation between the M235T polymorphism
and carotid atherosclerosis. The lack of association with
carotid atherosclerosis in the presence of an association with
brain lesions linked to arteriolosclerosis appears contradic-
tory at first glance. Yet, large- and small-vessel disease
represent distinct vascular pathologies, which may also be
reflected by differences in the profiles of genetic susceptibil-
ity factors.
The frequency of M and T homozygotes in our sample
paralleled that of population samples from France and North
America,1 New Zealand,4 and Germany,7 indicating that there
TABLE 1. Demographics and Risk Factors Among Angiotensinogen
M235T Genotypes
Variable
MM
(n�125)
MT
(n�228)
TT
(n�78) P
Age, y 60.0�6.1 59.8�6.1 61.9�6.2 0.3*
Gender, male 64 (51.2%) 109 (47.8%) 34 (43.6%) 0.57†
Hypertension 39 (31.4%) 69 (29.6%) 36 (45.6%) 0.03†
Systolic blood
pressure, mm Hg
140.1�21.7 136.3�18.5 142.8�22.6 0.10*
Diastolic blood
pressure, mm Hg
85.6�9.0 84.8�9.1 87.9�10.5 0.05*
Heart disease 42 (33.6%) 78 (34.2%) 39 (50%) 0.03†
Diabetes mellitus 6 (4.8%) 13 (5.7%) 5 (6.4%) 0.88†
Fasting glucose, mmol/L 5.1�0.06 5.3�1.3 5.3�1.4 0.80*
Smoking status
Never 73 (58.4%) 121 (53.1%) 52 (66.7%)
Ex-smoker 15 (12.0%) 30 (13.2%) 8 (10.3%)
Current 37 (29.6%) 77 (33.8%) 18 (23.1%) 0.33*
Triglycerides, mmol/L 1.6�1.0 1.6�0.9 1.7�1.1 0.98*
Total cholesterol, mmol/L 5.9�1.0 5.9�1.0 6.1�1.1 0.37‡
LDL cholesterol, mmol/L 3.8�0.9 3.9�0.9 4.1�1.0 0.12‡
HDL cholesterol, mmol/L 1.3�0.4 1.3.0�0.4 1.2�0.4 0.58*
Apolipoprotein B, �mol/L 2.4�0.5 2.4�0.5 2.4�0.7 0.63*
Apolipoprotein A-I, �mol/L 64.3�10.7 60.7�10.7 60.7�14.3 0.75*
Fibrinogen, �mol/L 8.8�2.3 8.8�2.3 9.1�2.3 0.75*
*Kruskal-Wallis test, †�2 test, ‡1-way ANOVA.
TABLE 2. Carotid Doppler Sonography Findings at Baseline
by Genotype
Maximum Doppler
Score*, n (%)
MM
(n�125)
MT
(n�228)
TT
(n�78) P
0 51 (40.8%) 111 (48.7%) 38 (48.7%)
1 9 (7.2%) 8 (3.5%) 2 (2.6%)
2 46 (36.8%) 70 (30.7%) 21 (26.9%)
3 15 (12.0%) 27 (11.8%) 12 (15.4%)
4 4 (3.2%) 12 (5.3%) 5 (6.4%) 0.45†
Sum of scores‡ 2.4�2.5 2.4�2.9 2.6�2.9 0.85§
*Doppler score 5 (complete obstruction) was not seen; †�2 test; ‡sum of
maximum score in left and right common and internal carotid arteries; §1-way
ANOVA.
Schmidt et al AGT M235T Variant and Ischemic Brain Lesions 113
Genetic Determinants of Carotid Atherosclerosis
99
was no sample bias in this community-dwelling cohort. The
modest overall association between the T235 polymorphism
with arterial hypertension is in keeping with a previous
meta-analysis of 69 case-control studies.3 Blood pressure
directly relates to plasma concentration of angiotensinogen,
with the angiotensinogen level being elevated in subjects
carrying the T235 variant.1 We observed a much closer
relation between the T235 variant and blood pressure among
women. Angiotensinogen gene expression is known to be
estrogen-dependent,19 but all female participants in our study
were postmenopausal. This implies other estrogen-
independent yet undetermined differential gene-gene or gene-
environment interactions across genders to contribute to the
gender-specific difference in the blood pressure of homozy-
gotes for the T allele, at least in higher age groups. Notably,
the NHLBI Family Heart Study, which had an age distribu-
tion similar to the current cohort, also reported a greater
association between the T235 polymorphism and hyperten-
sion in women than in men.20
Several histopathologic correlations substantiate that la-
cunes and WMH are linked to small-vessel disease of the
brain. Lacunes represent small cavities caused by infarctions,
which are often located in areas irrigated by the deep and
superficial cerebral arterioles,14 whereas the histological cor-
relates of WMH show much greater diversity.15 Punctate
lesions frequently correspond to a perivascular reduction in
myelin content with atrophy of the neuropil and thus consti-
tute only minor tissue damage, probably from low permeabil-
ity through thickened arteriolar walls. Early confluent and
confluent WMH indicate more extensive tissue damage
including myelin pallor, loss of fibers, reactive gliosis, and
sometimes even small lacunar cavities consistent with more
advanced microangiopathy. Arterial hypertension is the most
important risk factor for small-vessel disease–related brain
changes besides age.11,18
The mechanism(s) responsible for the effect(s) of the
angiotensinogen T235 variant on progression of small-vessel
disease–related cerebral abnormalities remains speculative at
this time. It is clear from our data that elevated blood pressure
can only partly explain this association because homozygos-
ity for the T allele predicted lesion progression independent
of arterial hypertension. One explanation for the relation is
that the T235 variant represents merely a marker in linkage
disequilibrium, with a close-by etiologically important poly-
morphism. Conceivably, this could be a recently identified
mutation in the promoter region of the angiotensinogen gene
(A-6), which was seen to be in tight linkage disequilibrium
with T235 and caused elevated angiotensinogen expression.21
Angiotensinogen is the precursor peptide of the vasoactive
hormone angiotensin II, which has multiple proatherogenic
effects, including induction of smooth muscle cell hypertro-
phy, stimulation of vascular fibrosis, plasminogen activator
inhibitor-1 stimulation, free radical formation, and increased
endothelin secretion.22 Most importantly in the context of our
results, there exists an independent renin-angiotensin system
in the brain that might contribute to or amplify cerebral
small-vessel disease, an effect that might not be reflected in
the systemic circulation.23 The fact that the M235T angioten-
sinogen polymorphism is at some distance from the angio-
tensin cleavage site supports that this genomic variant is
rather a marker for another functionally important mutation in
the vicinity. However, one cannot exclude with certainty that
angiotensinogen has other yet unknown functions unrelated
to its role as a prohormone. These functions could then be
altered by mutations distant from the site of cleavage, such as
T235. The large ratio of the size of the precursor (452 to 453
amino acids) to product (10 amino acids) encourages a
teleological argument regarding alternate functions of angio-
tensinogen.24 By contrast, a relatively high degree of se-
quence divergence (�35%) between rodents and human
angiotensinogens argues against such functions because it
shows that there is little pressure to conserve much of the
amino acid sequence of this protein.24 Whatever mechanism
is responsible for the association between the angioten-
TABLE 3. Angiotensinogen M235T Polymorphism and
Small-Vessel Disease–Related Cerebral Abnormalities on MRI:
Baseline Findings and 3-Year Progression
Baseline
MM
(n�118)
MT
(n�201)
TT
(n�77) P *
WMH grade, n (%)
0 60 (50.8) 115 (57.2) 38 (49.4)
1 39 (33.1) 56 (27.9) 17 (22.1)
2 14 (11.9) 22 (10.9) 20 (26.0)
3 5 (4.2) 8 (4.0) 2 (2.6) 0.04
WMH No. (mean�SD) 4.6�11.2 4.0�7.9 5.2�9.2 0.57
Lacunes, n (%)
Absent 110 (93.2) 188 (93.5) 66 (85.7)
Present 8 (6.8) 13 (6.5) 11 (14.3) 0.08
3-y Follow-up, n 82 135 50
Progression, n (%)†
Absent 70 (85.4) 115 (85.2) 30 (60.0)
Present 12 (14.6) 20 (14.8) 20 (40.0) 0.001
Progression extent,
n (%)‡
Minor 8 (9.8) 11 (8.1) 10 (20.0)
Marked 4 (4.9) 9 (6.7) 10 (20.0) 0.002
*�2 test; †progression of either type of abnormality; ‡minor represents
change of 1 to 4 punctate WMH, marked represents change of �4 WMH or
transition to early confluent or confluent WMH or new lacunar lesions.
TABLE 4. Logistic Regression Model of Risk Factors for
Progression of Small-Vessel Disease–Related Cerebral
Abnormalities on MRI
Variable OR 95% CI
TT genotype 3.19 1.54, 6.63
Hypertension 3.06 1.15, 8.20
Antihypertensive therapy 0.60 0.21, 1.75
Age, y 1.04 0.98, 1.10
Gender (male) 0.87 0.45, 1.68
Diabetes 0.69 0.17, 2.82
Heart disease 1.14 0.56, 2.29
Fibrinogen, mg/dL 1.002 0.99, 1.01
*Each OR is adjusted for other factors listed in the table.
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sinogen M235T polymorphism and progression of brain
abnormalities caused by small-vessel disease, our data sug-
gest components of the renin-angiotensin system to play a
role in the pathogenesis of arteriolosclerosis independent of
their effects on blood pressure. Consequently, intervention in
the renin-angiotensin system could exert beneficial effects on
the evolution of small-vessel disease–related brain damage
and its clinical consequences beyond what can be expected
from the lowering of blood pressure alone.
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-Fibrinogen Gene Polymorphism (C1483T) Is Associated
With Carotid Atherosclerosis
Results of the Austrian Stroke Prevention Study
Helena Schmidt, Reinhold Schmidt, Kurt Niederkorn, Susanne Horner, Peter Becsagh, Birgit Reinhart,
Martin Schumacher, Viktor Weinrauch, Gert M. Kostner
Abstract—Polymorphisms at the -fibrinogen locus have been shown to be associated with plasma concentration of
fibrinogen and coronary heart disease. The effect of the genetic heterogeneity of fibrinogen on carotid atherosclerosis has
not been determined so far. We examined the influence of the C1483T polymorphism on carotid disease in a large cohort
of middle-aged to elderly subjects without evidence of neuropsychiatric disease. This polymorphism is located close to the
consensus sequence of the interleukin-6 element and may represent a functional sequence variant. The genotype of 399
randomly selected, neurologically asymptomatic individuals, aged 45 to 75 years, was determined by denaturing gradient
gel electrophoresis. Carotid atherosclerosis was assessed by color-coded duplex scanning and was graded on a five-point
scale ranging from 0 (normal) to 5 (complete luminal obstruction). The C/C, C/T, and T/T genotypes were noted
in 226 (56.6%), 148 (37.1%), and 25 (6.3%) individuals, respectively. The T/T genotype group demonstrated higher grades
of carotid atherosclerosis than did the C/C and C/T genotypes (P.003). Logistic regression analysis created a model of
independent predictors of carotid atherosclerosis that included apolipoprotein B (odds ratio [OR], 1.17/10 mg/dL), age
(OR, 2.46/10 years), lifetime tobacco consumption (OR, 1.03/1000 g), presence of the -fibrinogen promoter T/T
genotype (OR, 6.17), plasma fibrinogen concentration (OR, 1.05/10 mg/dL), and cardiac disease (OR, 1.80). These data
suggest that the -fibrinogen promoter T/T148 genotype represents a genetic risk factor for carotid atherosclerosis in the
middle-aged to elderly. (Arterioscler Thromb Vasc Biol. 1998;18:487-492.)
Key Words: fibrinogen  genetics  atherosclerosis  carotid arteries
There are numerous studies describing an association be-tween plasma fibrinogen levels and coronary heart dis-
ease,1–6 stroke,5–7 and carotid atherosclerosis.8–18 However, it is
unclear whether the elevations in plasma fibrinogen level are a
causal factor in the development of atherosclerosis or only an
epiphenomenon of the atherogenic process.
Fibrinogen concentration is controlled by genetic and en-
vironmental factors, including smoking, obesity, use of con-
traceptives, trauma, and lack of exercise, which have been
reported to elevate fibrinogen concentrations.19–21 Fibrinogen
level also increases with age and in the presence of diabetes
mellitus, hypertension, or lipid abnormalities.5,6
The estimate of heritability for fibrinogen is in the range of
30% to 50%, depending on the study design.22,23 Theoretically,
any gene coding for proteins involved in fibrinogen metabo-
lism may have an impact on the genetic regulation of the
plasma fibrinogen level. The synthesis of the B chain has been
shown to be the rate-limiting step in the formation of
fibrinogen.24 The 5 region of the  gene contains binding sites
for several trans-acting factors, which largely control expression
of the gene.25–27 Several polymorphisms have been identified
within this region.28–30 One of them, the C1483T poly-
morphism, is located close to an interleukin-6–responsive
element and may affect fibrinogen gene expression, mainly in
response to the acute-phase reaction.28 There are some popu-
lation-based studies that have investigated the effect of poly-
morphisms in the promoter region of the -fibrinogen gene
on fibrinogen level and the risk of coronary atherosclerosis.30–32
Their results are controversial. To our knowledge, this is the
first investigation on the effect of the C1483T polymorphism
on carotid atherosclerosis.
Methods
Study Population
Individuals aged 45 to 75 years and stratified by gender and 5-year age
groups were randomly selected from the official register of residents of
the city of Graz, Austria. They were all white and of central European
origin. They received a written invitation to participate in the Austrian
Stroke Prevention Study, a single-center, prospective, follow-up study
in our community. The study had been approved by the Medical
Ethics Committee of the Karl-Franzens University of Graz. Written,
informed consent was obtained from all study participants. The
rationale and design of the Austrian Stroke Prevention Study have
been previously described.33 In brief, the objective of the study was to
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examine the frequency of cerebrovascular risk factors and their effects
on carotid atherosclerosis as well as on cerebral morphology and
function in the elderly. The inclusion criteria for the study were no
history of neuropsychiatric disease and a normal neurological exami-
nation. From a total of 8193 individuals invited between September
1991 and March 1994, a sample of 2794 subjects agreed to participate,
of whom 1998 individuals fulfilled the inclusion criteria. All study
participants underwent a structured clinical interview, a physical and
neurological examination, three blood pressure readings, electrocar-
diography, and echocardiography as well as laboratory investigations
including blood cell count and a complete blood chemistry panel.
Every fourth study participant was then invited to enter phase II of the
Austrian Stroke Prevention Study, which included Doppler sonogra-
phy, magnetic resonance imaging, single-photon emission computed
tomography, and neuropsychological testing. Since 1993 we also
performed -fibrinogen promoter genotyping in all phase II attendees.
The current study cohort consists of those 399 individuals who
underwent both carotid duplex scanning and assessment of the
-fibrinogen polymorphism. There were 204 women and 195 men.
The meanSD age of this cohort was 60.16.0 years.
Vascular Risk Factors
The diagnosis of major risk factors for stroke, including arterial
hypertension, diabetes mellitus, and cardiovascular disease, relied on
the individual’s history and appropriate laboratory findings. A detailed
description of the definition of these risk factors is given elsewhere.34,35
Study participants were defined as current smokers, ex-smokers, or
never-smokers. For current smokers and ex-smokers, information was
obtained about the daily number of items smoked and the smoking
duration in years. The data on the amount of tobacco were converted
to grams of tobacco consumed during their lifetime by using the
following conversion factors: 1 cigarette1 g, 1 cheroot3 g, and 1
cigar5 g. Body mass index was calculated as weight in kilograms
divided by the square of height in meters squared. The regular use of
estrogen replacement therapy was recorded among all female study
participants.
For measurements of hematocrit, blood was obtained from a large
antecubital vein without stasis. Lipid status, including the level of
triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol,
lipoprotein(a), apolipoprotein B, and apolipoprotein A-I, was deter-
mined for each study participant. Triglycerides and total cholesterol
were enzymatically determined by using commercially available kits
(Uni-Kit III “Roche” and MA-Kit 100 “Roche,” Hoffman –La
Roche). HDL cholesterol was measured by the use of the TDx REA
cholesterol assay (Abbott). LDL cholesterol was calculated by the
equation of Friedewald. The lipoprotein(a) concentration was deter-
mined by the electroimmunodiffusion method using a reagent kit
containing monospecific anti-lipoprotein(a) antiserum and the Rapi-
dophor M3 equipment (Immuno AG). The levels of apolipoprotein B
and A-I were assessed by an immunoturbidimetric method utilizing
polyclonal antibodies and a laser nephelometer (Behringwerke AG).
The plasma fibrinogen concentration was measured according to the
Clauss method35 by using the recommendations and reagents of
Behringwerke AG.
Isolation of DNA and Genotype Analysis
High-molecular-weight DNA was extracted from peripheral whole
blood by using Qiagen genomic tips (Qiagen Inc) according to the
protocol of the manufacturer. Genotyping was performed by dena-
turing gradient gel electrophoresis (DGGE). This procedure is rou-
tinely used in our laboratory and is preferred over restriction enzyme
digestion because it detects point mutations within the amplified DNA
fragment with high sensitivity and does not require further processing
of polymerase chain reaction (PCR) products.36,37 A 417-bp-long
fragment containing part of the promoter region and exon 1 (from
263 to 114 nucleotides) of the -fibrinogen gene and a 40-bp-
long GC clamp serving as an artificial high-melting-point domain for
DGGE was amplified by using two oligonucleotides (5-GC clamp
CTC TTT GAG GAG TGC CCT AAC TTC C-3 and 5-TGT
CGT TGA CAC CTT GGG ACT TAA C-3). PCR was performed
on 1 g of genomic DNA in a buffer containing 10 mmol/L Tris (pH
8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.2 mmol/L of each
dNTP, 0.5 mol/L of each primer, and 1 U of Taq DNA polymerase
in a final volume of 50 L. After 5 minutes at 94°C, amplification was
carried out in 40 cycles consisting of 1 minute at 94°C, 1 minute at
52°C, and 2 minutes at 72°C on a Mastercycler (Eppendorf). A final
elongation step was performed for 10 minutes at 72°C. Amplification
was assessed by electrophoresing 5 L of the PCR product on a 1.5%
agarose gel stained with ethidium bromide.
The melting domain map for the DGGE analysis was calculated
with the MELT87 computer algorithm.38 PCR products were ana-
lyzed on 8% polyacrylamide gels containing a 20% to 50% linearly
increasing denaturing gradient (100% denaturant is equivalent to 7
mol/L urea and 40% [vol/vol] deionized formamide). Electrophoresis
was performed at 100 V at 60°C for 16 hours in TAE buffer
(40 mmol/L Tris acetate, 1 mmol/L EDTA, pH 7.5). Gels were
stained with ethidium bromide and examined under UV illumination.
DNA samples with known genotypes were used initially to determine
the position of the bands of the different genotypes. The C/C
genotype corresponded to the lower band; the T/T genotype, the
higher band; and the C/T genotype, a four-band pattern resulting
from the two homoduplexes and two heteroduplexes.
Sequencing of the control DNA samples used as standards for the
DGGE analysis was performed on a model 373A automated DNA
sequencer (Perkin Elmer/Applied Biosystems Inc) and applying the
dye terminator cycle sequencing ready reaction kit (model No.
402079, Perkin Elmer/Applied Biosystems).
Carotid Artery Duplex Scanning
A color-coded device (Diasonics, VingMed CFM 750) was used to
determine atherosclerotic vessel wall abnormalities of the carotid
arteries. All B-mode and Doppler data were transferred to a Macintosh
personal computer for postprocessing and storage on optical disks. The
imaging protocol involved scanning of both common and internal
carotid arteries in multiple longitudinal and transverse planes and has
been previously described.33,34 The examinations were performed by
one experienced physician (S.H.). Image quality was assessed and
graded into good (common and internal carotid arteries clearly visible
and internal carotid arteries detectable for a distance 2 cm), fair
(common and internal carotid arteries sufficiently visible and internal
carotid arteries detectable for a distance of 2 cm), and poor
(common and internal carotid arteries insufficiently visible or internal
carotid arteries detectable for a distance2 cm). Examinations of poor
quality were excluded from further analysis. Measurements of maxi-
mal plaque diameter were done in longitudinal planes, and the extent
of atherosclerosis was graded according to the most severe visible
changes in the common and internal carotid arteries as follows:
0normal, 1vessel wall thickening (1 mm), 2minimal plaque
(one 2 mm), 3moderate plaque (two 3 mm), 4severe plaque
(3 mm), and 5lumen completely obstructed. Assessment of the
intrarater reliability of this score was done in 50 randomly selected
subjects and yielded a kappa value of 0.83.
Statistical Analysis
We used the Statistical Package for the Social Sciences (SPSS/PC)
for data analysis. Categorical variables among the three -fibrinogen
genotypes were compared by the 2 test. Assumption of a normal
distribution for continuous variables was tested by Lilliefors statistics.
Normally distributed continuous variables were compared by one-
way ANOVA, whereas the Kruskal-Wallis test was used for compar-
ison of nonnormally distributed variables. To assess the relative
contribution of the three -fibrinogen genotypes on the presence of
carotid atherosclerosis, we used multiple logistic regression analysis.
The sonographic score was dichotomized as normal (grade 0) or
abnormal (grades 1 to 5). Odds ratios (ORs) and 95% confidence
intervals (CIs) with and without adjustment for age were calculated
from the  coefficients and their SEs. We used first-order interaction
terms to evaluate whether or not the association between -fibrinogen
genotype and the presence of carotid atherosclerosis was modified by
plasma fibrinogen level, lifetime tobacco consumption, or use of
hormone replacement therapy.19–21 These factors were considered
because previous studies demonstrated that polymorphisms at the
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-fibrinogen locus may influence the plasma concentration of fibrinogen
and that this may in turn be modified by smoking and hormone therapy.
We used forward stepwise regression to create a model of independent
predictors of carotid disease. At each step, each variable not in the model
was assessed as to its contribution to the model, and the most significant
variable was added to the model. This process continued until no variable
not in the model made a significant (P.05) contribution. ORs and 95%
CIs were calculated from the  coefficients and their SEs.
Results
Using DGGE between nucleotides 263 and 114 in the
-fibrinogen gene, we were able to detect only one sequence
variation. This sequence alteration was identical to the known
C1483T polymorphism. The overall allele frequency of the
T148 allele was found to be .248, similar to what has been
observed in other countries in Europe.34,35 The C/C, C/T, and
T/T -fibrinogen promoter genotypes were noted in 226
(56.6%), 148 (37.1%), and 25 (6.3%) study participants, respec-
tively, and these values were in Hardy-Weinberg equilibrium.
Table 1 compares demographic variables and risk factors
among the three genotypes. As shown in this table, there were
no statistically significant differences among the three groups.
The plasma fibrinogen concentration was almost equal in the
three subsets. There were also no differences in fibrinogen
level among the C/C, C/T, and T/T -fibrinogen promoter
genotypes in current smokers (306.485.8 mg/dL,
300.662.5 mg/dL, and 299.795.0 mg/dL, respectively;
P.92) and in the subset of 55 women who were on estrogen
replacement therapy (282.369.6 mg/dL, 277.456.0 mg/
dL, and 288.046.0 mg/dL, respectively; P87).
The quality of carotid duplex examinations was good in 389
(97.5%) and fair in 8 (2.0%) subjects. Only 2 (0.2%) studies
were of poor quality and were thus excluded from further
analysis. As shown in Table 2, subjects carrying the T/T
-fibrinogen promoter genotype had atherosclerotic carotid
abnormalities more commonly than did their counterparts
with either the C/C or C/T genotype with very similar
sonographic findings. Table 2 demonstrates that the most
striking differences between the T/T genotype and the two
other genotypes were seen with respect to the extremes of the
duplex score. Normal findings occurred in only 12.0% of T/T
carriers but in 46.4% of C/C and 45.9% of C/T carriers. By
contrast, grade 4 atherosclerotic changes were noted in 20.0%
of subjects with the T/T genotype but in only 4.0% and 4.7%
of those with the C/C and C/T genotypes, respectively. There
TABLE 1. Demographics and Risk Factors Among -Fibrinogen Genotypes
Variable
Genotypes
PC/C (n226) C/T (n148) T/T (n25)
Age, y 60.15.8 59.76.0 61.96.6 .29*
Sex, male 110 (58.7) 71 (48.0) 14 (56.0) .76†
Hypertension, n (%) 76 (33.6) 47 (31.8) 7 (28.0) .82†
Diabetes mellitus, n (%) 9 (4.0) 10 (6.8) 2 (8.0) .41†
Fasting glucose, mg/dL 92.719.2 94.921.8 99.230.1 .31‡
Cardiac disease, n (%) 82 (36.3) 55 (37.2) 13 (52.0) .30†
Ex-smokers, n (%) 24 (10.6) 25 (16.9) 3 (12.0)
Current smokers, n (%) 78 (34.5) 46 (31.1) 8 (32.0) .52†
Lifetime tobacco consumption 103 g 85.6147.6 100.8156.7 138.0278.4 .57*
Estrogen replacement, n (%) 33 (28.7) 19 (24.7) 3 (27.3) .83†
Body mass index, kg/m2 26.73.6 26.43.9 26.63.5 .70*
Hematocrit, % 34.416.2 36.714.4 37.214.8 .33*
Triglycerides, mg/dL 147.486.6 141.684.1 154.3103.0 .54*
Cholesterol, mg/dL 229.538.1 229.842.2 233.141.5 .91‡
LDL cholesterol, mg/dL 149.734.7 150.937.6 158.128.9 .54‡
HDL cholesterol, mg/dL 50.415.6 50.615.3 44.312.4 .10*
Lipoprotein(a), mg/dL 22.526.5 27.934.7 18.717.9 .60*
Apolipoprotein B, mg/dL 142.331.4 144.237.1 147.833.3 .84*
Apolipoprotein A-l, mg/dL 174.931.9 174.030.6 167.423.6 .49*
Fibrinogen, mg/dL 304.776.8 306.268.9 300.869.7 .87*
*Kruskall-Wallis test.
†2 test.
‡One-way ANOVA.
TABLE 2. -Fibrinogen Promoter Genotypes and
Duplex Score
Duplex Score
Grade, n (%)
Genotype
P
C/C
(n224)
C/T
(n148)
T/T
(n25)
0 104 (46.4%) 68 (45.9%) 3 (12.0%)
1 5 (2.2%) 9 (6.1%) 2 (8.0%)
2 76 (33.9%) 45 (30.4%) 11 (44.0%)
3 30 (13.4%) 19 (12.8%) 4 (16.0%)
4 9 (4.0%) 7 (4.7%) 5 (20.0%) .003
*2 test.
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were no individuals with grade 5 changes. Overall, atheroscle-
rotic carotid abnormalities were recorded in 53.6% of the C/C
and 54.1% of the C/T carriers but in 88.0% of the T/T carriers,
and this difference was statistically significant (P.003). The
unadjusted and age-adjusted ORs for abnormal sonographic
findings in the T/T genotype relative to the other two
genotypes was 6.29 (1.91 to 20.71 95% CI; P.003) and 5.97
(1.77 to 20.15 95% CI; P.005), respectively. On the basis of
our finding that the T/T genotype subset was, on average,
slightly older than those with the C/C and C/T genotypes, we
repeated our analyses after matching the investigational groups
for age to avoid overreliance on statistical adjustment. For 22
individuals of the T/T group, we were able to randomly select
3 individuals of the C/C and C/T groups each of whose ages
were 2 years of that of a given T/T carrier. The ages of the
matched C/C, C/T, and T/T subgroups were 62.66.1,
62.96.4, and 62.86.5 years, respectively, (P.97), and
there were no significant between-group differences in demo-
graphics and vascular risk factors. As in the entire cohort, T/T
carriers demonstrated a higher frequency and severity of
carotid atherosclerosis (P.01). In this age-matched subset of
study participants, the ORs for the presence of carotid artery
disease associated with the T/T genotype was 4.38 (1.28 to
15.04 95% CI; P.02). The interaction terms T/T geno-
typeplasma fibrinogen, T/T genotypelifetime tobacco
consumption, and T/T genotypeuse of oral contraceptives
were not associated with evidence of carotid atherosclerosis in
the total study group. The respective ORs were 1.001 (0.98 to
1.02 95% CI; P.92), 1.0002 (0.99 to 1.001; P.65), and 0.50
(0.42 to 0.67; P.64). When we used forward stepwise
regression analysis to create a model of predictors of athero-
sclerotic changes in the carotid arteries, the T/T genotype
remained significantly and independently associated with evi-
dence of abnormal sonographic findings. Apolipoprotein B
entered the model first, age second, lifetime tobacco consump-
tion third, the T/T -fibrinogen promoter genotype fourth,
plasma fibrinogen fifth, and cardiac disease sixth (Table 3). All
other variables, including male sex, hypertension, diabetes
mellitus, fasting blood glucose level, current and former
smoking status, body mass index, other lipid fractions, and
hematocrit did not enter the model.
Discussion
In the current study, we have demonstrated an association
between the T/T148 genotype at the -fibrinogen locus and
the presence of carotid atherosclerosis in a neurologically
asymptomatic, randomly selected population aged 45 to 75
years. T/T carriers tended to be older than their counterparts
with the C/C or C/T genotype, but the -fibrinogen pro-
moter polymorphism remained significantly related with vessel
wall status even after adjustment for age by either multivariate
logistic regression analysis or analysis of subgroups of study
participants closely matched for age. We found that not only
the T/T genotype but also plasma fibrinogen concentration are
independent predictors of carotid atherosclerosis in addition to
the well-established risk factors age, apolipoprotein B, lifetime
tobacco consumption, and cardiac disease. The C1483T poly-
morphism was not correlated with plasma fibrinogen concen-
trations in our study participants.
There are at least 10 polymorphisms present in the -fibrin-
ogen gene.29 Of particular interest are sequence alterations in
the 5-flanking region of the gene, because this region contains
several regulatory elements that control gene expression under
different conditions.25–27 The increased fibrinogen synthesis
during the acute-phase reaction is due to a higher transcrip-
tional rate and is mainly mediated by interleukin-6.39 Anderson
et al26 characterized two distinct sequence elements required
for maximal induction of transcription by interleukin-6. One
of them is similar to the interleukin-6 responsive-element core
sequence of the rat 2-macroglobulin gene promoter and lies
between nucleotides 137 and 143. The other is a CAAT-
enhancer binding protein (C/EBP) binding site between
nucleotides 124 and 133. The C1483T polymorphism lies
in the direct vicinity of these regions. It is thought to modulate
acute-phase fibrinogen response by altering the binding of
hepatic nuclear proteins to this part of the DNA.40 Thus, this
polymorphism may represent a functional sequence variant.
Some evidence for such a mechanism has been given in a study
by Montgomery et al,41 who reported that the acute rise in
fibrinogen concentration after physical activity in young men
is influenced by the G4553A ( HaeIII) polymorphism, which
is tightly linked with the C1483T polymorphism.28,29 We have
found that subjects homozygous for the T148 allele have a
6.17-fold increased risk for carotid atherosclerotic abnormali-
ties when compared with subjects with the C/C or C/T
genotype after adjustment for age. Because this trend was seen
to occur independently of fibrinogen concentration, we spec-
ulate that a transient, fibrinogen promoter genotype–depen-
dent rise of fibrinogen levels in response to repeated extrinsic
and intrinsic stimuli might play a role in the etiology of carotid
atherosclerosis, irrespectively of the possible atherogenic effects
of baseline fibrinogen concentrations. We most likely mea-
sured baseline fibrinogen values, as our study participants were
clinically normal at the time of the examination. We found
that tobacco consumption in all subjects and use of oral
contraceptives in women did not modify the association of the
TABLE 3. Final Logistic Regression Model of Carotid Atherosclerosis
Variable  SE df P OR 95% CI
Apolipoprotein B, mg/dL 0.016 0.004 1 .00001 1.17/10 mg/dL 1.08; 1.26
Age, y 0.090 0.021 1 .00001 2.46/10 years 1.65; 3.67
Tobacco consumption, g 3.2106 9.3107 1 .0004 1.03/1000 g 1.01; 1.05
T/T -fibrinogen genotype 1.820 0.674 1 .007 6.17 1.70; 22.36
Fibrinogen, mg/dL 0.005 0.002 1 .006 1.05/10 mg/dL 1.01; 1.09
Cardiac disease 0.588 0.259 1 .023 1.80 1.09; 2.95
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-fibrinogen promoter genotype and carotid atherosclerosis. It
is therefore unlikely that these two factors were extrinsic
stimuli in the present study cohort.
There have been several studies that have addressed the
question of the extent of variation in the -fibrinogen gene
and its influence on the baseline plasma content of fibrinogen.
In the ECTIM Study, the G4553A ( HaeIII) polymorphism
was shown to be significantly associated with the level of
fibrinogen.31 In the EARS Study, the association between the
G4553A ( HaeIII) polymorphism and plasma fibrinogen was
present, but this relation was affected by sex, hormonal status,
and smoking habits.32 In a recent report from the ECTIM
Study, the presence of the BclI polymorphism in the 3-region,
which is also tightly linked with the C1483T polymorphism,29
was shown to be highly correlated with the severity of
coronary atherosclerosis in myocardial infarction patients. The
BclI polymorphism has also been implicated by Fowkes et al42
in occlusive peripheral artery disease. Similar to our results,
they found that the polymorphism was associated with the
presence of atherosclerosis without influencing plasma fibrin-
ogen levels. A recent study by Carter et al43 has investigated the
effect of the arginine-to-lysine substitution at position 448 on
fibrinogen levels and the risk for stroke. They observed an
association between the B448 polymorphism and baseline
fibrinogen levels in male patients only, but similar to our
results, not in male control subjects or females. Regarding the
effect of genotype on stroke, they found that the poly-
morphism was associated with a lower risk in females. The
authors therefore speculated that genetic variations at the
-fibrinogen locus might modulate the risk for stroke through
different mechanisms in males and females. The participants of
the EARS Study were young men and women (aged 18 to 26
years) and those of the ECTIM Study, young to middle-aged
men (25 to 64 years). The study population investigated by
Fowkes et al42 and Carter et al43 consisted of men and women
with an age range of 55 to 74 years and 68 to 82 years,
respectively, close to the age range of our study population. It
is conceivable that the effect of the polymorphism on fibrin-
ogen level and its dependence on environmental factors and
sex disappears with advancing age and therefore was not
detectable in older study populations like those examined by
Fowkes, Carter, and us.
Another explanation for the controversial results on the
association between genotype and fibrinogen level in the
different studies may be the high intraindividual variation in
fibrinogen level44–46 as measured by the Clauss method.35 This
method has been used not only by us but also by all major
previous investigations. The Clauss method is a functional
assay measuring the level of clottable fibrinogen with a
reported batch error of 5% to 7%.44–46 Using this method,
Rosenson et al44 examined the intraindividual variation in
fibrinogen concentration over a 6-week period. They found a
coefficient of variation of 17.8%, comprising both biological
fluctuations as well as methodological variations. On the basis
of their calculations, at least four measurements are required for
an accurate fibrinogen concentration assessment in a given
individual, which is not practicable for risk assessments in
population studies. In population-based studies, the ability of
the investigation to detect fibrinogen concentration–associated
effects is mainly dependent on sample size. According to
Rosenson et al,44 our sample was large enough to detect a
possible association between fibrinogen concentration and
carotid atherosclerosis in general. Nevertheless, the limited
number of subjects with the T/T genotype might have led to
an underestimation of the effect of genotype on fibrinogen
level in this subset. However, also on the basis of our data, we
cannot exclude the possibility that the C1483T polymorphism
per se is not a functional sequence variant but is in linkage
disequilibrium with another important, yet-undefined se-
quence alteration in the -fibrinogen gene or in another gene
in its neighborhood.
In summary, our study demonstrates the first evidence of a
significant association between the T/T148 genotype at the
-fibrinogen gene and carotid atherosclerosis. The results
should be interpreted with caution, given the small number of
T/T homozygotes. A larger cohort will ultimately be required
to confirm whether or not this association is real.
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In this thesis we studied the course of cerebral small vessel disease and its 
predictors. The studies presented here were conducted as part of the Austrian 
Stroke Prevention Study (ASPS), a single-center, longitudinal cohort study on the 
cerebral effects of vascular risk factors in the normal elderly population of the 
city of Graz, Austria. The ASPS was started in 1991 and enrolled 1998 men and 
women between the age of 50 and 75 years of whom 498 underwent extensive 
baseline and follow-up evaluations, including blood pressure readings, ECG, 
echocardiography, blood cell count and complete blood chemistry as well as brain 
MRI, Doppler sonography, SPECT and neuropsychiatric testing. The cohort is 
followed up in 3-year intervals. Currently the third follow-up panel of the ASPS is 
underway. A detailed description of the study design, definition of risk factors and 
the MRI protocol of the ASPS is given in Chapter 2.1.
In this chapter I will give a summary of main findings (Chapter 5.1) 
and discuss methodological issues of our studies (Chapter 5.2). I will address, 
the clinical relevance of these results (Chapter 5.3) and will extent on future 
objectives of research on cerebral small vessel disease (Chapter 5.4). 
5.1. Main findings
Progression studies
In 1999 we reported the first large-scale longitudinal study on the 
progression of white matter lesions (WML) (Chapter 2.1). The follow-up time 
was 3 years and 273 of the ASPS participants having baseline and follow-up MRI 
scans were included in the study. The rate of overall progression was 18%. Lesion 
progression was marked in 8% of study participants. Importantly, no regression 
of lesions was observed. Major predictors of progression were diastolic blood 
pressure and the grade of WML at baseline. A neuropsychological test battery 
assessing memory and learning abilities, conceptual reasoning, attention, and 
speed as well as visuopractical skills was administered at baseline and at follow-
up. We observed no decrease of cognitive functions in individuals with lesion 
progression during the three year of follow-up. 
Results of the 6-year follow-up study, largely confirmed the previous 
findings (Chapter 2.2). Remarkably, although we used a different measure of 
lesion progression as in the previous manuscript, rate of progression was very 
similar in the two analyses. It was 9% after 3 years and 17% after 6-years follow-
up. A novel finding of this study was that the grade of white matter lesions at 
baseline was the only significant predictor of progression explaining 28.5% of the 
variance in volume change. All participants with confluent and 58% of those with 
early-confluent WML at baseline showed progression over the 6-year follow-up, 
compared with 15% in participants with punctate lesions and 2% with normal 
MRI at baseline. The median volume change in subjects with confluent lesions at 
baseline was 4.8 cm3 after 3 years and 9.3cm3 after 6-years follow-up. 
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The median volume change in subjects with early confluent lesions at baseline 
was 0.7 cm3 after 3 years and 2.7cm3 after 6-years follow-up. By contrast subjects 
with punctuate lesions at baseline showed minimal increase in lesion load (median 
change 0.1 cm3 at 3-years; 0.2 cm3 at 6-years), while there was no volume increase 
in participants without WML at baseline. Again we did not observe regression of 
lesions during follow-up. Data on the relationship between lesion progression and 
cognitive performance for the 6-year follow-up is still under study. 
Heritability of cSVD 
The genetic aspects of cerebral small vessel disease are reviewed in 
Chapter 3.1. So far three studies have reported heritability estimates for WML 
volume. The first study was conducted in normal elderly male twins, the second 
was a family based approach including middle-aged and elderly men and women 
and the third studied hypertensive siblings (1-3). The latter two studies were 
published recently and are therefore not discussed in Chapter 3.1. Although the 
study design and populations were different in these studies, all three studies 
found that WML are highly heritable with h2 ranging between 0.55 and 0.73. 
These high heritability estimates underline the relevance of searching for genes 
involved in the etiology of WML. Identification of genes probably will provide a 
better understanding of the pathogenesis of this common pathology of the elderly 
and ultimately may lead to the development of novel preventive and therapeutic 
measures. This is of particular interest, given the fact that there exists no 
established therapy for this entity.
Different strategies can be followed for finding genes in complex traits. 
Most commonly used are non-parametric linkage studies, such as sib-pair studies 
or association studies. Candidate gene studies are most powerful if one has 
substantial knowledge of the pathways involved in a trait as is the case in cSVD. 
We hypothesize that early confluent and confluent WMLs as well 
as lacunar lesions represent ischemic damage of the brain parenchyma due 
to arteriolosclerosis. Based on this hypothesis we developed a model for the 
selection of candidate genes for these phenotypes, which we summarize in Figure 
1. In our earlier work we also used the term microangiopathy-related cerebral 
damage (MARCD), which described exactly the same phenotype.
The genes selected to initiate association studies included the 
apolipoprotein E gene (APOE), the paraoxonase 1 gene (PON1), angiotensinogen 
gene (AGT) and the beta fibrinogen gene (FGB). The APOE gene was selected 
based on its association with aging, serum lipid concentrations (vascular systemic 
factors), as well as brain parenchymal damage and repair (4). The PON1 gene was 
selected based on its protective role against oxidative damage through which it 
may modulate brain vulnerability to ischemic damage (5). The AGT gene was 
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Figure 1 Working model for selection of candidate genes for cerebral small vessel 
disease
selected due to its central role in the regulation of the renin-angiotensin system 
and blood pressure (6). Hypertension is besides age the major risk factor for 
cSVD. The FGB gene was selected because syntheses of the beta chain is rate 
limiting in fibrinogen assembly (7) and positive associations between plasma 
fibrinogen and cSVD have been reported previously (8).
 For each candidate gene, only polymorphisms with suspected functional 
relevance were studied. Functional relevance was evaluated based on location 
(promoter region, conserved sequence, functional domain) as well as based 
on available in vitro (biochemical activity, cell expression) and in vivo data 
(correlation with intermediate phenotype, eg. serum concentration, blood 
pressure) (6). 
In this thesis polymorphisms investigated in cSVD were also tested 
for association with carotid atherosclerosis. We use carotid atherosclerosis as a 
paradigm for large vessel disease. Common and differential associations in small 
and large vessel disease may shed light to shared and distinct features of these two 
vascular processes. 
Candidate genes involved only in cSVD
In Chapter 3.2. we investigated the association between cSVD and the 
apolipoprotein E isoforms 2, 3 and 4. We found, that carriers of the 2/3 genotype 
had a 3 fold higher risk for cSVD compared to carriers of the 3/3 genotype after 
adjustment for possible confounders. The association was highly significant 
(p=0.01) and was present inspite of a favourable effect of the 2/3 genotype on 
lipid levels. We did not find an association between the 3/4 genotype and cSVD.
The manuscript presented in Chapter 4.2 investigates the association 
between the frequent AGT gene variation, M235T and both prevalence and 
progression of cerebral small and large vessel disease. The M235T was neither 
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associated with baseline carotid pathology nor with progression of carotid 
plaques. The important finding of this study was, that the TT genotype enhanced 
the risk both for the severity of cSVD at baseline (statistical trend) and for the 
progression of cSVD (adjusted OR 3.2; 95% CI 1.5 to 6.6).  Contrary to our 
expectation, the effect of the M235T polymorphism on cSVD was independent of 
hypertension. Based on the fact that the M235T polymorphism is located outside 
of the renin cleavage site, we hypothesized that this polymorphism is a marker, 
and the enhanced risk associated with it is due to linkage disequilibrium with a 
functional variant possibly in the AGT promoter.
In Chapter 3.4 I report a series of three studies evaluating the role 
of angiotensinogen (AGT) gene promoter haplotypes in cSVD. In the first 
study presented in Chapter 3.4.1, we described the presence of 4 polymorphic 
nucleotides at position –6(g/a), -20(a/c), -152(g/a) and –217(g/a) in the AGT 
promoter. These single nucleotide polymorphic sites (SNPs) constructed five 
novel promoter haplotypes (coded as A,B,C,D and E). We found that subjects 
homozygous for the –20:c allele had a significantly higher frequency of cSVD 
than carriers of the –20:c/a or –20:a/a genotypes (50% vs. 22% and 20%, 
p=0.02). There was also a trend for higher cSVD frequency in carriers of the –6:
a/a genotype compared to carriers of the –6:g/a genotype and –6:g/g genotype 
(31% vs. 18% and 21% respectively; p=0.054). The major finding of this study 
was that homozygosity for the B-haplotype (-6:a; -20:c; -152:g and –217:g) 
enhanced the risk for cSVD 8-fold (95% CI 2.1 to 31.1; p=0.003) compared to 
the wild-type A-haplotype (-6:g; -20:a; -152:g and –217:g). The effect was much 
stronger than that of the SNPs by themselves. The association between the 
B-haplotype and cSVD was not mediated by hypertension. This suggests that 
the effect of the B-haplotype is probably mediated through an altered cerebral 
expression of AGT resulting in enhanced renin-angiotensin system (RAS) activity 
in the brain. 
In Chapter 3.4.2 we reviewed the literature on the molecular biology of 
the AGT gene and on the relevance of its genetic variations in vascular diseases 
and hypertension. We studied various pathways linking the AGT promoter B-
haplotype to cSVD. Based on this review our working hypothesis has focused on 
the effect of RAS on vascular smooth muscle cells in cerebral arterioles. 
 The first step in our working hypotheses was that the B-haplotype alters 
the promoter activity of the AGT gene. To test the hypothesis that it is rather the 
local brain RAS than the systemic that links the B-haplotype to cSVD, we studied 
transcriptional activity of the AGT gene in astrocytes, which are the major source 
of cerebral AGT, as well as in hepatocytes, which are the major source of systemic 
AGT (6). 
 In the following Chapter 3.4.3 we showed that the B-haplotype 
significantly enhances basal promoter activity compared to the A-haplotype in 
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both cell-types. Its effect was stronger in astrocytes than in hepatocytes (2.4±0.09 
fold vs. 1.6±0.06fold, respectively). Importantly the effect in astrocytes was 
dependent on the presence of both SNPs (-6:a and –20:c) distinguishing the 
A- and B-haplotypes, while in hepatocytes the –20:c on its own was sufficient to 
enhance promoter activity. This is in line with our epidemiological data showing, 
that the haplotype but not the single SNPs is relevant for cSVD.
In this chapter we also tested linkage disequilibrium between the 
promoter haplotypes and 5 newly genotyped SNPs scattered over the AGT gene. 
We inferred 9 haplotypes through this analysis. By investigating the evolutionary 
relation of these haplotypes also including the published chimpanzee sequence, 
we found, that the B-haplotype probably represents an ancient AGT promoter 
variant. This is a further, though indirect support for the functional relevance of 
this haplotype. 
Candidate genes involved only in carotid atherosclerosis
In Chapter 4.3 we investigated the association between the beta-
fibrinogen promoter polymorphism, C-148T and carotid atherosclerosis. 
Homozygosity for the T allele significantly and strongly enhanced the risk for 
carotid atherosclerosis (adjusted OR 6.2; 95%CI 1.7 to 22.4; p=0.007). The 
effect was independent of the measured fibrinogen level, which by itself was 
also associated with the phenotype. There was no relationship between the beta-
fibrinogen genotype and fibrinogen concentration in our cohort. We hypothesized 
that the lack of association is due to the fact that the polymorphism, which 
is located in the vicinity of two interleukin-6 responsive elements, modulates 
fibrinogen levels in the acute phase response, but not at baseline. However, a 
low statistical power due to the small number of TT homozygotes and high 
intraindividual variability of fibrinogen concentration may also explain the lack 
of association. We found no indication that the C-148T polymorphism modulates 
the risk for cSVD in our cohort (unpublished data).
Candidate genes involved in both cSVD and in carotid atherosclerosis
In Chapter 3.3. we present a study on the association between the 
PON1 polymorphisms at position 54 (L/M) and 191(A/B) and prevalence and 
progression of cSVD. Homozygotes for the L allele at position 54 tended to 
have higher grades of cSVD at baseline (p=0.08). The main finding of this 
study was the significant association between the LL genotype and progression 
of cSVD (adjusted OR=2.65; p=0.004). The association was not modulated by 
the A/B polymorphism at position 191, as the frequency of lesion progression in 
subjects with the LL/AA and LL/BB haplotypes was almost identical (23.9% vs. 
26.3%). Although the LL genotype also significantly increased the risk for carotid 
atherosclerosis (adjusted OR 1.9; 95% CI 1.14 to 3.2; p=0.01) (Chapter 4.1), its 
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effect on cSVD was not mediated by carotid atherosclerosis.
5.2. Methodological Issues
Definition of phenotypes
cSVD extend and progression
For the rating of WML the modified Fazekas rating scale was used (9). This 
scale differentiates deep white matter lesions from periventricular lesions and 
separates them into punctuate, early-confluent and confluent lesions. The scale 
is validated by histopathological correlations which showed that early-confluent 
and confluent lesions are associated with cerebral microangiopathy, while 
punctuate lesions frequently represent non-vascular changes (10). In our genetic 
epidemiological studies the phenotype cSVD was defined as the presence of early-
confluent or confluent WML or lacunar lesions (d<10mm). This definition does 
not quantify the extent of abnormalities and therefore semi-automated algorithms 
to measure white lesion volume have been also incorporated in the MRI protocol 
of the ASPS. In our first study with a 3-years follow-up period volumetric 
measurements were not yet available. Here we graded progression of WML 
according to the change in the number of lesions and lesion grade. A change was 
considered to be marked if it exceeded 4 punctate abnormalities or if there was 
a transition in WML grade to early-confluent or confluent WML. A problem of 
this method is that enlarging confluent lesions will not be considered to represent 
progression.
By contrast, a quantitative assessment of lesion volume was performed 
in the 6-year follow-up study. Further strength of this analysis was the long 
follow-up period with 3 MRI scans obtained in each individual separated by equal 
intervals. This allows to study not only progression but also the course of this 
process over time. Lesion progression was assessed as a continuous variable but 
it was also dichotomised. Progression was considered present if lesion volume 
change exceeded the possible measurement error of 1.81cm3, which was defined 
as 95% confidence interval of the most pronounced difference between repeated 
measurements on 50 randomly selected scans.
Carotid atherosclerosis
Ultrasonographic measures of the carotid arteries are frequently used 
as surrogate markers for generalised atherosclerosis (11). In the ASPS, carotid 
atherosclerosis is defined based on the most severe visible atherosclerotic plaque 
in the common and internal carotid arteries on either side. A detailed description 
of the protocol is given in Chapter 4.2. Briefly, severity of carotid atherosclerosis 
is graded as 0=normal vessel; 1=vessel wall thickening (<1mm), 2= minimal 
plaque (1mm<d<2mm), 3=moderate plaque (2mm<d<3mm), 4=severe plaque 
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(d>3mm), and 5=lumen completely obstructed. 
Carotid artery plaque (CAP) as surrogate marker for atherosclerosis is not 
as frequently used as carotid intima media thickness (IMT) (11). Its heritability 
is estimated to be lower than that of IMT (23-28% vs. 20-40%, respectively) 
(12,13). IMT and CAP describe different aspects of carotid atherosclerosis. IMT 
primarily assesses media thickening with the intima contributing only 2 to 20% 
to the IMT value. IMT is obtained as a mean value of several measurements at 
predefined sites of the carotid arteries. Although increased IMT may reflect the 
presence of a large single plaque forcing mean IMT to higher values, it more 
likely reflects the presence of vascular smooth muscle cell hyperplasia associated 
with early stages of atherosclerosis or with adaptation of the vessel to flow, shear 
or tensile stress. Yet, increased carotid IMT is a strong predictor of hypertensive 
end-organ disease and stroke, while CAP is a better predictor of coronary artery 
disease (11,12). CAP describes focal thickening of the vessel wall, which probably 
represents a later stage in atherosclerosis than the diffuse thickening of the media. 
Common vascular risk factors like cholesterol levels, smoking, hypertension, 
diabetes, age and gender explain about 15% of the variation seen in IMT and over 
50% of the variation seen in CAP (11). Based on these differences between CAP 
and IMT we expect that the proportion of shared genetic background with cSVD 
is less for CAP than for IMT. 
Association studies
Genetic dissection of a complex trait such as cSVD can be targeted 
through linkage and association studies (14). Association studies offer 
opportunities beyond linkage studies as they can evaluate the contribution of 
genes with low penetrance to the distribution of a trait in the population further 
they allow to estimate interactions between genetic and environmental factors. 
There is a still an ongoing debate on how to perform and analyze such 
studies correctly. Phenotypic complexity, genetic heterogeneity and the presence 
of gene-gene and gene-environment interactions are inherent to the nature of 
complex traits and represent challenges for both linkage and association studies. 
Other issues like level of statistical significance and interpretation of positive 
findings deserve particular attention in relation to association studies.
Phenotypic complexity
In order to maximize the probability of finding an association to 
a complex trait, it is crucial to define the phenotype with care. It has been 
recommended to use intermediate phenotypes, which are also commonly 
termed as endophenotypes instead of the manifest disease (15). An intermediate 
phenotype is a preclinical stage of a disease and represents a biological pathway 
leading to higher susceptibility to clinical disease. The advantage of using 
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intermediate phenotypes is that they are more directly related to the action of 
a gene and show less complexity than manifest diseases. In this context MRI 
detected early confluent and confluent WML and lacunes as well as Doppler 
sonography detected atherosclerosis in the carotid arteries can be regarded as 
intermediate phenotypes for cerebral small and large vessel disease and for 
their clinical manifestations stroke or subcortical vascular dementia. Optimally 
endophenotypes are measured on a quantitative scale and show considerable 
variation within the population. It has been shown that genetic an analysis of a 
quantitative trait is more powerful than analyses of the same trait dichotomized 
into discrete variables (16). It is therefore our major interest to measure the 
volume of WML and to use the extent of WML as a quantitative trait in 
our future genetic studies. A weakness of using endophenotypes instead of 
manifest disease is that genetic factors involved in outbreak of a disease can 
not be investigated. Also a significant proportion of people presenting the 
endophenotype will never manifest the disease. Therefore the interpolation of the 
results to the clinical practice has to be more cautious.
Another important issue in the genetic study of a complex trait is the 
precision of phenotypic information. The availability of such data is a prerequisite 
to detect the presence of phenotypic variability but also of genetic heterogeneity 
within a trait. Phenotypic variability refers to differences such as disease 
severity, age at onset or clinical symptoms in carriers of the same genotype. By 
definition subjects manifesting the disease within this variability are expected to 
be genetically homogenous and all of them should be defined as cases in order 
to enhance the power of an association study. On the other hand the observed 
phenotypic differences may define clinical subtypes and may potentially indicate 
the presence of genetic heterogeneity within the trait (17). The presence of genetic 
heterogeneity introduces noise into the data as the expected small effect of the 
gene under study will be masked by the effect of other genes and will reduce 
the power of the study to detect association. While in linkage studies only locus 
heterogeneity is of concern, in association studies also the presence of allelic 
heterogeneity represents a problem. Allelic heterogeneity is frequently observed in 
Mendelian diseases and is also expected to be present in complex traits (17).
The most straightforward approach to handle heterogeneity is sample 
stratification. The rationale of stratification is that different disease models 
operate within different strata and the pathological role of a gene is conditional 
on the presence or absence of the stratifying variable. The main disadvantage 
of sample stratification is the reduced sample size within the strata, and in turn 
a reduction in statistical power. Other methods aiming to handle heterogeneity 
in association studies include cluster analyses, latent class analyses and factor 
analyses. All of these methods like sample stratification are dependent on the 
availability of relevant covariate data and their usefulness for association studies 
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still has to be evaluated (17). 
Finally, the comparability of diagnostic criteria across studies has to 
be mentioned. It is desirable to use international guidelines and standardized 
protocols for phenotyping. A major drawback for genetic studies in cSVD is the 
lack of such guidelines. Each major study in the field uses its own scale to describe 
WMLs. Recently efforts were undertaken to correlate these different scales and 
evaluate their usefulness for cross-sectional and longitudinal studies. Based on 
these studies the Fazekas rating scale has an excellent inter-rater agreement and 
correlates well with other WML scoring systems, yet it is rather a typological than 
a quantitative scale (18).
Statistical significance
A major concern regarding association studies is the level of statistical 
significance of an observed positive association. Presently most association studies 
investigate only a small number of polymorphisms in a small number of candidate 
genes. A correction for multiple testing is generally not considered. Recently, it 
has been proposed that analogous to linkage studies more stringent significance 
levels should be used in association studies especially in genome wide studies. The 
point is that the prior probability that a gene variant will be associated with a trait 
of interest is very low (1 to 30.000 if one considers only the number of genes in 
the human genome). This would translate to a p-value as low as 2.6x10-7, which is 
hardly ever seen in association studies (19). Careful selection of candidate genes 
and polymorphisms based on previous evidence such as linkage and association 
data or functional data can increase prior probability. It has been suggested that 
journals should require explicit, standardized description of previous evidence 
and authors should propose estimates of prior probability based on this evidence 
(19). However it is difficult to envision how estimates for prior probability for 
an association should be calculated. Firstly, it can be expected that a complex 
trait will be associated with more than one gene and there will be interactions 
with other genes and with environmental factors and there will be a variation of 
these factors among populations. Secondly, a review of published data in order to 
search for previous evidence will probably overestimate prior probability due to 
publication bias. A search of the newly developed Genetic Association Database, 
which deposits association data in a standardized manner, may provide a less 
biased overview of data (20). 
With the advent of high-throughput genotyping a genome-wide scan 
in association studies become technically feasible. Depending on the linkage 
disequilibrium structure in a population the estimated number of markers needed 
to cover the genome is 50.000 to 60.000 (20). Contrary to linkage studies, where 
we expect, that one gene will be linked to a Mendelian disease, we expect true 
associations between several genes and a complex trait in association studies. The 
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question of statistical significance for genome-wide association studies is still not 
clarified, although different approaches, like the usage of the false discovery rate, 
have been proposed (21).
 
Interpretation of a positive association 
An observed positive association should be interpreted cautiously (22). 
The association might be true and causal, meaning that the mutation itself by 
altering function or availability of the gene product leads to the development of 
the disease. Proving the causality of a mutation requires supplementary studies 
including histopathology, cell expression or animal studies. Also replication of 
a positive association in an unrelated population is considered to be a strong 
indicator for a true and causal relationship between mutation and phenotype. 
However, it is uncommon that positive associations are replicated by follow-
up studies. Partly the difficulties for replicating results may have biological 
explanations like dependence of the gene effect on the presence of other genetic 
or environmental factors differentially present in the initial and in the follow-up 
population (22). Another explanation might be the use of non-standardized 
criteria for phenotype definitions across different studies.  A recent call for a 
“Human Phenome Project” in Nature Genetics to systematically collect and 
describe human phenotypic information illustrates the magnitude of this problem 
(23). As discussed in the previous section there is a need for an internationally 
accepted uniform protocol to define and type cSVD based on MRI findings and 
develop a uniformly used nomenclature for these lesions.
Beside a causal relationship a true positive association can also be due the 
presence of LD. There exist about 10 million SNPs in the human genome and 
most of them are neutral regarding human diseases. However, a portion of them 
will represent genetic factors enhancing the liability to common diseases. The 
demonstration of LD between disease and a marker SNP indicates the presence 
of a causal mutation within the neighborhood of the marker. Based on recent 
publications significant LD in humans is expected in a swept radius of over 100kb 
(24).
Nevertheless, there is a substantially high likelihood that the observed 
association is a false positive finding due to population stratification or due to 
chance (25). If a subgroup within the population has a higher susceptibility to 
disease and also has a higher frequency of the investigated allele, then a spurious 
positive association between disease and allele may be found. Awareness of 
this problem termed population admixture led to the use of ethnically more 
homogeneous study populations and more careful selection of cases and controls 
originating from the same source population. However even small stratification 
can introduce considerable bias, if sample sizes are large. The method of genomic 
control can adjust for bias due to hidden population substructure by using 
genotype information from additional unlinked markers (26). Other methods 
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like the transmission disequilibrium test (TDT), uses family-based controls, in 
order to prevent bias due to admixture (27). Recruiting relatives is however more 
difficult than recruiting unrelated controls and in some cases relatives are not 
available (26). 
Expression study
As discussed above dissecting the causality of an observed association 
requires supplementary studies. In this thesis we investigated the biological effect 
of AGT promoter variants using a transient transfection assay. As a model system 
we used cultured astrocytoma cells transfected with a reporter plasmid containing 
the luciferase gene driven by the inserted promoter variants. Our results showing 
an enhanced transcriptional activity of the risk B-haplotype suggest a causal 
relationship between AGT promoter B-haplotype and cSVD. There are however 
some methodological issues, which have to be discussed in order to interpret the 
biological relevance of these findings. 
Complexity of gene regulation in eukaryotes 
Transient transfection assays measure the rate of transcription initiation, 
which is generally considered as the major controlling mechanism of gene 
expression. Other mechanisms such as RNA processing and post-translational 
modification however may influence the amount of mature protein synthesized. 
Also recent studies indicate that gene expression in eukaryotes is regulated in 
a hierarchical manner including regulation at the DNA sequence level, at the 
chromatin level and at the nuclear level (28-29). Due to the lack of experimental 
methods to manipulate nuclear organization or chromatin structure there is 
little knowledge on how these different regulatory mechanisms interact with 
each other. The importance of interactions between different levels is, however, 
demonstrated by the observation of transvection, where regulatory elements 
located on one allele can interact with the promoter of the other allele on the 
homologous chromosome by probably coming physically close to each other 
due to nuclear compartmentalization. Hierarchically higher order regulatory 
mechanisms may even compensate the enhanced transcriptional activity of a 
promoter. In transient transfection assays the promoter is cloned into a reporter 
plasmid lacking its natural chromatin and nuclear context. Also the large copy 
number the plasmids present in the transfected cell may lead to aberrant function 
(39). Thus one should be cautious about transferring results from transient 
transfection assays to intact organisms. 
It is also important to note that transcriptional initiation is a highly 
dynamic process fluctuating by orders of magnitude within minutes. Adjacent 
cells within a tissue may show very different transcriptional activity depending on 
the availability of transcription factors and on environmental or developmental 
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conditions of the cell. In our experiments promoter activity was studied under 
constant basal conditions. The AGT promoter contains several putative binding 
sites for transcription factors such as estrogen and glucocorticoid responsive 
elements or acute phase response elements. Their effect might be mediated 
differentially by the B-haplotype. Thus investigation of the promoter activity 
under induced conditions such as hormonal treatment or hypoxia is of interest.
In or experiments we used a 1.3 kb long fragment of the AGT promoter 
spanning nucleotides from +44 to –1222 relative to the transcriptional start 
site. Previous studies have shown that this fragment is functionally active in 
hepatocytes and astrocytes. Our results showing a differential transcriptional 
activity of the haplotypes indicate that haplotype dependent regulatory 
mechanisms can be investigated by using this fragment (31-34). Clearly, cis-acting 
elements interacting with the B-haplotype may be present further upstream, in 
introns or downstream of the AGT gene. Recent studies showed that the physical 
distance between a core promoter and its cis-acting elements ranges between 
some few hundreds up to >100kb in humans (28). Looping or bending of the 
DNA allows proteins associated with these distant elements to interact with the 
core promoter. Distant control regions including enhancers, silencers or locus 
control regions, probably represent a higher position in the regulatory hierarchy 
and may influence the accessibility of the whole locus (28,30). Therefore some 
researchers argue that before initiating promoter studies efforts should be 
undertaken to find distant control regions (30). However, these are difficult to 
find and frequently do not function in transient assays, which makes such studies 
more time-consuming. Due to limited resources we decided to perform our 
experiments using the published 1.3kb promoter sequence. It is important to be 
aware of the probable presence of distant regions controlling AGT expression and 
to adapt the experimental design accordingly, if such sequences become known.
Selection of cell model
Cells being studied in a transient transfection assay must fulfill three 
criteria (30). The cells must express the gene of interest endogenously. They must 
survive in culture for the time of the experiment and a protocol to transfect 
them with the reporter plasmid must be available. In general immortal cell lines 
represent the best choice for such studies, while primary cell are more difficult 
to isolate and maintain and are rarely available in sufficient quantity. Primary 
cells are also more resistant to transfection procedures than transformed cells. 
In our experiments we used the A172, a grade III astrocytoma cell line as a 
cellular model for cerebral AGT expression and HepG2 cells, a hepatoma cell 
line as cellular model for hepatic AGT expression. Both cell lines produce AGT 
endogenously and have been used by other groups to study the AGT promoter 
(34). 
A disadvantage of using transformed cell lines compared to primary cells 
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is that due to their malignant phenotype these cells will probably not express all 
the transcription factors of normal astrocytes and, and contrary, they probably 
also express transcription factors, such as oncogens, which are normally not 
present in astrocytes. Recently, primary human astrocytes became commercially 
available but their usefulness for studying AGT promoter activity still has to 
be evaluated. While primary astrocytes represent a more physiological model 
than astrocytoma cells, one should bear in mind that gene expression is also 
dependent on the area surrounding a cell located in the brain (35). Therefore 
immunohistochemistry or in situ hybridization to visualize AGT expression in 
post mortem brain tissue from subjects carrying different promoter haplotypes 
may deliver more information on the effect of the haplotypes in their natural 
context. Beside astrocytes also other cell types like vascular smooth muscle 
cells, endothel cells and neurons have been shown to synthesize AGT and may 
contribute to AGT synthesis at the site of cSVD (36). The effect of the promoter 
haplotypes in these cells has not yet been investigated.
5.3. What did we learn from these studies about cSVD? 
Natural course of cSVD
We have shown that the type of WMLs determines the rate by what 
these lesions progress, with early-confluent and confluent lesions progressing at 
the highest speed. Importantly subjects with confluent WML have a “malignant” 
course as lesion volume almost doubles over a relatively short time period of 6 
years. We never observed regression of lesions. Even though the use of different 
scales to estimate extent and progression of lesions hampers the comparability of 
results of different studies, all studies published so far confirm that these lesions 
progress over time (37). Studies are however less coherent regarding predictors 
of progression. Diastolic and systolic blood pressure, age, diabetes, cigarette 
smoking and infarcts on the initial scan have been indicated to be related to lesion 
progression (38). In our cohort baseline WML grade was the strongest predictor 
of progression and if this variable was included in a multivariable model all other 
associations including age and blood pressure, became non-significant. One may 
debate if defining WML grade at baseline as a predictor of WML progression 
is meaningful as both baseline WML as well as progression of WML is the 
manifestation of the same process observed at different time points and their 
strong correlation is self-evident. Nonetheless, this observation is important in 
daily routine in order to estimate a subject’s prognosis based on the baseline MR 
finding. 
There are only a few studies with longitudinal MRI and clinical 
assessments. So far only the Cardiovascular Health Study found a positive 
association between WML progression and cognitive decline, the other studies 
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were negative (38). Probably, the follow-up time of these studies is still too short 
to measure cognitive decline due to lesion progression with acceptable power. 
Increasing gait and balance dysfunctions due to WML progression have also been 
reported (39). The clinical consequences of progression still need to be evaluated 
in our cohort.
Etiology of cSVD
We have determined novel genetic risk factors for cSVD. In the first 
place our results on the AGT gene deserve special attention. Our epidemiological 
and molecular biological data on this gene strongly suggest that overactivity 
of the cerebral RAS is involved in the development of cSVD. The vascular 
effects of AT-II, which represent the biologically active end-product of RAS in 
the plasma, are well documented. It is a potent vasoconstrictor and promotes 
vSMC hyperplasia and hypertrophy. It modulates NADH/NADPH oxidase 
and extracellular superoxide dismutase activity and extracellular matrix protein 
syntheses (40-43). Systemic RAS activity is regulated at the synthesis of hepatic 
AGT, which is in turn controlled by the transcriptional rate of the AGT gene (6, 
36). Regulation of cerebral RAS activity is less well understood. If cerebral RAS 
is regulated similarly as systemic RAS, then increased promoter activity of the 
AGT gene may lead to RAS overactivity in the brain. This in turn may result 
in an imbalance of physiological processes like brain perfusion, autoregulation 
of cerebral blood flow, oxidative state of the vessel wall or blood brain barrier 
function. Each of these processes are likely to be involved in cSVD (44).
The findings that the PON1 LL genotype is independently associated 
with both small and large vessel disease, suggest that it acts through different 
mechanisms in the two vascular pathologies. The association with carotid 
atherosclerosis probably depends on a reduced protection of LDL against 
oxidation, which is a crucial and early event during atherosclerosis (45). The 
capacity of paraoxonase to protect LDL from oxidation is indeed lowest in 
individuals with the LL genotype (5). The effect of the LL genotype on cSVD 
may depend on its cerebral action. Paraoxonase is located on a subfraction of 
HDL together with clusterin. This subfraction of HDL is highly abundant in 
interstitial fluid and it is the only lipoprotein found in the brain. Its suggested 
function is to protect cellular membranes and possibly also myelin from 
oxidation. The association between cSVD and PON1 polymorphism suggests 
that oxidative damage plays a role in these lesions and that PON1 polymorphism 
modulates vulnerability of the brain to radicals. Oxidative damage is part of the 
aging process and may therefore partly explain the strong association of cSVD 
with age (46).
Our findings on the apoE gene and cSVD are controversial. Our study is 
the only study showing an association between the apoE 2 allele and cSVD, while 
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other studies found association with the apoE 4 allele or showed no association 
with either apoE variant (47). Based on diverse functions apoE has in the central 
nervous and in the vascular system, the hypothesis that apoE is involved in cSVD 
is well supported (4). ApoE may enhance arteriolosclerosis, as it can modulate 
vascular smooth muscle cell proliferation, or may modulate repair mechanisms, 
remyelinisation in the brain upon ischemia by delivering lipids. Yet, most of the 
pathologic functions are assigned to the apoE 4 allele, while the apoE 2 allele is 
rather considered to be protective. Nonetheless, some epidemiological studies 
reported deleterious effects for the apoE 2 allele (48). Further studies on the role 
of apoE variants in cSVD are needed. 
The lack of association between the beta-fibrinogen polymorphism and 
cSVD and its strong association with carotid atherosclerosis may suggest that 
the thrombosis-haemostasis pathway does not play a significant role in cSVD 
while it is important in atherosclerosis. We also did not observe an association 
between plasma fibrinogen level and cSVD in our cohort, although some other 
studies reported such association. It is important to keep in mind that the C-148T 
polymorphism probably modulates the increase of fibrinogen upon iterleukin-6 
response, which occurs during acute phase or in smokers while it probably 
does not influence baseline fibrinogen level (49). Therefore an analysis of the 
association between the C-148T polymorphism and cSVD stratified on smoking 
is of interest, but due to the low frequency of the T allele for such an analyses a 
larger sample than in our study is needed.
 In summary the results presented in this thesis suggest that cSVD 
manifested as early confluent and confluent WML or lacunes on MRI represents 
a chronic and progressive brain pathology. We identified genetic factors, 
which significantly alter the risk for this entity. Although we observed an 
association between AGT haplotype and blood pressure, PON1 polymorphism 
and paraoxonase concentration and apoE isoforms and serum lipid levels, the 
increased risk for cSVD was not mediated by these associations. We hypothesize 
that these genetic variations most probably act through local cerebral effects 
rather then through systemic effects. In order to test this hypothesis it will 
be important to study the localization of the candidate gene products at the 
mRNA and protein level in areas of brain damage. Our finding indicating that 
overactivity of the cerebral RAS is involved in the etiology of cSVD suggests this 
pathway is a possible treatment target and that drugs acting on the RAS exerts 
effects beyond those expected by lowering blood pressure.
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5.4. Future research
Refined assessment of WML features (threshold, location, atrophy) and new 
imaging techniques (magnetization transfer, diffusion tensor imaging)
Although a moderate association between leuko-araiosis and cognitive 
as well as affective disturbances has been repeatedly described in cross-sectional 
studies, this could not yet be shown in longitudinal investigations (50,51). Also, 
clinicians are commonly confronted with cases that have extensive white-matter 
lesions and/or lacunes but virtually normal cognitive and affective functions. In 
contrast, other persons with the same extent of lesions may exhibit pronounced 
deficits. The advent of new MRI techniques including diffusion tensor imaging, 
magnetisation transfer imaging, functional MRI, but also the functional imaging 
methods such as SPECT or PET promise to characterise brain lesions beyond 
what can be expected from conventional MRI sequences (52). These methods 
have the potential to demonstrate interruptions of white-matter fibre tracks, to 
determine the severity of tissue destruction and axonal damage in the area of a 
given lesion but also in normal appearing white matter (52,53). Probably, these 
methods will also allow to study remote effects of lesions in different brain areas 
and to evaluate the plasticity of the brain in order to compensate for lesion-related 
detrimental effects.
The natural course of small vessel disease-related brain damage and its clinical 
consequences
The most important finding of studies on the natural course of 
microangiopathy-associated brain damage was that the lesion type substantially 
predicts the rate of future progression (37). While punctate white-matter lesions 
show negligible progression over a six-year observational period, it was shown 
that the volume of confluent abnormalities almost doubles within the same 
time interval (37). This indicates a malignant course even though the clinical 
consequences of this process are yet unclear. Validation of confluent white-matter 
lesions as surrogate markers in dementia trials is an important research topic for 
the coming years. 
Future Genetic Research
Identification of risk factors and factors that modify the course of the 
disease has high priority in this field as this may ultimately allow developing 
effective treatment strategies. Genetic linkage and association studies will 
probably contribute to establish such factors. First genetic association studies 
provided promising results but these findings have to be replicated in independent 
populations. Association studies investigating new candidate genes such as other 
members of the RAS, and its antagonist, the nitric oxide system, as well as genes 
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involved in free radical production and antioxidative mechanisms or in brain 
repair should be performed in order to extend the results of our previous studies 
on the relevance of these pathways in cSVD pathology. It will be important 
to establish international collaborations with the aim to replicate results in 
independent samples as well as to investigate to gene-gene and gene-environment 
interactions in large samples.
Linkage studies using affected pedigree members or isolated populations 
will allow genome-wide screening for risk factors and disease-modifying factors, 
and very likely will extent and supplement the results of genetic association 
studies. We are currently estimate the feasibility of such a study by contacting 
relatives of the ASPS participants. 
Future molecular biological research
Concomitant histopathological correlation and investigations on the 
expression of genes at tissue and cellular level will be mandatory to determine the 
functional importance of gene variants identified by genetic studies. A brain bank 
of cSVD cases has been initiated in our laboratory. Samples embedded in paraffin 
are currently used for immunohistochemistry and for in situ hybridization 
experiments to investigate expression pattern of individual candidate genes in 
such lesions. We also collect snap frozen tissue samples, which should allow 
studying gene expression pattern using a global approach such as microarray 
experiments (54). The advantage of global approaches is the possibility to identify 
novel pathways leading to cSVD indicated by altered expression of gene clusters.
 Success of future research on cSVD will depend on the international 
collaboration of large epidemiological studies and on the interdisciplinary efforts 
of experts to dissect molecular pathways leading to this pathology.
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Summary
Cerebral small vessel disease (cSVD) is a common finding in the elderly. It 
is manifested as early-confluent and confluent white matter lesions as well as 
lacunar lesions on magnetic resonance imaging of the brain. These lesions may 
lead to cognitive impairment, gait disturbances and depression as they progress. 
Risk factors for cSVD are age and hypertension. The heritability is estimated 
to range from 55 to 75%. The aim of this thesis was to better understand the 
pathogenesis of cSVD by investigating the development of these lesions over 
time and by the identification of genetic risk factors for cSVD. These results 
may ultimately lead to the development of preventive and therapeutic measures 
of cSVD and its clinical consequences. 
All studies presented in this thesis were conducted as part of the 
Austrian Stroke Prevention Study, a single-center, longitudinal cohort study on 
the cerebral effects of vascular risk factors in the normal elderly population 
of the city of Graz, Austria. The ASPS was started in 1991 and enrolled 1998 
participants aged between of 50 and 75 years of whom 498 underwent extensive 
baseline and follow-up evaluations, including blood pressure readings, ECG, 
echocardiography, blood cell count and complete blood chemistry as well as 
brain MRI, Doppler sonography, SPECT and neuropsychiatric testing and 
DNA banking. The cohort is followed up in 3-year intervals.
this study was that the only significant predictor of lesion progression is the 
grade of white matter lesions at the baseline MRI. All participants with conflu-
ent and 58% of those with early-confluent WML at baseline showed progression 
over the 6-year follow-up, compared with 15% in participants with punctate 
lesions and 2% with normal MRI at baseline. We never observed regression of 
lesions. Thus early-confluent and confluent lesions represent progressive and 
probably malignant cerebrovascular pathology.
In Chapter 3 we give a review on the genetic aspects of cSVD and 
present a series of 5 studies investigating the association between cSVD and 
genetic variants in candidate genes. We found that the APOE 2/2 genotype, the 
PON1 54 L/L genotype and the AGT promoter B/B genotype increase the risk 
for cSVD. In case of the AGT promoter B-haplotype, we showed that its effect 
might be due to an increased transcriptional activity of the AGT promoter in 
astrocytes, which represent the major source of AGT in the brain. By using an 
evolution-based approach, we showed that the B-haplotype represent an ancient 
promoter variant in humans.
In chapter 4 we present three studies investigating the association of 
genetic variants in candidate genes and CAP. We argue that simultaneous inves-
tigation of genetic factors in both cSVD and CAP may shed light to overlapping 
and distinguishing features of cerebral small and large vessel pathology. Our 
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result showed that the PON1 L/L genotype enhances the risk for CAP, but 
its effect on cSVD is not mediated by the association with CAP. We found no 
association between the AGT gene variant M235T and CAP, a variant which 
enhanced the risk both for the severity of cSVD at baseline and for the progres-
sion of cSVD. On the contrary, the FGB T/T –148 genotype showed a strong 
association with CAP, but had no effect on cSVD risk.
Chapter 5 provides a general discussion on our main findings, meth-
odological issues of our studies and the clinical relevance of the results. Finally 
future objectives of research on cerebral small vessel disease in the context of 
this thesis are discussed.
Samenvatting
Cerebrale micro-angiopathie, de zgn. ‘cerebral small vessel disease’(cSVD), 
komt vaak voor bij ouderen. De afwijkingen hiervan manifesteren zich op MRI 
(magnetic resonance imaging) afbeeldingen, zowel als (vroeg-) confluerende witte 
stof laesies, als ook in de vorm van lacunaire laesies. Bij progressie kunnen deze 
laesies symptomen veroorzaken als cognitieve achteruitgang, stoornissen in de gang 
en depressie. Risicofactoren voor cSVD zijn leeftijd en hypertensie. De erfelijkheid 
(heritability) wordt geschat op 55% tot 75%. Het doel van dit proefschrift was een 
beter begrip van de pathogenese van cSVD, door het onderzoeken van de ontwik-
keling van dit soort laesies door de tijd en door het identificeren van genetische 
risicofactoren voor cSVD. Deze resultaten zouden uiteindelijk kunnen leiden tot 
de ontwikkeling van preventieve en therapeutische mogelijkheden voor cSVD en 
de klinische sequelae ervan.
Alle studies die in dit proefschrift worden beschreven, zijn uitgevoerd in 
het kader van de ‘ASPS’ (Austrian Stroke Prevention Study, een Oostenrijkse studie 
naar de preventie van cerebrovasculaire accidenten), een longitudinale cohort stu-
die, uitgevoerd in en door één centrum, naar de cerebrale effecten van vasculaire 
risicofactoren onder ouderen (binnen de algemene bevolking) van de stad Graz in 
Oostenrijk. De ASPS is gestart in 1991 en er zijn 1998 deelnemers zijn geïncludeerd, 
in leeftijd variërend van 50 tot 75 jaar, van wie er 498 uitgebreid onderzoek onder-
gingen bij de start van de studie en tijdens vervolgonderzoeken. Deze hielden o.a. 
in: bloeddruk metingen, ECG, bloedonderzoek en MRI cerebrum, doppler onder-
zoek, SPECT, neuropsychiatrische testen en DNA opslag. De vervolgonderzoeken 
vonden plaats met een interval van 3 jaar.
Hoofdstuk 1 is een algemene inleiding betreffende de epidemiologie, 
pathophysiologie en genetica van cSVD. In dit hoofdstuk worden de definiëring 
beschreven van de phenotypes, cSVD en plaques in de arteria carotis (CAP), welke 
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gebruikt werden in de genetische associatie studies. Voorts worden ook het doel 
van de studie en de onderzoeksopzet beschreven.
In hoofdstuk 2 worden de snelheid en determinanten van progressie 
van witte stof laesies beschreven na 3 en 6 jaar vervolgonderzoek. Een nieuwe 
bevinding van deze studie was, dat de enige significante voorspeller van progres-
sie de gradatie van de witte stof laesies is op de MRI scan bij de start van het 
onderzoek. Bij alle deelnemers met confluerende witte stof laesies en 58% van hen 
met vroeg-confluerende laesies was er sprake van progressie gedurende 6 jaar ver-
volgonderzoek. Dit in vergelijk met 15% progressie bij deelnemers met punt laesies, 
en 2% bij deelnemers met een normale MRI bij de start van het onderzoek. Dus 
zijn vroeg-confluerende en confluerende laesies een indicator voor progressieve en 
waarschijnlijk kwaadaardige cerebrovasculaire pathologie.
In hoofdstuk 3 geven wij een overzicht van de genetische aspecten van 
cSVD en presenteren wij een serie van 5 studies, waarin de associatie tussen cSVD 
en genetische varianten van kandidaat-genen werd onderzocht. Het APOE 2/2 
genotype, het PON1 54 L/L genotype en het AGT promoter B/B genotype bleken 
geassocieerd met een verhoogd risico op cSVD. Bij het AGT promoter B-haplo-
type werd aangetoond, dat het effect mogelijk kon worden toegeschreven aan een 
toename in transcriptie van de AGT promoter in astrocyten, die de grootste bron 
van AGT zijn in de hersenen. Door gebruik te maken van een vergelijk van de 
sequentie, konden wij aantonen dat het B-haplotype een zeer oude promotor vari-
ant in mensen vertegenwoordigt.
In hoofdstuk 4 presenteren wij drie studies naar de associatie tussen geneti-
sche varianten in kandidaat-genen en CAP. Wij bespreken, dat gelijktijdig onderzoek 
naar genetische factoren en zowel cSVD als CAP, mogelijk meer duidelijkheid zou 
kunnen geven over overlappende maar ook onderscheidende kenmerken van cere-
brale micro- en macro-angiopathie. Onze resultaten toonden aan dat PON1 L/L 
genotype het risico op CAP vergroot, maar dat het effect op cSVD niet gemedieerd 
wordt door de associatie met CAP. Wij vonden geen associatie tussen de AGT 
genvariant M235T en CAP, een variant die wel het risico op zowel op de ernst van 
cSVD bij het begin van het onderzoek, als op progressie van cSVD vergroot. In 
tegendeel toonde het FGB TT –148 genotype een sterke associatie met CAP, maar 
had het geen effect op het risico op cSVD.
Hoofdstuk 5 biedt een algemene discussie van onze belangrijkste bevin-
dingen, methodologie van onze studies en de klinische relevantie van de resultaten. 
Tot slot worden toekomstige onderzoeksdoelen, in de context van deze promotie, 
voor onderzoek rond cerebrale micro-angiopathie besproken.
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